"ChEMBL ID";"Assay Type";"Description";"Organism";"Compounds";"Activities";"BAO Format ID";"BAO Format";"Confidence Score";"Confidence Label";"Strain";"Source";"Tax ID";"Tissue ChEMBL ID";"Tissue Name";"Cell Type";"Subcellular Fraction";"Document ChEMBL ID";"PubMed ID";"DOI";"Year";"Journal";"Volume";"First Page";"Last Page";"Assay Parameters";"Assay Classification L1";"Assay Classification L2";"Assay Classification L3";"Variant Sequence Accession";"Variant Sequence Mutation"
"CHEMBL734245";"F";"In vivo activity against transplanted Mam-16/C/Adr tumors of mice";"Mus musculus";"8";"8";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1134487";"11356111";"10.1021/jm0005149";"2001";"J Med Chem";"44";"1758";"1776";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL1613914";"F";"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) ";"Homo sapiens";"39332";"39754";"BAO_0000019";"assay format";"9";"9 - Direct single protein target assigned";"";"PubChem BioAssays";"9606";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL734250";"F";"In vivo activity against transplanted Squam lung-LC12 tumors of mice";"Mus musculus";"11";"11";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1134487";"11356111";"10.1021/jm0005149";"2001";"J Med Chem";"44";"1758";"1776";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL1964065";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line. (Class of assay: confirmatory) ";"";"34103";"34374";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"SR";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL965578";"B";"Inhibition of mouse brain MAOA";"Mus musculus";"385";"391";"BAO_0000019";"assay format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1152129";"18834112";"10.1021/jm800656v";"2008";"J Med Chem";"51";"6740";"6751";"";"";"";"";"";""
"CHEMBL965584";"B";"Inhibition of bovine brain MAOB";"Bos taurus";"56";"56";"BAO_0000019";"assay format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9913";"";"";"";"";"CHEMBL1152129";"18834112";"10.1021/jm800656v";"2008";"J Med Chem";"51";"6740";"6751";"";"";"";"";"";""
"CHEMBL1697722";"A";"Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset";"";"530";"544";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"";"";"";"";"CHEMBL1697692";"20553011";"10.1021/tx1000865";"2010";"Chem Res Toxicol";"23";"1215";"1222";"";"";"";"";"";""
"CHEMBL648663";"F";"Compound was evaluated for the antineoplastic activity on B16 Melanoma cells at the optimal dose of 100 mg/kg through intraperitoneal route on days 1,5,9";"Mus musculus";"3";"6";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"B16";"";"CHEMBL1122849";"4067995";"10.1021/jm00149a025";"1985";"J Med Chem";"28";"1685";"1691";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Melanoma Oncology Models | Melanoma Oncology Models | Neoplasm Oncology Models";"Experimental Melanoma | General Melanoma | Neoplasms";"";""
"CHEMBL1794584";"F";"PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860]";"";"63980";"64461";"BAO_0000019";"assay format";"8";"8 - Homologous single protein target assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909184";"B";"DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP)";"Homo sapiens";"871";"1742";"BAO_0000221";"tissue-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"DrugMatrix";"9606";"";"";"Platelet";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909097";"B";"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)";"Sus scrofa";"871";"1742";"BAO_0000221";"tissue-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"DrugMatrix";"9823";"CHEMBL3638187";"Heart";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL926687";"A";"Oral bioavailability in human";"Homo sapiens";"295";"299";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1141299";"17870541";"10.1016/j.bmc.2007.08.060";"2007";"Bioorg Med Chem";"15";"7738";"7745";"";"";"";"";"";""
"CHEMBL1794499";"F";"PUBCHEM_BIOASSAY: Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504856]";"";"13678";"13785";"BAO_0000019";"assay format";"8";"8 - Homologous single protein target assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1697779";"A";"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents";"Rodentia";"944";"951";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9989";"CHEMBL3559723";"Liver";"";"";"CHEMBL1697731";"20014752";"10.1021/tx900326k";"2010";"Chem Res Toxicol";"23";"171";"183";"";"";"";"";"";""
"CHEMBL1614670";"A";"Volume of distribution at steady state in human after iv administration";"Homo sapiens";"667";"669";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1614632";"18426954";"10.1124/dmd.108.020479";"2008";"Drug Metab Dispos";"36";"1385";"1405";"";"";"";"";"";""
"CHEMBL1909130";"B";"DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid)";"Homo sapiens";"871";"1742";"BAO_0000221";"tissue-based format";"9";"9 - Direct single protein target assigned";"";"DrugMatrix";"9606";"";"";"Platelet";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909155";"B";"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"5";"5 - Multiple direct protein targets may be assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3638246";"Spinal cord";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909156";"B";"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909148";"B";"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3638188";"Brain";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909206";"B";"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"Insect cells";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909111";"B";"DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3638188";"Brain";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909089";"B";"DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909143";"B";"DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909214";"B";"DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HEK293";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909139";"B";"DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909162";"B";"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)";"";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"DrugMatrix";"32644";"";"";"U-937";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909168";"B";"DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HEK293";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909188";"B";"DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF)";"";"871";"1742";"BAO_0000219";"cell-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"DrugMatrix";"32644";"";"";"NIH3T3";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909192";"B";"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)";"Oryctolagus cuniculus";"871";"1742";"BAO_0000221";"tissue-based format";"9";"9 - Direct single protein target assigned";"";"DrugMatrix";"9986";"CHEMBL3638235";"Lung";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909137";"B";"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"BTI-TN-5B1-4";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909112";"B";"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3638188";"Brain";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909211";"B";"DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909191";"B";"DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020)";"Bos taurus";"871";"1742";"BAO_0000221";"tissue-based format";"9";"9 - Direct single protein target assigned";"";"DrugMatrix";"9913";"CHEMBL3638197";"Uterus";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909095";"B";"DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde)";"Rattus norvegicus";"871";"1742";"BAO_0000221";"tissue-based format";"9";"9 - Direct single protein target assigned";"";"DrugMatrix";"10116";"CHEMBL3638191";"Lens of camera-type eye";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909215";"B";"DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909129";"B";"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"1321-N1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909177";"B";"DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine)";"";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"DrugMatrix";"32644";"";"";"IMR-32";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909181";"B";"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HEK293";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909131";"B";"DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"Sf21";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909132";"B";"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"BTI-TN-5B1-4";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909153";"B";"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3559724";"Cerebral cortex";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909166";"B";"DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HEK293";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1827911";"F";"Cytotoxicity against human HeLa cells by MTT assay";"Homo sapiens";"36";"36";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HeLa";"";"CHEMBL1821576";"21689869";"10.1016/j.ejmech.2011.05.065";"2011";"Eur J Med Chem";"46";"3934";"3941";"";"";"";"";"";""
"CHEMBL1827912";"F";"Cytotoxicity against human DU145 cells by MTT assay";"Homo sapiens";"36";"36";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"DU-145";"";"CHEMBL1821576";"21689869";"10.1016/j.ejmech.2011.05.065";"2011";"Eur J Med Chem";"46";"3934";"3941";"";"";"";"";"";""
"CHEMBL727528";"F";"Number of survivors on day 60 at a dose of 100 mg/kg; 0/6";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123176";"3701785";"10.1021/jm00155a022";"1986";"J Med Chem";"29";"716";"727";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL1633752";"T";"Toxicity in MAV-1 infected nonimmunosuppressed BALB/c mouse assessed as effect on survival at 100 mg/kg, ip treated 8 days before infection for 2 to 4 weeks";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors";"General Immunosuppressive Activity";"";""
"CHEMBL1633756";"F";"Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as B cells suppression at 100 mg/kg, ip treated 8 days before infection for 4 weeks measured 14 days post infection by flow cytometry";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"B";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors";"General Immunosuppressive Activity";"";""
"CHEMBL1633754";"F";"Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as leukopenia in lymph node at 100 mg/kg, ip treated 8 days before infection measured 3 days post infection by flow cytometry";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors";"General Immunosuppressive Activity";"";""
"CHEMBL734739";"F";"Percentage increase in life span of L1210 leukemia implanted mice at a dose of 200 mg/kg";"Mus musculus";"6";"6";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123954";"3336021";"10.1021/jm00396a036";"1988";"J Med Chem";"31";"226";"230";"standard_type:DOSE standard_relation:= standard_value:200.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models";"General Leukemia | L1210 Experimental Leukemia";"";""
"CHEMBL1634557";"F";"Antiviral activity against MAV-1 infected in immunocompromized BALB/c mouse assessed as effect on viral DNA load in liver at 100 mg/kg, ip treated 8 days before infection for 3 weeks by RT-PCR";"Murine adenovirus 1";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10530";"CHEMBL3559723";"Liver";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL1634559";"F";"Antiviral activity against MAV-1 infected in immunocompromized BALB/c mouse assessed as decrease in viral DNA load in liver at 100 mg/kg, ip treated 8 days before infection measured after 28 days post infection by RT-PCR";"Murine adenovirus 1";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10530";"CHEMBL3559723";"Liver";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL1964062";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DMS 273 Small Cell Lung cell line. (Class of assay: confirmatory) ";"";"13726";"13816";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"DMS-273";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL868096";"T";"Toxicity in ip dosed mouse";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1138959";"16682187";"10.1016/j.bmcl.2006.04.049";"2006";"Bioorg Med Chem Lett";"16";"3727";"3730";"";"";"";"";"";""
"CHEMBL1909185";"B";"DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP)";"";"871";"1742";"BAO_0000219";"cell-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"DrugMatrix";"32644";"";"";"U-937";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909203";"B";"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"Insect cells";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909183";"B";"DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu)";"Mus musculus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"ICR";"DrugMatrix";"10090";"CHEMBL3638188";"Brain";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909124";"B";"DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909136";"B";"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"BTI-TN-5B1-4";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909121";"B";"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3638188";"Brain";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909098";"B";"DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat))";"Cavia porcellus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Dunkin-Hartley";"DrugMatrix";"10141";"CHEMBL3638251";"Adrenal gland";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909199";"B";"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)";"Escherichia coli";"871";"1742";"BAO_0000357";"single protein format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"562";"";"";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909109";"B";"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HEK293";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909127";"B";"DRUGMATRIX: Chemokine CXCR1 (IL-8A)";"";"871";"1742";"BAO_0000357";"single protein format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909135";"B";"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"BTI-TN-5B1-4";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909141";"B";"DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909171";"B";"DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909208";"B";"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)";"Oryctolagus cuniculus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"New Zealand albino";"DrugMatrix";"9986";"CHEMBL3638205";"Urinary bladder";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909209";"B";"DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909101";"B";"DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon))";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"T47D";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1963889";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the LXFL 529 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ";"";"13980";"14071";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"LXFL 529";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1043588";"A";"Volume of distribution at steady state in human";"Homo sapiens";"300";"300";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1156824";"20070106";"10.1021/jm901371v";"2010";"J Med Chem";"53";"1098";"1108";"";"";"";"";"";""
"CHEMBL734248";"F";"In vivo activity against transplanted Panc-02 tumors of mice";"Mus musculus";"10";"10";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1134487";"11356111";"10.1021/jm0005149";"2001";"J Med Chem";"44";"1758";"1776";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL1963991";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ";"";"36454";"36745";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"HOP-92";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1613933";"B";"PUBCHEM_BIOASSAY: qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1484, AID504370, AID504374, AID504375]";"Homo sapiens";"7185";"7272";"BAO_0000224";"protein format";"5";"5 - Multiple direct protein targets may be assigned";"";"PubChem BioAssays";"9606";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL734253";"F";"In vivo activity against transplanted colon-51 tumors of mice";"Mus musculus";"10";"10";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1134487";"11356111";"10.1021/jm0005149";"2001";"J Med Chem";"44";"1758";"1776";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL1963990";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) ";"";"40970";"41313";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"UO-31";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL733134";"F";"Body weight change between days 0 and the day when the animal weight was the lowest";"Mus musculus";"3";"5";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1133719";"10780911";"10.1021/jm990514c";"2000";"J Med Chem";"43";"1541";"1549";"";"";"";"";"";""
"CHEMBL1963961";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line. (Class of assay: confirmatory) ";"";"39679";"40011";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"CCRF-CEM";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL726931";"F";"The compound was tested for the anticancer activity against Lewis lung carcinoma cells implanted in male C57BL mice at a dose of 100x1 mg/kg";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL1123176";"3701785";"10.1021/jm00155a022";"1986";"J Med Chem";"29";"716";"727";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models | Carcinoma Oncology Models | Neoplasm Oncology Models";"Carcinoma | Lewis Lung Carcinoma | Neoplasms";"";""
"CHEMBL634283";"P";"Partition coefficient (logD6.5)";"";"114";"115";"BAO_0000100";"small-molecule physicochemical format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"";"";"";"";"";"CHEMBL1133765";"10891117";"10.1021/jm0000564";"2000";"J Med Chem";"43";"2575";"2585";"";"";"";"";"";""
"CHEMBL729839";"F";"Weight change in mice bearing L1210 leukemia after administration of 25 mg compound";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1136807";"12570384";"10.1021/jm0203433";"2003";"J Med Chem";"46";"634";"637";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models";"General Leukemia | L1210 Experimental Leukemia";"";""
"CHEMBL722139";"F";"Effect of compound on life span of mice inoculated intravenously with lewis lung carcinoma at the dose of 75 mg/kg in experiment 3";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:75.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models | Carcinoma Oncology Models";"Carcinoma | Lewis Lung Carcinoma";"";""
"CHEMBL730730";"F";"Average body weight in grams on day 5 minus average body weight on day 1 at the dose of 75 mg/kg in experiment 3";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:75.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL730495";"F";"Median survival time (MST) of treated mice infected by P-388 leukemia, as percent of the MST of untreated controls when treated with a dose of 250 mg/Kg of compound";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1124137";"3373492";"10.1021/jm00401a028";"1988";"J Med Chem";"31";"1240";"1244";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models";"General Leukemia | P388 Experimental Leukemia";"";""
"CHEMBL722602";"F";"Number of survivors out of 10 mice after 60 days infected with lewis lung carcinoma at the dose of 300 mg/kg in experiment 3";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:300.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models | Carcinoma Oncology Models";"Carcinoma | Lewis Lung Carcinoma";"";""
"CHEMBL1948875";"F";"Immunostimulatory activity in Kunming mouse xenografted with human H22 cells assessed as change in spleen mass at 20 mg/kg, po qd for 10 days (Rvb = 6.61 +/- 1.84 mg/kg)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"Kunming";"Scientific Literature";"10090";"CHEMBL3559722";"Spleen";"H22";"";"CHEMBL1944612";"22196118";"10.1016/j.bmcl.2011.11.104";"2012";"Bioorg Med Chem Lett";"22";"1082";"1085";"";"";"";"";"";""
"CHEMBL700817";"F";"Concentration required to reduce the viability of L1210 cells by 50% after 1-h incubation at 37 degrees C";"Mus musculus";"16";"16";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL1125866";"1992116";"10.1021/jm00105a030";"1991";"J Med Chem";"34";"197";"203";"";"";"";"";"";""
"CHEMBL728803";"F";"Number of survivors out of 10 mice after 60 days infected with lewis lung carcinoma at the dose of 37 mg/kg in experiment 3";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:37.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models | Carcinoma Oncology Models";"Carcinoma | Lewis Lung Carcinoma";"";""
"CHEMBL722593";"F";"Number of survivors out of 10 mice after 60 days infected with lewis lung carcinoma at the dose of 150 mg/kg in experiment 3";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:150.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models | Carcinoma Oncology Models";"Carcinoma | Lewis Lung Carcinoma";"";""
"CHEMBL729565";"F";"In vivo antitumor activity measured in mice against the Mam16/C murine solid tumors.";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1131098";"9733489";"10.1021/jm9708083";"1998";"J Med Chem";"41";"3645";"3654";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL3063280";"F";"Cytotoxicity against Homo sapiens (human) T47D cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay";"Homo sapiens";"19";"19";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"T47D";"";"CHEMBL3045323";"None";"10.1007/s00044-011-9899-3";"2012";"Med Chem Res";"21";"3620";"3628";"";"";"";"";"";""
"CHEMBL880124";"F";"Number of survivors on day 60 at a dose of 200 mg/kg; 4/7";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123176";"3701785";"10.1021/jm00155a022";"1986";"J Med Chem";"29";"716";"727";"standard_type:DOSE standard_relation:= standard_value:200.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL797498";"F";"Antiinflammatory activity against D-adjuvant arthritis in injected rat paw at the dose of 25 mg/kg by oral administration";"Rattus norvegicus";"4";"4";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10116";"";"";"";"";"CHEMBL1125290";"1732553";"10.1021/jm00080a022";"1992";"J Med Chem";"35";"350";"361";"standard_type:DOSE standard_relation:= standard_value:25.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | MUSCULO-SKELETAL SYSTEM";"Methods for Testing Immunological Factors | Anti-Inflammatory Activity";"Adjuvant Arthritis in Rats | General Anti-Inflammatory Models";"";""
"CHEMBL733630";"F";"Tested in vivo for immunosuppressive activity in mouse using graft vs. Host rejection technique (GVHR); % suppression at a dose of 200 mg/kg";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1130359";"None";"10.1016/S0960-894X(97)10072-5";"1997";"Bioorg Med Chem Lett";"7";"2781";"2786";"standard_type:DOSE standard_relation:= standard_value:200.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors | Methods for Testing Immunological Factors";"Acute Graft Versus Host Disease GVHD in Rats | General Immunosuppressive Activity";"";""
"CHEMBL1963945";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line. (Class of assay: confirmatory) ";"";"26355";"26576";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"Hs-578T";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL728038";"F";"Percent reduction in spleen weight in mice as compared to infected untreated controls at 25 mg/kg";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"CHEMBL3559722";"Spleen";"";"";"CHEMBL1122410";"6644739";"10.1021/jm00366a010";"1983";"J Med Chem";"26";"1710";"1715";"standard_type:DOSE standard_relation:= standard_value:25.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL1963895";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line. (Class of assay: confirmatory) ";"";"39421";"39735";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"SK-OV-3";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL730722";"F";"Average body weight in grams on day 5 minus average body weight on day 1 at the dose of 37 mg/kg in experiment 3";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:37.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL717766";"F";"Average weight change on day 5 in mice infected by P-388 leukemia when treated with a dose of 125 mg/Kg of compound";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1124137";"3373492";"10.1021/jm00401a028";"1988";"J Med Chem";"31";"1240";"1244";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models";"General Leukemia | P388 Experimental Leukemia";"";""
"CHEMBL620511";"A";"Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group";"Mus musculus";"6";"6";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"CHEMBL3559721";"Plasma";"ADJ/PC6";"";"CHEMBL1121753";"7310816";"10.1021/jm00144a006";"1981";"J Med Chem";"24";"1399";"1403";"";"";"";"";"";""
"CHEMBL734017";"F";"Percent animals surviving 50 days from day 1; Administered alone and concurrently with the preceding compounds onday 1 at a dose of 100 mg/kg (in vivo)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121408";"7365745";"10.1021/jm00177a018";"1980";"J Med Chem";"23";"300";"304";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL635885";"A";"The half life at a pH 1.2";"";"1";"1";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"";"";"";"";"";"CHEMBL1127411";"7966159";"10.1021/jm00049a018";"1994";"J Med Chem";"37";"3986";"3993";"";"";"";"";"";""
"CHEMBL958103";"B";"Effect on DNA cleavage in ampicillin resistant Escherichia coli DH5alpha transformed pBluescript 2 KS+ DNA assessed as number of colonies at 10 mM after 15 hrs by transformation assay";"Escherichia coli";"1";"1";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"DH5alpha";"Scientific Literature";"562";"";"";"";"";"CHEMBL1150296";"18434165";"10.1016/j.bmc.2008.04.009";"2008";"Bioorg Med Chem";"16";"5441";"5451";"";"";"";"";"";""
"CHEMBL3788650";"A";"Apparent volume of distribution at steady state in iv dosed patient with normal renal function";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL1964099";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line. (Class of assay: confirmatory) ";"";"25166";"25375";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"BT-549";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3993836";"F";"Antitumor activity against human NCI-H522 cells xenografted in Balb/c nude mouse assessed as tumor growth inhibition at 50 mg/kg, ig administered once daily for 28 days relative to control";"Homo sapiens";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"NCI-H522";"";"CHEMBL3992535";"28092860";"10.1016/j.ejmech.2016.12.055";"2017";"Eur J Med Chem";"127";"442";"458";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL1964009";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line. (Class of assay: confirmatory) ";"";"36915";"37215";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"RXF 393";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1283850";"F";"Antibacterial activity against Pasteurella multocida pm0527 after 24 hrs by broth dilution method";"Pasteurella multocida";"24";"24";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"pm0527";"Scientific Literature";"747";"";"";"";"";"CHEMBL1275542";"18725450";"10.1128/aac.00245-08";"2008";"Antimicrob Agents Chemother";"52";"4166";"4171";"";"";"";"";"";""
"CHEMBL721653";"F";"Increase in life span of mice bearing L1210 leukemia after administration of 25 mg compound";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1136807";"12570384";"10.1021/jm0203433";"2003";"J Med Chem";"46";"634";"637";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models";"General Leukemia | L1210 Experimental Leukemia";"";""
"CHEMBL1285395";"F";"Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay";"Saccharomyces cerevisiae";"66";"66";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"AD1-8u";"Scientific Literature";"4932";"";"";"";"";"CHEMBL1275276";"20739103";"10.1016/j.ejmech.2010.07.050";"2010";"Eur J Med Chem";"45";"4813";"4826";"";"";"";"";"";""
"CHEMBL729566";"F";"In vivo antitumor activity measured in mice against the Panc 02 murine solid tumors.";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1131098";"9733489";"10.1021/jm9708083";"1998";"J Med Chem";"41";"3645";"3654";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL3992948";"T";"Toxicity in ICR mouse implanted with mouse H22-H8D8 cells assessed as body weight at 20 mg/kg, iv (Rvb = 29.89 to 33.78 g)";"Mus musculus";"5";"5";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"ICR";"Scientific Literature";"10090";"";"";"";"";"CHEMBL3992500";"27836197";"10.1016/j.ejmech.2016.10.068";"2017";"Eur J Med Chem";"127";"928";"943";"";"";"";"";"";""
"CHEMBL722143";"F";"Effect of compound on life span of mice inoculated intravenously with lewis lung carcinoma at the dose of 90 mg/kg in experiment 2";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:90.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models | Carcinoma Oncology Models";"Carcinoma | Lewis Lung Carcinoma";"";""
"CHEMBL1285393";"F";"Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay";"Saccharomyces cerevisiae";"66";"66";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"AD1-8u";"Scientific Literature";"4932";"";"";"";"";"CHEMBL1275276";"20739103";"10.1016/j.ejmech.2010.07.050";"2010";"Eur J Med Chem";"45";"4813";"4826";"";"";"";"";"";""
"CHEMBL1634563";"F";"Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as inhibition of production of protective antibodies at 100 mg/kg, ip treated 8 days before infection for 2 weeks measured after 62 days postinfection";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors";"General Immunosuppressive Activity";"";""
"CHEMBL1794345";"F";"PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850]";"Plasmodium falciparum";"170142";"170462";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"5833";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1964037";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line. (Class of assay: confirmatory) ";"";"40395";"40740";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"OVCAR-3";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1799635";"F";"Antitumor activity against mouse H22 cells xenografted in kunming mouse assessed as inhibition of tumor growth at 15 mg/kg, ip for 7 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL1795221";"21514015";"10.1016/j.ejmech.2011.03.050";"2011";"Eur J Med Chem";"46";"2652";"2661";"standard_type:DOSE standard_relation:= standard_value:15.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL3582837";"T";"Toxicity in KM mouse assessed as peripheral WBC number in blood per liter at 60 mg/kg, po single dose after 48 hrs (Rvb = 11.10 x 2.69/L x 10'-9)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"KM";"Scientific Literature";"10090";"CHEMBL3638178";"Blood";"";"";"CHEMBL3580594";"25905540";"10.1021/jm5012963";"2015";"J Med Chem";"58";"3693";"3703";"";"";"";"";"";""
"CHEMBL868090";"F";"Antitumor activity against S180 cells implanted in mouse at 30 mg/kg, ip";"Mus musculus";"15";"15";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"CCRF S-180";"";"CHEMBL1138959";"16682187";"10.1016/j.bmcl.2006.04.049";"2006";"Bioorg Med Chem Lett";"16";"3727";"3730";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL1043580";"A";"Fraction unbound in human plasma";"Homo sapiens";"276";"276";"BAO_0000366";"cell-free format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559721";"Plasma";"";"";"CHEMBL1156824";"20070106";"10.1021/jm901371v";"2010";"J Med Chem";"53";"1098";"1108";"";"";"";"";"";""
"CHEMBL1697798";"A";"FDA HLAED, alkaline phosphatase increase";"Homo sapiens";"486";"1470";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1697781";"16472241";"10.2174/1570163043334794";"2004";"Curr Drug Discov Technol";"1";"243";"254";"";"";"";"";"";""
"CHEMBL1909122";"B";"DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"Chem-1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909138";"B";"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"BTI-TN-5B1-4";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909170";"B";"DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909142";"B";"DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909119";"B";"DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HT-29";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909120";"B";"DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HEK293";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909105";"B";"DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1634565";"F";"Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as T cells suppression at 100 mg/kg, ip treated 8 days before infection for 4 weeks measured 14 days post infection by flow cytometry";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"T-cell";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors";"General Immunosuppressive Activity";"";""
"CHEMBL1614682";"A";"Volume of distribution at steady state in human after iv administration";"Homo sapiens";"103";"103";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1614629";"15920768";"10.1002/jps.20373";"2005";"J Pharm Sci";"94";"1467";"1483";"";"";"";"";"";""
"CHEMBL993349";"B";"Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy";"Homo sapiens";"185";"185";"BAO_0000219";"cell-based format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"HEK293";"";"CHEMBL1140113";"18788725";"10.1021/jm8003152";"2008";"J Med Chem";"51";"5932";"5942";"";"";"";"";"";""
"CHEMBL903031";"F";"Antitumor activity against LLC cells inoculated in C57BL/6J mouse assessed as lung weight at 100 mg/kg, ip administered alternatively for 12 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"CHEMBL3638235";"Lung";"Lewis lung carcinoma cell line";"";"CHEMBL1138358";"18052315";"10.1021/jm070639e";"2007";"J Med Chem";"50";"6700";"6705";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL724097";"F";"Tumor free mice out of 8 surviving to day 60 or beyond was determined";"Mus musculus";"2";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1122849";"4067995";"10.1021/jm00149a025";"1985";"J Med Chem";"28";"1685";"1691";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL1283852";"F";"Antibacterial activity against TolC deficient Pasteurella multocida pm1980 after 24 hrs by broth dilution method";"Pasteurella multocida";"24";"24";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"pm1980";"Scientific Literature";"747";"";"";"";"";"CHEMBL1275542";"18725450";"10.1128/aac.00245-08";"2008";"Antimicrob Agents Chemother";"52";"4166";"4171";"";"";"";"";"";""
"CHEMBL3137738";"T";"Comments (NB not yet translated). [column 'COMMENTAIRES' in source]";"Homo sapiens";"1214";"1216";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL3137736";"T";"Animal toxicity known. [column 'TOXIC' in source]";"Homo sapiens";"1214";"1216";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL1614240";"F";"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase). (Class of assay: confirmatory) ";"Homo sapiens";"5299";"5346";"BAO_0000019";"assay format";"9";"9 - Direct single protein target assigned";"";"PubChem BioAssays";"9606";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1043584";"A";"Oral bioavailability in human";"Homo sapiens";"308";"308";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1156824";"20070106";"10.1021/jm901371v";"2010";"J Med Chem";"53";"1098";"1108";"";"";"";"";"";""
"CHEMBL1043581";"A";"Total clearance in human";"Homo sapiens";"308";"308";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1156824";"20070106";"10.1021/jm901371v";"2010";"J Med Chem";"53";"1098";"1108";"";"";"";"";"";""
"CHEMBL1697778";"A";"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans";"Homo sapiens";"944";"951";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"";"CHEMBL1697731";"20014752";"10.1021/tx900326k";"2010";"Chem Res Toxicol";"23";"171";"183";"";"";"";"";"";""
"CHEMBL1007927";"F";"Antitumor activity against human MX1 cells xenografted in SCID mouse assessed as tumor volume at 12.5 mg/kg/day, ip after 34 days";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"MX1";"";"CHEMBL1139389";"19143569";"10.1021/jm801171j";"2009";"J Med Chem";"52";"514";"523";"standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL3788321";"A";"First order absorption rate constant in po dosed lymphoma patient (7 patients) by one compartment open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL1285394";"B";"Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u";"Candida albicans";"66";"66";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"5476";"";"";"";"";"CHEMBL1275276";"20739103";"10.1016/j.ejmech.2010.07.050";"2010";"Eur J Med Chem";"45";"4813";"4826";"";"";"";"";"";""
"CHEMBL1614211";"F";"PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1).   (Class of assay: confirmatory) ";"";"36499";"36798";"BAO_0000019";"assay format";"8";"8 - Homologous single protein target assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3137729";"T";"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]";"Homo sapiens";"1214";"1216";"BAO_0000221";"tissue-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL3137727";"T";"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]";"Homo sapiens";"1214";"1216";"BAO_0000221";"tissue-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL3788652";"A";"First order inter-compartment transfer rate constant from peripheral to central compartment in iv dosed patient (7 patients) with renal insufficiency";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL3137731";"T";"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]";"Homo sapiens";"1214";"1216";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL1738442";"F";"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404]";"Homo sapiens";"90360";"91293";"BAO_0000019";"assay format";"9";"9 - Direct single protein target assigned";"";"PubChem BioAssays";"9606";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3285886";"P";"Octanol-water partition coefficient, log P of the compound";"";"6";"6";"BAO_0000100";"small-molecule physicochemical format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"";"";"";"";"";"CHEMBL3272203";"722720";"10.1021/jm00209a011";"1978";"J Med Chem";"21";"1146";"1149";"";"";"";"";"";""
"CHEMBL1738610";"F";"PUBCHEM_BIOASSAY: qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962]";"Homo sapiens";"593";"594";"BAO_0000019";"assay format";"9";"9 - Direct single protein target assigned";"";"PubChem BioAssays";"9606";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909176";"B";"DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"KAN-TS";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909161";"B";"DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta)";"";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"DrugMatrix";"32644";"";"";"NIH3T3";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909151";"B";"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3559724";"Cerebral cortex";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1614678";"A";"Volume of distribution at steady state in dog after iv administration";"Canis lupus familiaris";"103";"103";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9615";"";"";"";"";"CHEMBL1614629";"15920768";"10.1002/jps.20373";"2005";"J Pharm Sci";"94";"1467";"1483";"";"";"";"";"";""
"CHEMBL4296190";"F";"Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570)";"Cryptococcus neoformans";"6133";"6235";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"ATCC 208821";"CO-ADD antimicrobial screening data";"5207";"";"";"";"";"CHEMBL4296181";"None";"10.6019/CHEMBL4296181";"None";"None";"None";"None";"None";"standard_type:ASSAY_TEST standard_relation:None standard_value:None standard_units:None comments:None | standard_type:DETECTION_METHOD standard_relation:None standard_value:None standard_units:None comments:None | standard_type:MEDIA standard_relation:None standard_value:None standard_units:None comments:None | standard_type:PLATE_TYPE standard_relation:None standard_value:None standard_units:None comments:None | standard_type:TIME standard_relation:= standard_value:18.0 standard_units:hr comments:None";"";"";"";"";""
"CHEMBL4296185";"F";"Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600)";"Escherichia coli";"4585";"4681";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"ATCC 25922";"CO-ADD antimicrobial screening data";"562";"";"";"";"";"CHEMBL4296181";"None";"10.6019/CHEMBL4296181";"None";"None";"None";"None";"None";"standard_type:ASSAY_TEST standard_relation:None standard_value:None standard_units:None comments:None | standard_type:DETECTION_METHOD standard_relation:None standard_value:None standard_units:None comments:None | standard_type:MEDIA standard_relation:None standard_value:None standard_units:None comments:None | standard_type:PLATE_TYPE standard_relation:None standard_value:None standard_units:None comments:None | standard_type:TIME standard_relation:= standard_value:18.0 standard_units:hr comments:None";"";"";"";"";""
"CHEMBL4296184";"F";"Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600)";"Staphylococcus aureus subsp. aureus";"4588";"4684";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"ATCC 43300";"CO-ADD antimicrobial screening data";"46170";"";"";"";"";"CHEMBL4296181";"None";"10.6019/CHEMBL4296181";"None";"None";"None";"None";"None";"standard_type:ASSAY_TEST standard_relation:None standard_value:None standard_units:None comments:None | standard_type:DETECTION_METHOD standard_relation:None standard_value:None standard_units:None comments:None | standard_type:MEDIA standard_relation:None standard_value:None standard_units:None comments:None | standard_type:PLATE_TYPE standard_relation:None standard_value:None standard_units:None comments:None | standard_type:TIME standard_relation:= standard_value:18.0 standard_units:hr comments:None";"";"";"";"";""
"CHEMBL1909108";"B";"DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HeLa";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909092";"B";"DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909172";"B";"DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909179";"B";"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)";"Escherichia coli";"871";"1742";"BAO_0000357";"single protein format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"562";"";"";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909198";"B";"DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"Sf9";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909102";"B";"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3638188";"Brain";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909154";"B";"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3559724";"Cerebral cortex";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1697802";"A";"FDA HLAED, gamma-glutamyl transferase (GGT) increase";"Homo sapiens";"486";"1470";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1697781";"16472241";"10.2174/1570163043334794";"2004";"Curr Drug Discov Technol";"1";"243";"254";"";"";"";"";"";""
"CHEMBL1909194";"B";"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)";"Homo sapiens";"871";"1742";"BAO_0000221";"tissue-based format";"9";"9 - Direct single protein target assigned";"";"DrugMatrix";"9606";"";"";"Neutrophil";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909117";"B";"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)";"";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"DrugMatrix";"32644";"";"";"U-937";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909096";"B";"DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909099";"B";"DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin)";"Bacillus cereus";"871";"1742";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"DrugMatrix";"1396";"";"";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3788651";"A";"Total body clearance in iv dosed patient with normal renal function";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL1909213";"B";"DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL740757";"F";"Number of mice that survived on day 60 at a dose of 120 mg/kg; 1/12";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123954";"3336021";"10.1021/jm00396a036";"1988";"J Med Chem";"31";"226";"230";"standard_type:DOSE standard_relation:= standard_value:120.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL1963918";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the P388/ADR Leukemia cell line. (Class of assay: confirmatory) ";"";"1001";"1008";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"P388/ADR";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3214990";"F";"PubChem BioAssay. qHTS profiling for inhibitors of Plasmodium falciparum (3D7) proliferation.   (Class of assay: confirmatory) ";"";"256";"262";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL802256";"F";"Percent decrease in the microsomal activation determined with pretreatment with phenobarbital.";"Rattus norvegicus";"4";"4";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10116";"";"";"";"";"CHEMBL1125916";"1995881";"10.1021/jm00106a018";"1991";"J Med Chem";"34";"588";"592";"";"";"";"";"";""
"CHEMBL729562";"F";"In vivo antitumor activity measured in mice against the Colon26/A murine solid tumors.";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1131098";"9733489";"10.1021/jm9708083";"1998";"J Med Chem";"41";"3645";"3654";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL3061800";"F";"Cytotoxicity against Homo sapiens (human) K562 cells after 48 hr by MTT assay";"Homo sapiens";"11";"11";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"K562";"";"CHEMBL3045968";"None";"10.1007/s00044-011-9737-7";"2012";"Med Chem Res";"21";"2185";"2195";"";"";"";"";"";""
"CHEMBL3063279";"F";"Cytotoxicity against Homo sapiens (human) HCT15 cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay";"Homo sapiens";"19";"19";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HCT-15";"";"CHEMBL3045323";"None";"10.1007/s00044-011-9899-3";"2012";"Med Chem Res";"21";"3620";"3628";"";"";"";"";"";""
"CHEMBL3063282";"F";"Cytotoxicity against Homo sapiens (human) NCI-H522 cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay";"Homo sapiens";"19";"19";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"NCI-H522";"";"CHEMBL3045323";"None";"10.1007/s00044-011-9899-3";"2012";"Med Chem Res";"21";"3620";"3628";"";"";"";"";"";""
"CHEMBL3232316";"F";"Cytotoxicity against rat Walker 256 cells assessed as growth inhibition in presence of microsomal activation";"Rattus norvegicus";"1";"1";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10116";"";"";"W256";"";"CHEMBL3227956";"423194";"10.1021/jm00188a006";"1979";"J Med Chem";"22";"151";"158";"";"";"";"";"";""
"CHEMBL802254";"F";"Percent decrease in the microsomal activation determined with no pretreatment";"Rattus norvegicus";"4";"4";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10116";"";"";"";"";"CHEMBL1125916";"1995881";"10.1021/jm00106a018";"1991";"J Med Chem";"34";"588";"592";"";"";"";"";"";""
"CHEMBL3070545";"F";"Cytotoxicity against Homo sapiens (human) PA1 cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay";"Homo sapiens";"24";"24";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"PA-1";"";"CHEMBL3044972";"None";"10.1007/s00044-012-0439-6";"2013";"Med Chem Res";"22";"4278";"4285";"";"";"";"";"";""
"CHEMBL1963976";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line. (Class of assay: confirmatory) ";"";"27593";"27827";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"MDA-N";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1964017";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory) ";"";"28020";"28262";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"DU-145";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1964066";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line. (Class of assay: confirmatory) ";"";"40373";"40696";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"TK-10";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL4029349";"T";"Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index";"Homo sapiens";"929";"929";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL4028802";"26948801";"10.1016/j.drudis.2016.02.015";"2016";"Drug Discov Today";"21";"648";"653";"";"";"";"";"";""
"CHEMBL793922";"F";"Evaluated for effect against passive cutaneous anaphylaxis in rats immunized with DNP-As and B. pertussis; PCA (log2)";"Rattus norvegicus";"14";"14";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10116";"";"";"";"";"CHEMBL1121993";"7154011";"10.1021/jm00354a021";"1982";"J Med Chem";"25";"1495";"1499";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors";"Passive Cutaneous Anaphylaxis";"";""
"CHEMBL3788307";"A";"Elimination half life in iv dosed lymphoma patient (6 patients) by two-compartmental open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL734247";"F";"In vivo activity against transplanted Mam-17/Adr tumors of mice";"Mus musculus";"9";"9";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1134487";"11356111";"10.1021/jm0005149";"2001";"J Med Chem";"44";"1758";"1776";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL1963953";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line. (Class of assay: confirmatory) ";"";"40772";"41108";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"786-0";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL877178";"F";"Compound was evaluated for immunological activity in mice as the percentage of suppression of the humoral response to EI4 tumor cells at 10 mg/kg, po";"Mus musculus";"22";"22";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121658";"7277388";"10.1021/jm00139a012";"1981";"J Med Chem";"24";"830";"834";"standard_type:DOSE standard_relation:= standard_value:10.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL726159";"F";"Compound was ested for antitumor activity against Lewis lung carcinoma cells implanted in male C57BL mice at a dose of 20 mg/kg";"Mus musculus";"1";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL1123176";"3701785";"10.1021/jm00155a022";"1986";"J Med Chem";"29";"716";"727";"standard_type:DOSE standard_relation:= standard_value:20.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models | Carcinoma Oncology Models | Neoplasm Oncology Models";"Carcinoma | Lewis Lung Carcinoma | Neoplasms";"";""
"CHEMBL633098";"A";"Oral bioavailability in human";"Homo sapiens";"184";"185";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1133765";"10891117";"10.1021/jm0000564";"2000";"J Med Chem";"43";"2575";"2585";"";"";"";"";"";""
"CHEMBL3992945";"F";"Antitumor activity against mouse H22-H8D8 cells implanted in ICR mouse assessed as tumor growth inhibition at 20 mg/kg, iv relative to control";"Mus musculus";"5";"5";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"10090";"";"";"H22-H8D8";"";"CHEMBL3992500";"27836197";"10.1016/j.ejmech.2016.10.068";"2017";"Eur J Med Chem";"127";"928";"943";"";"";"";"";"";""
"CHEMBL727529";"F";"Number of survivors on day 60 at a dose of 100 mg/kg; 0/7";"Mus musculus";"4";"5";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123176";"3701785";"10.1021/jm00155a022";"1986";"J Med Chem";"29";"716";"727";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL1043582";"A";"Hepatic clearance in human";"Homo sapiens";"308";"308";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"";"CHEMBL1156824";"20070106";"10.1021/jm901371v";"2010";"J Med Chem";"53";"1098";"1108";"";"";"";"";"";""
"CHEMBL2149357";"F";"Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 17";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL2146434";"22574992";"10.1021/jm300468t";"2012";"J Med Chem";"55";"5077";"5087";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL3257519";"F";"Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span at 200 mg/kg, ip administered 24 hrs relative to control";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"standard_type:DOSE standard_relation:= standard_value:200.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL726367";"F";"Antitumor activity in BDF1 male mice bearing L1210 Leukemia, at a dose of 250 mg/kg; survivors for 30 days was reported";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1133719";"10780911";"10.1021/jm990514c";"2000";"J Med Chem";"43";"1541";"1549";"standard_type:DOSE standard_relation:= standard_value:250.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models | Methods for Testing Immunological Factors | Neoplasm Oncology Models";"General Leukemia | L1210 Experimental Leukemia | Spontaneous Autoimmune Diseases In Animals | Neoplasms";"";""
"CHEMBL3257528";"F";"Antileukemic activity against mouse L1210 cells allografted in iv dosed BDF1 mouse assessed as maximum tolerated dose for survival over 60 days administered 24 hrs";"Mus musculus";"4";"4";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL3788922";"A";"Drug elimination in patient with normal renal function using 14C labeled compound measured over 72 hrs";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL3788273";"A";"Drug recovery in normal human urine";"Homo sapiens";"1";"1";"BAO_0000221";"tissue-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"CHEMBL3638201";"Urine";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL1697801";"A";"FDA HLAED, lactate dehydrogenase (LDH) increase";"Homo sapiens";"486";"1470";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1697781";"16472241";"10.2174/1570163043334794";"2004";"Curr Drug Discov Technol";"1";"243";"254";"";"";"";"";"";""
"CHEMBL3788644";"A";"Disposition rate constant in patient (7 patients) with renal insufficiency at 50 mg/kg, po";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL1043585";"A";"Fraction absorbed in human";"Homo sapiens";"308";"308";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1156824";"20070106";"10.1021/jm901371v";"2010";"J Med Chem";"53";"1098";"1108";"";"";"";"";"";""
"CHEMBL728964";"F";"Number of survivors out of 10 mice after 60 days infected with lewis lung carcinoma at the dose of 90 mg/kg in experiment 2";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:90.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models | Carcinoma Oncology Models";"Carcinoma | Lewis Lung Carcinoma";"";""
"CHEMBL1634556";"F";"Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as effect on parenchymal inflammation in liver at 100 mg/kg, ip treated 8 days before infection for 2 weeks by flow cytometry";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"CHEMBL3559723";"Liver";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | MUSCULO-SKELETAL SYSTEM";"Methods for Testing Immunological Factors | Anti-Inflammatory Activity";"General Immunosuppressive Activity | General Anti-Inflammatory Models";"";""
"CHEMBL878472";"F";"In vivo activity was measured against 3LL metastasis in BDF1 mice after ip administration at 300 mg/kg dose, dosing on days 3 after tumor challenge";"Mus sp.";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10095";"";"";"";"";"CHEMBL1125643";"2002471";"10.1021/jm00107a007";"1991";"J Med Chem";"34";"914";"918";"standard_type:DOSE standard_relation:= standard_value:300.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Metastatic Oncology Models | Methods for Testing Immunological Factors | Neoplasm Oncology Models";"Metastatic Activity | Spontaneous Autoimmune Diseases In Animals | Neoplasms";"";""
"CHEMBL1909307";"A";"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia";"";"888";"888";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"CHEMBL3559723";"Liver";"";"";"CHEMBL1909294";"22194678";"10.1371/journal.pcbi.1002310";"2011";"PLoS Comput Biol";"7";"1";"13";"";"";"";"";"";""
"CHEMBL1909315";"A";"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly";"";"888";"888";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"CHEMBL3559723";"Liver";"";"";"CHEMBL1909294";"22194678";"10.1371/journal.pcbi.1002310";"2011";"PLoS Comput Biol";"7";"1";"13";"";"";"";"";"";""
"CHEMBL737225";"F";"Percentage increase in life span of L1210 leukemia implanted mice at a dose of 150 mg/kg";"Mus musculus";"5";"5";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123954";"3336021";"10.1021/jm00396a036";"1988";"J Med Chem";"31";"226";"230";"standard_type:DOSE standard_relation:= standard_value:150.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models";"General Leukemia | L1210 Experimental Leukemia";"";""
"CHEMBL741650";"T";"Lethal dose to kill 50% of the mice after single ip injection to healthy female CD2F1 mice";"Mus musculus";"5";"5";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123954";"3336021";"10.1021/jm00396a036";"1988";"J Med Chem";"31";"226";"230";"";"";"";"";"";""
"CHEMBL648409";"F";"Compound was evaluated for the antineoplastic activity on B16 Melanoma cells at the optimal dose of 70 mg/kg through intraperitoneal route on days 1,5,9";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"B16";"";"CHEMBL1122849";"4067995";"10.1021/jm00149a025";"1985";"J Med Chem";"28";"1685";"1691";"standard_type:DOSE standard_relation:= standard_value:70.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Melanoma Oncology Models | Melanoma Oncology Models | Neoplasm Oncology Models";"Experimental Melanoma | General Melanoma | Neoplasms";"";""
"CHEMBL3252590";"F";"Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as minimum effective dose administered as single dose";"Mus musculus";"6";"6";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"P388";"";"CHEMBL3244336";"490545";"10.1021/jm00195a002";"1979";"J Med Chem";"22";"1024";"1030";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Neoplasm Oncology Models";"P388 Experimental Leukemia | Neoplasms";"";""
"CHEMBL3253040";"T";"Toxicity in mouse P388 cells allografted ip dosed mouse assessed as maximum tolerated dose administered as single dose";"Mus musculus";"6";"6";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"P388";"";"CHEMBL3244336";"490545";"10.1021/jm00195a002";"1979";"J Med Chem";"22";"1024";"1030";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models";"P388 Experimental Leukemia";"";""
"CHEMBL1633750";"F";"Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as viral-induced mortality rate at 100 mg/kg, ip treated 8 days before infection for 3 weeks";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors";"General Immunosuppressive Activity";"";""
"CHEMBL868091";"F";"Antitumor activity against H22 cells implanted in mouse at 30 mg/kg, ip";"Mus musculus";"13";"13";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL1138959";"16682187";"10.1016/j.bmcl.2006.04.049";"2006";"Bioorg Med Chem Lett";"16";"3727";"3730";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL1964047";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line. (Class of assay: confirmatory) ";"";"41644";"41993";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"U-251";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL726342";"F";"Hematological effects in female CDF1 mice at the dose of 30 mg, in platelet cells";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1133719";"10780911";"10.1021/jm990514c";"2000";"J Med Chem";"43";"1541";"1549";"";"";"";"";"";""
"CHEMBL1964059";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line. (Class of assay: confirmatory) ";"";"41127";"41477";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"SNB-19";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL740759";"F";"Number of mice that survived on day 60 at a dose of 150 mg/kg; 1/19";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123954";"3336021";"10.1021/jm00396a036";"1988";"J Med Chem";"31";"226";"230";"standard_type:DOSE standard_relation:= standard_value:150.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL1283851";"F";"Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm0527";"Pasteurella multocida";"24";"24";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"747";"";"";"";"";"CHEMBL1275542";"18725450";"10.1128/aac.00245-08";"2008";"Antimicrob Agents Chemother";"52";"4166";"4171";"";"";"";"";"";""
"CHEMBL1283853";"F";"Antibacterial activity against Pasteurella multocida pm1980 after 24 hrs by broth dilution method";"Pasteurella multocida";"24";"24";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"pm1980";"Scientific Literature";"747";"";"";"";"";"CHEMBL1275542";"18725450";"10.1128/aac.00245-08";"2008";"Antimicrob Agents Chemother";"52";"4166";"4171";"";"";"";"";"";""
"CHEMBL3232311";"T";"Toxicity in mouse allografted with mouse ADJ/PC6 cells";"Mus musculus";"7";"7";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"ADJ/PC6";"";"CHEMBL3227956";"423194";"10.1021/jm00188a006";"1979";"J Med Chem";"22";"151";"158";"";"";"";"";"";""
"CHEMBL1963860";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line. (Class of assay: confirmatory) ";"";"37184";"37494";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"HCC 2998";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1634558";"F";"Antiviral activity against MAV-1 infected in immunocompromized BALB/c mouse assessed as effect on viral DNA load in liver at 100 mg/kg, ip treated 8 days before infection for 4 weeks by RT-PCR";"Murine adenovirus 1";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10530";"CHEMBL3559723";"Liver";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL1909134";"B";"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"BTI-TN-5B1-4";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909086";"B";"DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"9";"9 - Direct single protein target assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3559723";"Liver";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909118";"B";"DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HUVEC";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1614673";"A";"Mean residence time in human after iv administration";"Homo sapiens";"667";"669";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1614632";"18426954";"10.1124/dmd.108.020479";"2008";"Drug Metab Dispos";"36";"1385";"1405";"";"";"";"";"";""
"CHEMBL1614674";"A";"Half life in human after iv administration";"Homo sapiens";"667";"669";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1614632";"18426954";"10.1124/dmd.108.020479";"2008";"Drug Metab Dispos";"36";"1385";"1405";"";"";"";"";"";""
"CHEMBL1614681";"A";"Clearance in human after iv administration";"Homo sapiens";"103";"103";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1614629";"15920768";"10.1002/jps.20373";"2005";"J Pharm Sci";"94";"1467";"1483";"";"";"";"";"";""
"CHEMBL1909190";"B";"DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HEK293";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909158";"B";"DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA)";"Escherichia coli";"871";"1742";"BAO_0000357";"single protein format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"562";"";"";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909114";"B";"DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909174";"B";"DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909196";"B";"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)";"Homo sapiens";"871";"1742";"BAO_0000221";"tissue-based format";"9";"9 - Direct single protein target assigned";"";"DrugMatrix";"9606";"";"Rheumatoid synovial fibroblasts";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909090";"B";"DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"Sf9";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1963885";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line. (Class of assay: confirmatory) ";"";"28139";"28384";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"PC-3";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909128";"B";"DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL2071972";"A";"Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH";"Homo sapiens";"221";"221";"BAO_0000251";"microsome format";"2";"2 - Target assigned is subcellular fraction";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"Microsome";"CHEMBL2069259";"22931300";"10.1021/tx300075j";"2012";"Chem Res Toxicol";"25";"2067";"2082";"";"";"";"";"";""
"CHEMBL1035434";"A";"Renal clearance in human";"Homo sapiens";"390";"390";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3638241";"Kidney";"";"";"CHEMBL1151930";"19445515";"10.1021/jm900403j";"2009";"J Med Chem";"52";"4844";"4852";"";"";"";"";"";""
"CHEMBL4029770";"T";"Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as hematocrit at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 39.9 +/- 3.7 %)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4028815";"28342398";"10.1016/j.ejmech.2017.03.028";"2017";"Eur J Med Chem";"132";"63";"80";"";"";"";"";"";""
"CHEMBL954890";"F";"Antitumor activity in human U87 MG cells xenografted mouse at 80 mg/kg, iv administered in Q2D x 5 schedule";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"U-87MG ATCC";"";"CHEMBL1150326";"18450456";"10.1016/j.bmc.2008.04.024";"2008";"Bioorg Med Chem";"16";"5413";"5423";"standard_type:DOSE standard_relation:= standard_value:80.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL3582845";"T";"Toxicity in KM mouse assessed as peripheral WBC number in blood per liter at 30 mg/kg/day, po 5 doses (Rvb = 7.47 +/- 33.77 /L x 10'-9 cells)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"KM";"Scientific Literature";"10090";"CHEMBL3638178";"Blood";"";"";"CHEMBL3580594";"25905540";"10.1021/jm5012963";"2015";"J Med Chem";"58";"3693";"3703";"";"";"";"";"";""
"CHEMBL1743267";"A";"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP2B6";"Homo sapiens";"8";"8";"BAO_0000019";"assay format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1743201";"None";"None";"2008";"None";"None";"161";"304";"";"";"";"";"";""
"CHEMBL1964087";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line. (Class of assay: confirmatory) ";"";"40248";"40590";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"NCI-H322M";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL2076240";"F";"TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells";"";"14";"14";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"TP-search Transporter Database";"";"";"";"NIH-3T3-G185";"";"CHEMBL2073899";"11743742";"10.1021/tx010125x";"2001";"Chem Res Toxicol";"14";"1596";"1603";"";"";"";"";"";""
"CHEMBL4028921";"A";"Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay";"Homo sapiens";"629";"629";"BAO_0000219";"cell-based format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL4028801";"23956101";"10.1093/toxsci/kft176";"2013";"Toxicol Sci";"136";"216";"241";"";"";"";"";"";""
"CHEMBL1964007";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line. (Class of assay: confirmatory) ";"";"40987";"41343";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"SK-MEL-28";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL843490";"F";"Antiinflammatory activity dosed orally against D-adjuvant arthritis in rat.";"Rattus norvegicus";"4";"5";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10116";"";"";"";"";"CHEMBL1125290";"1732553";"10.1021/jm00080a022";"1992";"J Med Chem";"35";"350";"361";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | MUSCULO-SKELETAL SYSTEM";"Methods for Testing Immunological Factors | Anti-Inflammatory Activity";"Adjuvant Arthritis in Rats | General Anti-Inflammatory Models";"";""
"CHEMBL1964015";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12K1 Renal cell line. (Class of assay: confirmatory) ";"";"1040";"1047";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"SN12K1";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1633753";"T";"Toxicity in BALB/c mouse assessed as effect on survival rate at 100 mg/kg, ip after 2 to 4 weeks";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL1964006";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line. (Class of assay: confirmatory) ";"";"41564";"41913";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"HT-29";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL725498";"F";"Number of mice bearing L1210 leukemia that survived after 30 days, after administration of 25 mg compound";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1136807";"12570384";"10.1021/jm0203433";"2003";"J Med Chem";"46";"634";"637";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models";"General Leukemia | L1210 Experimental Leukemia";"";""
"CHEMBL727527";"F";"Number of survivors on day 60 at a dose of 100 x 1 mg/kg; 0/7";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123176";"3701785";"10.1021/jm00155a022";"1986";"J Med Chem";"29";"716";"727";"standard_type:DOSE standard_relation:= standard_value:1.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL708204";"T";"Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after ip administration at 400 mg/kg dose days 3 after tumor challenge";"Mus sp.";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10095";"";"";"";"";"CHEMBL1125643";"2002471";"10.1021/jm00107a007";"1991";"J Med Chem";"34";"914";"918";"standard_type:DOSE standard_relation:= standard_value:400.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors | Neoplasm Oncology Models";"Spontaneous Autoimmune Diseases In Animals | Neoplasms";"";""
"CHEMBL1964049";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line. (Class of assay: confirmatory) ";"";"40562";"40898";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"OVCAR-5";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1964021";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) ";"";"40703";"41045";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"SK-MEL-5";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL728440";"F";"Antitumor activity in mice bearing L1210 Leukemia, at a dose of 30 mg/kg at 50 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1133719";"10780911";"10.1021/jm990514c";"2000";"J Med Chem";"43";"1541";"1549";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models | Neoplasm Oncology Models";"General Leukemia | L1210 Experimental Leukemia | Neoplasms";"";""
"CHEMBL701072";"F";"In vivo antitumor activity against intraperitoneal murine wild type L1210 Leukemia cells at 680 umol/kg";"Mus musculus";"4";"4";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL1125770";"1920355";"10.1021/jm00114a013";"1991";"J Med Chem";"34";"3044";"3052";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models | Neoplasm Oncology Models";"General Leukemia | L1210 Experimental Leukemia | Neoplasms";"";""
"CHEMBL797575";"F";"Antiinflammatory activity against D-adjuvant arthritis in uninjected rat paw at the dose of 25 mg/kg by oral administration";"Rattus norvegicus";"4";"4";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10116";"";"";"";"";"CHEMBL1125290";"1732553";"10.1021/jm00080a022";"1992";"J Med Chem";"35";"350";"361";"standard_type:DOSE standard_relation:= standard_value:25.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | MUSCULO-SKELETAL SYSTEM";"Methods for Testing Immunological Factors | Anti-Inflammatory Activity";"Adjuvant Arthritis in Rats | General Anti-Inflammatory Models";"";""
"CHEMBL700916";"F";"In vivo antitumor activity against intraperitoneal murine wild type L1210 Leukemia cells at 340 umol/kg";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL1125770";"1920355";"10.1021/jm00114a013";"1991";"J Med Chem";"34";"3044";"3052";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models | Neoplasm Oncology Models";"General Leukemia | L1210 Experimental Leukemia | Neoplasms";"";""
"CHEMBL2071969";"A";"Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis";"Homo sapiens";"32";"32";"BAO_0000251";"microsome format";"2";"2 - Target assigned is subcellular fraction";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"Microsome";"CHEMBL2069259";"22931300";"10.1021/tx300075j";"2012";"Chem Res Toxicol";"25";"2067";"2082";"";"";"";"";"";""
"CHEMBL1963935";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the RXF-631 Renal cell line. (Class of assay: confirmatory) ";"";"11325";"11391";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"RXF 631";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1963929";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line. (Class of assay: confirmatory) ";"";"41263";"41617";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"IGROV-1";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL727530";"F";"Number of survivors on day 60 at a dose of 100 mg/kg; 4/7";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123176";"3701785";"10.1021/jm00155a022";"1986";"J Med Chem";"29";"716";"727";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL1963901";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ";"";"40342";"40685";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"NCI-H460";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1963911";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line. (Class of assay: confirmatory) ";"";"38809";"39125";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"CAKI-1";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL946963";"F";"Effect on body weight in mouse bearing H22 cells at 30 mg/kg/day, ip after 10 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL1142371";"18226907";"10.1016/j.bmc.2007.11.048";"2008";"Bioorg Med Chem";"16";"2550";"2557";"standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL903542";"F";"Antitumor activity in H22 cells xenografted ICR mouse assessed as tumor weight at 30 mg/kg, iv after 4 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL1139134";"17275295";"10.1016/j.bmcl.2006.09.096";"2007";"Bioorg Med Chem Lett";"17";"1475";"1478";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL700917";"F";"In vivo antitumor activity against intraperitoneal murine wild type L1210 Leukemia cells at 510 umol/kg";"Mus musculus";"5";"5";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL1125770";"1920355";"10.1021/jm00114a013";"1991";"J Med Chem";"34";"3044";"3052";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models | Neoplasm Oncology Models";"General Leukemia | L1210 Experimental Leukemia | Neoplasms";"";""
"CHEMBL1963954";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SNB-78 Central Nervous System cell line. (Class of assay: confirmatory) ";"";"13960";"14049";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"SNB-78";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL723593";"F";"Effect of compound on life span of mice inoculated intravenously with lewis lung carcinoma at the dose of 150 mg/kg in experiment 3";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:150.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models | Carcinoma Oncology Models";"Carcinoma | Lewis Lung Carcinoma";"";""
"CHEMBL722131";"F";"Effect of compound on life span of mice inoculated intravenously with lewis lung carcinoma at the dose of 37 mg/kg in experiment 3";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:37.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models | Carcinoma Oncology Models";"Carcinoma | Lewis Lung Carcinoma";"";""
"CHEMBL730349";"F";"Antitumor activity in BDF1 male mice bearing L1210 Leukemia, at a dose of 125 mg/kg; survivors for 30 days was reported";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1133719";"10780911";"10.1021/jm990514c";"2000";"J Med Chem";"43";"1541";"1549";"standard_type:DOSE standard_relation:= standard_value:125.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models | Methods for Testing Immunological Factors | Neoplasm Oncology Models";"General Leukemia | L1210 Experimental Leukemia | Spontaneous Autoimmune Diseases In Animals | Neoplasms";"";""
"CHEMBL850451";"A";"Therapeutic index as the ratio of LD50 to ED50 of the compound";"";"5";"5";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"";"";"";"";"";"CHEMBL1121753";"7310816";"10.1021/jm00144a006";"1981";"J Med Chem";"24";"1399";"1403";"";"";"";"";"";""
"CHEMBL1035433";"A";"Total body clearance in human";"Homo sapiens";"390";"390";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1151930";"19445515";"10.1021/jm900403j";"2009";"J Med Chem";"52";"4844";"4852";"";"";"";"";"";""
"CHEMBL1697797";"A";"FDA HLAED, liver enzyme composite activity";"Homo sapiens";"486";"1470";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"";"CHEMBL1697781";"16472241";"10.2174/1570163043334794";"2004";"Curr Drug Discov Technol";"1";"243";"254";"";"";"";"";"";""
"CHEMBL1697780";"A";"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents";"";"944";"951";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"CHEMBL3559723";"Liver";"";"";"CHEMBL1697731";"20014752";"10.1021/tx900326k";"2010";"Chem Res Toxicol";"23";"171";"183";"";"";"";"";"";""
"CHEMBL1007928";"F";"Antitumor activity against human MX1 cells xenografted in SCID mouse assessed as growth inhibition at 12.5 mg/kg/day, ip after 34 days relative to control";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"MX1";"";"CHEMBL1139389";"19143569";"10.1021/jm801171j";"2009";"J Med Chem";"52";"514";"523";"standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL4315143";"F";"Induction of apoptosis in human MV4-11 cells harboring FLT3 ITD mutant assessed as increase in caspase 3/7 activity incubated for 24 hrs by caspase glo 3/7 assay";"Homo sapiens";"4";"4";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"MV4-11";"";"CHEMBL4311995";"31614258";"10.1016/j.ejmech.2019.111710";"2019";"Eur J Med Chem";"184";"111710";"111710";"";"";"";"";"";""
"CHEMBL965582";"B";"Inhibition of bovine brain MAOA";"Bos taurus";"92";"92";"BAO_0000019";"assay format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9913";"";"";"";"";"CHEMBL1152129";"18834112";"10.1021/jm800656v";"2008";"J Med Chem";"51";"6740";"6751";"";"";"";"";"";""
"CHEMBL3999443";"F";"Antitumor activity against human MCF7 cells xenografted in Balb/c nude mouse assessed as tumor growth inhibition at 20 mg/kg/day, iv for 4 weeks relative to control";"Homo sapiens";"4";"4";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"MCF7";"";"CHEMBL3997810";"28165738";"10.1021/acs.jmedchem.6b01652";"2017";"J Med Chem";"60";"1449";"1468";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL648665";"F";"Compound was evaluated for the antineoplastic activity on B16 Melanoma cells at the optimal dose of 120 mg/kg through intraperitoneal route on days 1,5,9";"Mus musculus";"7";"8";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"B16";"";"CHEMBL1122849";"4067995";"10.1021/jm00149a025";"1985";"J Med Chem";"28";"1685";"1691";"standard_type:DOSE standard_relation:= standard_value:120.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Melanoma Oncology Models | Melanoma Oncology Models | Neoplasm Oncology Models";"Experimental Melanoma | General Melanoma | Neoplasms";"";""
"CHEMBL1043583";"A";"Renal clearance in human";"Homo sapiens";"308";"308";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3638241";"Kidney";"";"";"CHEMBL1156824";"20070106";"10.1021/jm901371v";"2010";"J Med Chem";"53";"1098";"1108";"";"";"";"";"";""
"CHEMBL1909087";"B";"DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HEK293";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909160";"B";"DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"9";"9 - Direct single protein target assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3559723";"Liver";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909180";"B";"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HEK293";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909100";"B";"DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"Chem-1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909106";"B";"DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630)";"";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"DrugMatrix";"32644";"";"";"HEK293";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909200";"B";"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)";"Escherichia coli";"871";"1742";"BAO_0000357";"single protein format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"562";"";"";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909104";"B";"DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909197";"B";"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909201";"B";"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)";"Escherichia coli";"871";"1742";"BAO_0000357";"single protein format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"562";"";"";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1614679";"A";"Clearance in monkey after iv administration";"Macaca";"103";"103";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9539";"";"";"";"";"CHEMBL1614629";"15920768";"10.1002/jps.20373";"2005";"J Pharm Sci";"94";"1467";"1483";"";"";"";"";"";""
"CHEMBL1614675";"A";"Clearance in rat after iv administration";"Rattus norvegicus";"103";"103";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"10116";"";"";"";"";"CHEMBL1614629";"15920768";"10.1002/jps.20373";"2005";"J Pharm Sci";"94";"1467";"1483";"";"";"";"";"";""
"CHEMBL1614671";"A";"Clearance in human after iv administration";"Homo sapiens";"667";"669";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1614632";"18426954";"10.1124/dmd.108.020479";"2008";"Drug Metab Dispos";"36";"1385";"1405";"";"";"";"";"";""
"CHEMBL1614677";"A";"Clearance in dog after iv administration";"Canis lupus familiaris";"103";"103";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9615";"";"";"";"";"CHEMBL1614629";"15920768";"10.1002/jps.20373";"2005";"J Pharm Sci";"94";"1467";"1483";"";"";"";"";"";""
"CHEMBL1909210";"B";"DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"9";"9 - Direct single protein target assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3559724";"Cerebral cortex";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1646603";"F";"Anticancer activity against human U87MG cells xenografted in athymic mouse assessed as tumor suppression at 80 mg/kg, iv Q2D for 6 days";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"U-87MG ATCC";"";"CHEMBL1641520";"21106377";"10.1016/j.bmc.2010.11.005";"2011";"Bioorg Med Chem";"19";"471";"485";"standard_type:DOSE standard_relation:= standard_value:80.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL1909202";"B";"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)";"Escherichia coli";"871";"1742";"BAO_0000357";"single protein format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"562";"";"";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909150";"B";"DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HeLa S3";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909152";"B";"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3638188";"Brain";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3301365";"A";"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.";"Homo sapiens";"1614";"1614";"BAO_0000366";"cell-free format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"AstraZeneca Deposited Data";"9606";"CHEMBL3559721";"Plasma";"";"";"CHEMBL3301361";"None";"10.6019/CHEMBL3301361";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3215154";"F";"PubChem BioAssay. Cell Proliferation Assay Versus the ED40515 IL2 Independent  ATL cell lines.   (Class of assay: confirmatory) ";"";"198";"198";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL726366";"F";"Antitumor activity in BDF1 male mice bearing L1210 Leukemia, at a dose of 188 mg/kg; survivors for 30 days was reported";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1133719";"10780911";"10.1021/jm990514c";"2000";"J Med Chem";"43";"1541";"1549";"standard_type:DOSE standard_relation:= standard_value:188.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models | Methods for Testing Immunological Factors | Neoplasm Oncology Models";"General Leukemia | L1210 Experimental Leukemia | Spontaneous Autoimmune Diseases In Animals | Neoplasms";"";""
"CHEMBL3214913";"B";"PubChem BioAssay. qHTS for Inhibitors of binding or entry into cells for Marburg Virus.   (Class of assay: confirmatory) ";"";"4591";"5133";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3252927";"F";"Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as mean survival time at 400 mg/kg, ip administered 24 hrs (Rvb 4.6 +/- 0.16 days)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"standard_type:DOSE standard_relation:= standard_value:400.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL1633749";"F";"Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as viral-induced mortality rate at 100 mg/kg, ip treated 8 days before infection for 2 weeks";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors";"General Immunosuppressive Activity";"";""
"CHEMBL1909314";"A";"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis";"";"888";"888";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"CHEMBL3559723";"Liver";"";"";"CHEMBL1909294";"22194678";"10.1371/journal.pcbi.1002310";"2011";"PLoS Comput Biol";"7";"1";"13";"";"";"";"";"";""
"CHEMBL726234";"F";"Hematological effects in female CDF1 mice at the dose of 30 mg, in white blood cells";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1133719";"10780911";"10.1021/jm990514c";"2000";"J Med Chem";"43";"1541";"1549";"";"";"";"";"";""
"CHEMBL738289";"T";"Lethal dose was evaluated after single intraperitoneal injection in mice";"Mus musculus";"4";"4";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1127411";"7966159";"10.1021/jm00049a018";"1994";"J Med Chem";"37";"3986";"3993";"";"";"";"";"";""
"CHEMBL721384";"F";"Increased life span against L1210 lymphoid leukemia cells in male BDF1 mice at a dose of 100x1 mg/kg";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL1123176";"3701785";"10.1021/jm00155a022";"1986";"J Med Chem";"29";"716";"727";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL723422";"F";"Hematological effects in female CDF1 mice at the dose of 30 mg, in red blood cells cells";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1133719";"10780911";"10.1021/jm990514c";"2000";"J Med Chem";"43";"1541";"1549";"";"";"";"";"";""
"CHEMBL1964030";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line. (Class of assay: confirmatory) ";"";"40735";"41067";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"K562";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL651603";"F";"In vitro cytotoxicity in BALB/c3T3 mouse embryo fibroblasts.";"Mus musculus";"5";"5";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1125916";"1995881";"10.1021/jm00106a018";"1991";"J Med Chem";"34";"588";"592";"";"";"";"";"";""
"CHEMBL1963960";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line. (Class of assay: confirmatory) ";"";"41287";"41632";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"UACC-257";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL2114777";"F";"PubChem BioAssay. Cell Proliferation Assay against a hMSC Cell Line. (Class of assay: confirmatory) ";"";"271";"272";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL802253";"F";"Alkylating activity determined by incubating with rat hepatic microsomes and time dependent release of alkylating species with phenobarbital pretreatment; Activity expressed as uM of mechlorethamine equiv/g of liver/h";"Rattus norvegicus";"4";"5";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10116";"CHEMBL3559723";"Liver";"";"Microsomes";"CHEMBL1125916";"1995881";"10.1021/jm00106a018";"1991";"J Med Chem";"34";"588";"592";"";"";"";"";"";""
"CHEMBL2071963";"A";"Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins";"Homo sapiens";"221";"221";"BAO_0000357";"single protein format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL2069259";"22931300";"10.1021/tx300075j";"2012";"Chem Res Toxicol";"25";"2067";"2082";"";"";"";"";"";""
"CHEMBL3788327";"A";"Drug metabolism in iv dosed lymphoma patient (6 patients) assessed as dose normalised AUC for plasma alkylating activity";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559721";"Plasma";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3070108";"F";"Cytotoxicity against Homo sapiens (human) COLO320 cells at 156 ug/mL by MTT assay";"Homo sapiens";"1";"1";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"COLO 320";"";"CHEMBL3045925";"None";"10.1007/s00044-012-0393-3";"2013";"Med Chem Res";"22";"3823";"3830";"";"";"";"";"";""
"CHEMBL1909204";"B";"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"Insect cells";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909147";"B";"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3638188";"Brain";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909144";"B";"DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL721387";"F";"Increased life span against L1210 lymphoid leukemia cells in male BDF1 mice at a dose of 200 mg/kg";"Mus musculus";"4";"4";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL1123176";"3701785";"10.1021/jm00155a022";"1986";"J Med Chem";"29";"716";"727";"standard_type:DOSE standard_relation:= standard_value:200.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL1274285";"F";"Cytotoxicity against human Hep2 cells by MTT assay";"Homo sapiens";"9";"9";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HEp-2";"";"CHEMBL1268823";"20850303";"10.1016/j.bmcl.2010.06.001";"2010";"Bioorg Med Chem Lett";"20";"6324";"6326";"";"";"";"";"";""
"CHEMBL1963985";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ";"";"41631";"41977";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"NCI-H23";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL4479083";"A";"Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NADPH measured after 24 hrs in absence of compound, CYP3A4 and NADPH by cell titer-glo luminescence assay relative to BSO alone";"Homo sapiens";"88";"88";"BAO_0000219";"cell-based format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL4477225";"27397500";"10.1016/j.bmcl.2016.06.088";"2016";"Bioorg Med Chem Lett";"26";"4003";"4006";"";"";"";"";"";""
"CHEMBL795510";"F";"Evaluated for effect against passive hemagglutinination in rats immunized with DNP-As and B. pertussis; PHA(log2)";"Rattus norvegicus";"8";"8";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10116";"";"";"";"";"CHEMBL1121993";"7154011";"10.1021/jm00354a021";"1982";"J Med Chem";"25";"1495";"1499";"";"";"";"";"";""
"CHEMBL1283854";"F";"Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm1980";"Pasteurella multocida";"24";"24";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"747";"";"";"";"";"CHEMBL1275542";"18725450";"10.1128/aac.00245-08";"2008";"Antimicrob Agents Chemother";"52";"4166";"4171";"";"";"";"";"";""
"CHEMBL1283849";"F";"Antibacterial activity against TolC deficient Pasteurella multocida pm0527 after 24 hrs by broth dilution method";"Pasteurella multocida";"24";"24";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"pm0527";"Scientific Literature";"747";"";"";"";"";"CHEMBL1275542";"18725450";"10.1128/aac.00245-08";"2008";"Antimicrob Agents Chemother";"52";"4166";"4171";"";"";"";"";"";""
"CHEMBL954892";"T";"Toxicity against human U87 MG cells xenografted mouse assessed as body weight loss at 80 mg/kg, iv administered in Q2D x 5 schedule";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"U-87MG ATCC";"";"CHEMBL1150326";"18450456";"10.1016/j.bmc.2008.04.024";"2008";"Bioorg Med Chem";"16";"5413";"5423";"standard_type:DOSE standard_relation:= standard_value:80.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL1633751";"F";"Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as viral-induced mortality rate at 100 mg/kg, ip treated 8 days before infection for 4 weeks";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors";"General Immunosuppressive Activity";"";""
"CHEMBL1634560";"F";"Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as enhancement of cidofovir-induced antiviral activity at 100 mg/kg, ip cyclophosphamide treated 8 days before infection for 2 to 4 weeks";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors";"General Immunosuppressive Activity";"";""
"CHEMBL737842";"F";"Number of mice that survived on day 60 at a dose of 200 mg/kg; 8/12";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123954";"3336021";"10.1021/jm00396a036";"1988";"J Med Chem";"31";"226";"230";"standard_type:DOSE standard_relation:= standard_value:200.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL2071967";"A";"Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins";"Homo sapiens";"221";"221";"BAO_0000357";"single protein format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL2069259";"22931300";"10.1021/tx300075j";"2012";"Chem Res Toxicol";"25";"2067";"2082";"";"";"";"";"";""
"CHEMBL2114890";"F";"PubChem BioAssay. qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway. (Class of assay: confirmatory) ";"Homo sapiens";"1142";"1339";"BAO_0000019";"assay format";"9";"9 - Direct single protein target assigned";"";"PubChem BioAssays";"9606";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1963844";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line. (Class of assay: confirmatory) ";"";"38877";"39199";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"SK-MEL-2";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1964091";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line. (Class of assay: confirmatory) ";"";"39577";"39897";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"OVCAR-4";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3854307";"T";"Toxicity in nude mouse xenografted with human HepG2 cells assessed as body weight change at 20 mg/kg, ip administered every day for 15 times measured from day 12 to 26";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"HepG2";"";"CHEMBL3853295";"27162123";"10.1016/j.ejmech.2016.04.068";"2016";"Eur J Med Chem";"119";"183";"196";"";"";"";"";"";""
"CHEMBL1964095";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the P388 Leukemia cell line. (Class of assay: confirmatory) ";"";"1024";"1031";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"P388";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL4348178";"A";"Mutagenic index, ratio of cyclophosphamide effect to hydroxyethylcellulose effect for Swiss albino mouse assessed as frequency of micronucleated reticulocytes per 2000 cells at 50 mg/kg, ip";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"Swiss";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4346679";"30913526";"10.1016/j.ejmech.2019.03.032";"2019";"Eur J Med Chem";"171";"116";"128";"";"";"";"";"";""
"CHEMBL1964048";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line. (Class of assay: confirmatory) ";"";"41865";"42213";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"OVCAR-8";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1964043";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ";"";"40357";"40693";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"HOP-62";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1963887";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DMS 114 Small Cell Lung cell line. (Class of assay: confirmatory) ";"";"14897";"14993";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"DMS-114";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1963882";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line. (Class of assay: confirmatory) ";"";"28394";"28635";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"MCF7";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1963868";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line. (Class of assay: confirmatory) ";"";"41234";"41579";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"HCT-15";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL716274";"F";"In vivo activity was measured against 3LL metastasis in BDF1 mice after ip administration at 400 mg/kg dose, dosing on days 3 after tumor challenge";"Mus sp.";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10095";"";"";"";"";"CHEMBL1125643";"2002471";"10.1021/jm00107a007";"1991";"J Med Chem";"34";"914";"918";"standard_type:DOSE standard_relation:= standard_value:400.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Metastatic Oncology Models | Methods for Testing Immunological Factors | Neoplasm Oncology Models";"Metastatic Activity | Spontaneous Autoimmune Diseases In Animals | Neoplasms";"";""
"CHEMBL1964072";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line. (Class of assay: confirmatory) ";"";"41891";"42241";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"SW-620";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1963994";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) ";"";"37749";"38068";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"HL-60";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL734743";"F";"Percentage increase in life span of L1210 leukemia implanted mice at a dose of 400 mg/kg";"Mus musculus";"5";"5";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123954";"3336021";"10.1021/jm00396a036";"1988";"J Med Chem";"31";"226";"230";"standard_type:DOSE standard_relation:= standard_value:400.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models";"General Leukemia | L1210 Experimental Leukemia";"";""
"CHEMBL745966";"F";"Tested in vivo for immunosuppressive activity in mouse using graft vs. Host rejection technique (GVHR); weight change at a dose of 200 mg/kg";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1130359";"None";"10.1016/S0960-894X(97)10072-5";"1997";"Bioorg Med Chem Lett";"7";"2781";"2786";"standard_type:DOSE standard_relation:= standard_value:200.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors | Methods for Testing Immunological Factors";"Acute Graft Versus Host Disease GVHD in Rats | General Immunosuppressive Activity";"";""
"CHEMBL1963876";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line. (Class of assay: confirmatory) ";"";"41148";"41498";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"SF-268";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1963866";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line. (Class of assay: confirmatory) ";"";"38557";"38887";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"SNB-75";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1963880";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line. (Class of assay: confirmatory) ";"";"40605";"40938";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"EKVX ";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1781339";"F";"Antitumor activity against mouse H22 tumor-nearing ICR mouse assessed as inhibition of tumor growth at 10 mg/kg, ip for 7 days measured on day 9";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL1777774";"21515048";"10.1016/j.bmcl.2011.03.108";"2011";"Bioorg Med Chem Lett";"21";"3427";"3430";"standard_type:DOSE standard_relation:= standard_value:10.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL1964075";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ";"";"37652";"37966";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"NCI-H522";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL904664";"F";"Antitumor activity against S180 cells inoculated in ICR mouse assessed as tumor weight at 50 mg/kg, ip after 8 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"CCRF S-180";"";"CHEMBL1142889";"17137679";"10.1016/j.ejmech.2006.10.004";"2007";"Eur J Med Chem";"42";"226";"234";"standard_type:DOSE standard_relation:= standard_value:50.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL2150145";"F";"Anticancer activity against mouse H22 cells allografted in Kunming mouse at 30 mg/kg, ip for 7 days measured after 7 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL2146364";"22901410";"10.1016/j.ejmech.2012.07.047";"2012";"Eur J Med Chem";"56";"308";"319";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL2150754";"F";"Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 24";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL2146434";"22574992";"10.1021/jm300468t";"2012";"J Med Chem";"55";"5077";"5087";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL734243";"F";"In vivo activity against transplanted Mam-16/C tumors of mice";"Mus musculus";"11";"11";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1134487";"11356111";"10.1021/jm0005149";"2001";"J Med Chem";"44";"1758";"1776";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL859316";"F";"In vivo activity against transplanted Mel-B16 tumors of mice";"Mus musculus";"10";"10";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1134487";"11356111";"10.1021/jm0005149";"2001";"J Med Chem";"44";"1758";"1776";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL1909116";"B";"DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2)";"Homo sapiens";"871";"1742";"BAO_0000221";"tissue-based format";"9";"9 - Direct single protein target assigned";"";"DrugMatrix";"9606";"";"";"Platelet";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909140";"B";"DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL2154618";"T";"Genotoxicity in human lymphocytes assessed as micronucleated binucleate cells level at 12.5 ug/mL incubated for 3 hrs measured post 21 hrs recovery in presence of rat liver S9 fraction (Rvb = 0.40%)";"Homo sapiens";"1";"1";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"Lymphocyte";"Liver S9 fraction";"CHEMBL2150875";"21353728";"10.1016/j.ejmech.2011.01.071";"2011";"Eur J Med Chem";"46";"1524";"1535";"";"";"";"";"";""
"CHEMBL2154753";"T";"Genotoxicity in human lymphocytes assessed as micronucleated binucleate cells level at 12.5 ug/mL incubated for 3 hrs measured post 45 hrs recovery in presence of rat liver S9 fraction (Rvb = 0.0%)";"Homo sapiens";"1";"1";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"Lymphocyte";"Liver S9 fraction";"CHEMBL2150875";"21353728";"10.1016/j.ejmech.2011.01.071";"2011";"Eur J Med Chem";"46";"1524";"1535";"";"";"";"";"";""
"CHEMBL1909207";"B";"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)";"Escherichia coli";"871";"1742";"BAO_0000357";"single protein format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"562";"";"";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909189";"B";"DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide)";"";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"DrugMatrix";"32644";"";"";"HIT-T15";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3788324";"A";"Drug excretion in lymphoma patient (7 patients) assessed as unchanged parent compound in urine relative to control";"Homo sapiens";"1";"1";"BAO_0000221";"tissue-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"CHEMBL3638201";"Urine";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL904666";"F";"Antitumor activity against S180 cells inoculated in ICR mouse assessed as inhibition at 50 mg/kg, ip after 8 days relative to control";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"CCRF S-180";"";"CHEMBL1142889";"17137679";"10.1016/j.ejmech.2006.10.004";"2007";"Eur J Med Chem";"42";"226";"234";"standard_type:DOSE standard_relation:= standard_value:50.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL734405";"F";"Effective dose that causes 50% increase in life span of mice";"Mus musculus";"5";"5";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123954";"3336021";"10.1021/jm00396a036";"1988";"J Med Chem";"31";"226";"230";"";"";"";"";"";""
"CHEMBL728599";"F";"Average body weight in grams on day 5 minus average body weight on day 1 at the dose of 120 mg/kg in experiment 2";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:120.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL730733";"F";"Average body weight in grams on day 5 minus average body weight on day 1 at the dose of 90 mg/kg in experiment 2";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:90.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL1794424";"F";"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771]";"";"30566";"30997";"BAO_0000019";"assay format";"8";"8 - Homologous single protein target assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL658551";"F";"Effect on collateral sensitivity of CHRC5 cells to local anesthetics/steroids.";"Cricetulus griseus";"6";"6";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10029";"";"";"CHRC5 cell line";"";"CHEMBL1124835";"2362268";"10.1021/jm00169a014";"1990";"J Med Chem";"33";"1914";"1919";"";"";"";"";"";""
"CHEMBL1007929";"F";"Antitumor activity against human MX1 cells xenografted in SCID mouse assessed as tumor volume at 12.5 mg/kg/day, ip after 48 days";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"MX1";"";"CHEMBL1139389";"19143569";"10.1021/jm801171j";"2009";"J Med Chem";"52";"514";"523";"standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL3788261";"A";"Drug excretion in urine of patient (6 patients) with severe renal insufficiency at 1.1 +/- 0.2 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000221";"tissue-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"CHEMBL3638201";"Urine";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL1274286";"F";"Cytotoxicity against human HL60 cells by MTT assay";"Homo sapiens";"9";"9";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HL-60";"";"CHEMBL1268823";"20850303";"10.1016/j.bmcl.2010.06.001";"2010";"Bioorg Med Chem Lett";"20";"6324";"6326";"";"";"";"";"";""
"CHEMBL1763515";"F";"Antitumor activity against mouse H22 cells xenografted in Kunming mouse assessed as tumor growth inhibition rate at 20 mg/kg, po administered for 10 days relative to control";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL1759888";"21316818";"10.1016/j.ejmech.2011.01.036";"2011";"Eur J Med Chem";"46";"1172";"1180";"standard_type:DOSE standard_relation:= standard_value:20.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL1697730";"A";"Human drug-induced liver injury (DILI) modelling dataset from Ekins et al";"Homo sapiens";"529";"532";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"";"CHEMBL1697723";"20843939";"10.1124/dmd.110.035113";"2010";"Drug Metab Dispos";"38";"2302";"2308";"";"";"";"";"";""
"CHEMBL1909091";"B";"DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1697799";"A";"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase";"Homo sapiens";"486";"1470";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1697781";"16472241";"10.2174/1570163043334794";"2004";"Curr Drug Discov Technol";"1";"243";"254";"";"";"";"";"";""
"CHEMBL1909187";"B";"DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF)";"Homo sapiens";"871";"1742";"BAO_0000221";"tissue-based format";"9";"9 - Direct single protein target assigned";"";"DrugMatrix";"9606";"";"";"Platelet";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909103";"B";"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3559724";"Cerebral cortex";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909123";"B";"DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA))";"Homo sapiens";"871";"1742";"BAO_0000221";"tissue-based format";"9";"9 - Direct single protein target assigned";"";"DrugMatrix";"9606";"";"";"Erythrocyte";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL734252";"F";"In vivo activity against transplanted colon-38 tumors of mice";"Mus musculus";"11";"11";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1134487";"11356111";"10.1021/jm0005149";"2001";"J Med Chem";"44";"1758";"1776";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL1909157";"B";"DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909167";"B";"DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HEK293";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909175";"B";"DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"SK-N-MC";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL729383";"F";"In vivo activity against iv transplanted AML Leukemia 1498 tumors of mice";"Mus musculus";"6";"6";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1134487";"11356111";"10.1021/jm0005149";"2001";"J Med Chem";"44";"1758";"1776";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Neoplasm Oncology Models";"General Leukemia | Neoplasms";"";""
"CHEMBL903543";"F";"Antitumor activity in H22 cells xenografted ICR mouse assessed as tumor growth inhibition at 30 mg/kg, iv after 4 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL1139134";"17275295";"10.1016/j.bmcl.2006.09.096";"2007";"Bioorg Med Chem Lett";"17";"1475";"1478";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL1274287";"F";"Cytotoxicity against human HEK293T cells by MTT assay";"Homo sapiens";"9";"9";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HEK-293T";"";"CHEMBL1268823";"20850303";"10.1016/j.bmcl.2010.06.001";"2010";"Bioorg Med Chem Lett";"20";"6324";"6326";"";"";"";"";"";""
"CHEMBL721972";"F";"In vivo activity against transplanted Mam-16/C/ Taxol tumors of mice; Not active";"Mus musculus";"7";"7";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1134487";"11356111";"10.1021/jm0005149";"2001";"J Med Chem";"44";"1758";"1776";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL734249";"F";"In vivo activity against transplanted Panc-03 tumors of mice";"Mus musculus";"10";"10";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1134487";"11356111";"10.1021/jm0005149";"2001";"J Med Chem";"44";"1758";"1776";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL721383";"F";"Increased life span against L1210 lymphoid leukemia cells in male BDF1 mice at a dose of 100 mg/kg";"Mus musculus";"5";"9";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL1123176";"3701785";"10.1021/jm00155a022";"1986";"J Med Chem";"29";"716";"727";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL633649";"A";"Delta logD (logD6.5 - logD7.4)";"";"111";"112";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"";"";"";"";"";"CHEMBL1133765";"10891117";"10.1021/jm0000564";"2000";"J Med Chem";"43";"2575";"2585";"";"";"";"";"";""
"CHEMBL717564";"T";"Drug related lethality is percent animals in treated groups dying prior to first tumor related death in untreated groups measured in BDF1 mice after ip administration at 300 mg/kg dose days 3 after tumor challenge";"Mus sp.";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10095";"";"";"";"";"CHEMBL1125643";"2002471";"10.1021/jm00107a007";"1991";"J Med Chem";"34";"914";"918";"standard_type:DOSE standard_relation:= standard_value:300.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors | Neoplasm Oncology Models";"Spontaneous Autoimmune Diseases In Animals | Neoplasms";"";""
"CHEMBL721923";"F";"Antitumor activity was tested in mice and percent increase of life span at a dose of 125 ug/kg was reported";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1133719";"10780911";"10.1021/jm990514c";"2000";"J Med Chem";"43";"1541";"1549";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL4029350";"T";"Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status";"Homo sapiens";"929";"929";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL4028802";"26948801";"10.1016/j.drudis.2016.02.015";"2016";"Drug Discov Today";"21";"648";"653";"";"";"";"";"";""
"CHEMBL874960";"P";"Ionization constant (pKa)";"";"42";"43";"BAO_0000100";"small-molecule physicochemical format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"";"";"";"";"";"CHEMBL1133765";"10891117";"10.1021/jm0000564";"2000";"J Med Chem";"43";"2575";"2585";"";"";"";"";"";""
"CHEMBL1613808";"F";"PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay. (Class of assay: confirmatory) ";"Homo sapiens";"7224";"7260";"BAO_0000019";"assay format";"9";"9 - Direct single protein target assigned";"";"PubChem BioAssays";"9606";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1634562";"F";"Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as inhibition of production of protective antibodies at 100 mg/kg, ip treated 8 days before infection for 3 weeks measured after 62 days postinfection";"Mus musculus";"1";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors";"General Immunosuppressive Activity";"";""
"CHEMBL1909310";"A";"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis";"";"888";"888";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"CHEMBL3559723";"Liver";"";"";"CHEMBL1909294";"22194678";"10.1371/journal.pcbi.1002310";"2011";"PLoS Comput Biol";"7";"1";"13";"";"";"";"";"";""
"CHEMBL1909316";"A";"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice";"";"888";"888";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"CHEMBL3559723";"Liver";"";"";"CHEMBL1909294";"22194678";"10.1371/journal.pcbi.1002310";"2011";"PLoS Comput Biol";"7";"1";"13";"";"";"";"";"";""
"CHEMBL1909320";"A";"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score";"";"888";"888";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"CHEMBL3559723";"Liver";"";"";"CHEMBL1909294";"22194678";"10.1371/journal.pcbi.1002310";"2011";"PLoS Comput Biol";"7";"1";"13";"";"";"";"";"";""
"CHEMBL1909311";"A";"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests";"";"888";"888";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"CHEMBL3559723";"Liver";"";"";"CHEMBL1909294";"22194678";"10.1371/journal.pcbi.1002310";"2011";"PLoS Comput Biol";"7";"1";"13";"";"";"";"";"";""
"CHEMBL1909313";"A";"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis";"";"888";"888";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"CHEMBL3559723";"Liver";"";"";"CHEMBL1909294";"22194678";"10.1371/journal.pcbi.1002310";"2011";"PLoS Comput Biol";"7";"1";"13";"";"";"";"";"";""
"CHEMBL4028922";"A";"Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay";"Homo sapiens";"598";"598";"BAO_0000219";"cell-based format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL4028801";"23956101";"10.1093/toxsci/kft176";"2013";"Toxicol Sci";"136";"216";"241";"";"";"";"";"";""
"CHEMBL4028923";"A";"Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay";"Homo sapiens";"629";"629";"BAO_0000219";"cell-based format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL4028801";"23956101";"10.1093/toxsci/kft176";"2013";"Toxicol Sci";"136";"216";"241";"";"";"";"";"";""
"CHEMBL628290";"P";"Calculated membrane partition coefficient (Kmemb)";"";"75";"76";"BAO_0000100";"small-molecule physicochemical format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"";"";"";"";"";"CHEMBL1149124";"15027870";"10.1021/jm0309001";"2004";"J Med Chem";"47";"1783";"1788";"";"";"";"";"";""
"CHEMBL1909319";"A";"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal";"";"888";"888";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"CHEMBL3559723";"Liver";"";"";"CHEMBL1909294";"22194678";"10.1371/journal.pcbi.1002310";"2011";"PLoS Comput Biol";"7";"1";"13";"";"";"";"";"";""
"CHEMBL3232313";"A";"Therapeutic index, ratio of LD50 for mouse allografted with mouse ADJ/PC6 cells to ED90 for mouse ADJ/PC6 cells allografted in mouse";"Mus musculus";"7";"7";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"10090";"";"";"ADJ/PC6";"";"CHEMBL3227956";"423194";"10.1021/jm00188a006";"1979";"J Med Chem";"22";"151";"158";"";"";"";"";"";""
"CHEMBL721668";"F";"Percent increase in life span of mice bearing L1210 ascites cells compared to control; Administered alone and concurrently with the preceding compounds onday 1 at a dose of 100 mg/kg (in vivo)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL1121408";"7365745";"10.1021/jm00177a018";"1980";"J Med Chem";"23";"300";"304";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL1108963";"P";"Octanol-water partition coefficient, log P of the compound";"";"55";"55";"BAO_0000100";"small-molecule physicochemical format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"";"";"";"";"";"CHEMBL1157036";"20106561";"10.1016/j.ejmech.2009.12.043";"2010";"Eur J Med Chem";"45";"1639";"1647";"";"";"";"";"";""
"CHEMBL3788638";"A";"Apparent volume of distribution in beta-phase in iv dosed patient (7 patients) with renal insufficiency";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL1104816";"F";"Antitumor activity against mouse S180 cells xenografted in ICR mouse assessed as reduction of tumor weight at 100 mg/kg, ig administered 2 days after tumor inoculation qd for 7 days";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"CCRF S-180";"";"CHEMBL1157124";"20403695";"10.1016/j.bmcl.2010.03.112";"2010";"Bioorg Med Chem Lett";"20";"3078";"3083";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL1948800";"F";"Antitumor activity against human H22 cells xenografted in Kunming mouse assessed as reduction in tumor volume at 20 mg/kg, po qd for 10 days";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"H22";"";"CHEMBL1944612";"22196118";"10.1016/j.bmcl.2011.11.104";"2012";"Bioorg Med Chem Lett";"22";"1082";"1085";"standard_type:DOSE standard_relation:= standard_value:20.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL1964086";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the XF 498 Central Nervous System cell line. (Class of assay: confirmatory) ";"";"12281";"12354";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"XF498";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1964077";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line. (Class of assay: confirmatory) ";"";"41347";"41698";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"KM12";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL700915";"F";"In vivo antitumor activity against intraperitoneal murine wild type L1210 Leukemia cells at 170 umol/kg";"Mus musculus";"4";"4";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL1125770";"1920355";"10.1021/jm00114a013";"1991";"J Med Chem";"34";"3044";"3052";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models | Neoplasm Oncology Models";"General Leukemia | L1210 Experimental Leukemia | Neoplasms";"";""
"CHEMBL1104818";"F";"Antitumor activity against mouse S180 cells xenografted in ICR mouse assessed as inhibition of tumor weight at 100 mg/kg, ig administered 2 days after tumor inoculation qd for 7 days relative to control";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"CCRF S-180";"";"CHEMBL1157124";"20403695";"10.1016/j.bmcl.2010.03.112";"2010";"Bioorg Med Chem Lett";"20";"3078";"3083";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL1964092";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line. (Class of assay: confirmatory) ";"";"38953";"39286";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"LOX IMVI ";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL726930";"F";"The compound was tested for the anticancer activity against Lewis lung carcinoma cells implanted in male BALB/c mice at a dose of 100x1 mg/kg";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL1123176";"3701785";"10.1021/jm00155a022";"1986";"J Med Chem";"29";"716";"727";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models | Carcinoma Oncology Models | Neoplasm Oncology Models";"Carcinoma | Lewis Lung Carcinoma | Neoplasms";"";""
"CHEMBL734242";"F";"In vivo activity against iv transplanted Leukemia L1210 tumors of mice";"Mus musculus";"10";"10";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1134487";"11356111";"10.1021/jm0005149";"2001";"J Med Chem";"44";"1758";"1776";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Neoplasm Oncology Models";"General Leukemia | Neoplasms";"";""
"CHEMBL1963848";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the KM20L2 Colon cell line. (Class of assay: confirmatory) ";"";"14290";"14389";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"KM-20L2";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3562088";"F";"PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel.   (Class of assay: confirmatory) ";"";"570";"570";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3562112";"F";"PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel.   (Class of assay: confirmatory) ";"";"556";"556";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL655141";"F";"Antitumor activity against C26 implants through intraperitoneal route along with the optimal dose of 125 mg/kg through intraperitoneal injection on 1,4 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Colon 26";"";"CHEMBL1122849";"4067995";"10.1021/jm00149a025";"1985";"J Med Chem";"28";"1685";"1691";"standard_type:DOSE standard_relation:= standard_value:125.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL3562133";"F";"PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel.   (Class of assay: confirmatory) ";"";"570";"570";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3257529";"F";"Antileukemic activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as maximum tolerated dose for survival over 60 days administered 24 hrs";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL3253042";"F";"Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as dose providing 40% increase in life span administered as single dose";"Mus musculus";"6";"6";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"P388";"";"CHEMBL3244336";"490545";"10.1021/jm00195a002";"1979";"J Med Chem";"22";"1024";"1030";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Neoplasm Oncology Models";"P388 Experimental Leukemia | Neoplasms";"";""
"CHEMBL734251";"F";"In vivo activity against transplanted colon-26 tumors of mice";"Mus musculus";"9";"9";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1134487";"11356111";"10.1021/jm0005149";"2001";"J Med Chem";"44";"1758";"1776";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL1806104";"F";"Antitumor activity against human MX1 cells xenografted in nude mouse adjuvant model assessed as increase in mouse survival time at 120 mg/kg, po BID measured up to 3 weeks";"Homo sapiens";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"MX1";"";"CHEMBL1800055";"20726512";"10.1021/jm100669j";"2010";"J Med Chem";"53";"6653";"6680";"standard_type:DOSE standard_relation:= standard_value:120.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL1909133";"B";"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"BTI-TN-5B1-4";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1614052";"F";"PUBCHEM_BIOASSAY: qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction. (Class of assay: confirmatory) ";"Homo sapiens";"14862";"14887";"BAO_0000019";"assay format";"9";"9 - Direct single protein target assigned";"";"PubChem BioAssays";"9606";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909085";"B";"DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"9";"9 - Direct single protein target assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3987361";"Submaxillary gland";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1614680";"A";"Volume of distribution at steady state in monkey after iv administration";"Macaca";"103";"103";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9539";"";"";"";"";"CHEMBL1614629";"15920768";"10.1002/jps.20373";"2005";"J Pharm Sci";"94";"1467";"1483";"";"";"";"";"";""
"CHEMBL1909205";"B";"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"Insect cells";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL965580";"B";"Inhibition of mouse brain MAOB";"Mus musculus";"241";"244";"BAO_0000019";"assay format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1152129";"18834112";"10.1021/jm800656v";"2008";"J Med Chem";"51";"6740";"6751";"";"";"";"";"";""
"CHEMBL965579";"B";"Inhibition of mouse liver MAOB";"Mus musculus";"23";"23";"BAO_0000019";"assay format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1152129";"18834112";"10.1021/jm800656v";"2008";"J Med Chem";"51";"6740";"6751";"";"";"";"";"";""
"CHEMBL1909186";"B";"DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP)";"Homo sapiens";"871";"1742";"BAO_0000221";"tissue-based format";"9";"9 - Direct single protein target assigned";"";"DrugMatrix";"9606";"";"";"Platelet";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3788306";"A";"First order rate constant for slow elimination phase in iv dosed lymphoma patient (6 patients) by two-compartmental open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL1909318";"A";"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty";"";"888";"888";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"CHEMBL3559723";"Liver";"";"";"CHEMBL1909294";"22194678";"10.1371/journal.pcbi.1002310";"2011";"PLoS Comput Biol";"7";"1";"13";"";"";"";"";"";""
"CHEMBL1909312";"A";"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure";"";"888";"888";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"CHEMBL3559723";"Liver";"";"";"CHEMBL1909294";"22194678";"10.1371/journal.pcbi.1002310";"2011";"PLoS Comput Biol";"7";"1";"13";"";"";"";"";"";""
"CHEMBL1909317";"A";"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease";"";"888";"888";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"CHEMBL3559723";"Liver";"";"";"CHEMBL1909294";"22194678";"10.1371/journal.pcbi.1002310";"2011";"PLoS Comput Biol";"7";"1";"13";"";"";"";"";"";""
"CHEMBL1909308";"A";"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis";"";"888";"888";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"CHEMBL3559723";"Liver";"";"";"CHEMBL1909294";"22194678";"10.1371/journal.pcbi.1002310";"2011";"PLoS Comput Biol";"7";"1";"13";"";"";"";"";"";""
"CHEMBL1909309";"A";"Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis";"";"888";"888";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"CHEMBL3559723";"Liver";"";"";"CHEMBL1909294";"22194678";"10.1371/journal.pcbi.1002310";"2011";"PLoS Comput Biol";"7";"1";"13";"";"";"";"";"";""
"CHEMBL4734029";"F";"Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs";"Homo sapiens";"35";"35";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"MDA-MB-231";"";"CHEMBL4732084";"33139111";"10.1016/j.ejmech.2020.112948";"2021";"Eur J Med Chem";"210";"112948";"112948";"";"";"";"";"";""
"CHEMBL737846";"F";"Number of mice that survived on day 60 at a dose of 300 mg/kg; 16/18";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123954";"3336021";"10.1021/jm00396a036";"1988";"J Med Chem";"31";"226";"230";"standard_type:DOSE standard_relation:= standard_value:300.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL3788909";"A";"First order inter-compartment transfer rate constant from peripheral to central compartment in iv dosed patient with normal renal function";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL1697800";"A";"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase";"Homo sapiens";"486";"1470";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1697781";"16472241";"10.2174/1570163043334794";"2004";"Curr Drug Discov Technol";"1";"243";"254";"";"";"";"";"";""
"CHEMBL3788916";"A";"Plasma alkylating activity in patient with normal renal function assessed as AUC for total NBP alkylating activity at 300 mg/kg by NBP based colorimetric assay";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL4713491";"F";"Antitumor activity against human Lewis lung cancer cells xenografted in BALB/c mouse assessed as tumor weight at 20 mg/kg, ig administered every day for 10 days (Rvb = 1.68 +/- 0.78 g)";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL4706663";"33450619";"10.1016/j.ejmech.2020.113142";"2021";"Eur J Med Chem";"212";"113142";"113142";"";"";"";"";"";""
"CHEMBL1963854";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line. (Class of assay: confirmatory) ";"";"41955";"42298";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"A549";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL4029762";"T";"Hepatotoxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as liver weight at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 1.2 +/- 0.13 g)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"CHEMBL3559723";"Liver";"";"";"CHEMBL4028815";"28342398";"10.1016/j.ejmech.2017.03.028";"2017";"Eur J Med Chem";"132";"63";"80";"";"ALIMENTARY TRACT AND METABOLISM";"Liver Function";"General Models of Hepatotoxic and Hepatoprotective Activity";"";""
"CHEMBL1964025";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) ";"";"38812";"39141";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"Malme-3M";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909193";"B";"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)";"Escherichia coli";"871";"1742";"BAO_0000357";"single protein format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"562";"";"";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909173";"B";"DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909182";"B";"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909107";"B";"DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808)";"Cavia porcellus";"871";"1742";"BAO_0000249";"cell membrane format";"9";"9 - Direct single protein target assigned";"Dunkin-Hartley";"DrugMatrix";"10141";"CHEMBL3638255";"Striatum";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909084";"B";"DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine)";"Cavia porcellus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Dunkin-Hartley";"DrugMatrix";"10141";"CHEMBL3559724";"Cerebral cortex";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909088";"B";"DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"Sf9";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909115";"B";"DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone)";"Escherichia coli";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"562";"";"";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909126";"B";"DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HEK293";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909146";"B";"DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"Sf9";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909164";"B";"DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO-K1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909110";"B";"DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"Jurkat";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909113";"B";"DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"CHO";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909094";"B";"DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"MDCK";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909149";"B";"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3559724";"Cerebral cortex";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909292";"T";"FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI";"";"85";"85";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"";"CHEMBL3559723";"Liver";"";"";"CHEMBL1909281";"21624500";"10.1016/j.drudis.2011.05.007";"2011";"Drug Discov Today";"16";"697";"703";"";"";"";"";"";""
"CHEMBL1614672";"A";"Fraction unbound in human after iv administration";"Homo sapiens";"554";"554";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1614632";"18426954";"10.1124/dmd.108.020479";"2008";"Drug Metab Dispos";"36";"1385";"1405";"";"";"";"";"";""
"CHEMBL4029768";"T";"Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as RBC level at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 8.6 +/- 0.9 10'6/uL)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4028815";"28342398";"10.1016/j.ejmech.2017.03.028";"2017";"Eur J Med Chem";"132";"63";"80";"";"";"";"";"";""
"CHEMBL1964088";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line. (Class of assay: confirmatory) ";"";"38535";"38847";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"RPMI-8226";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL700914";"F";"In vivo antitumor activity against intraperitoneal murine cyclophosphamide resistant L1210 Leukemia cells at 340 umol/kg";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL1125770";"1920355";"10.1021/jm00114a013";"1991";"J Med Chem";"34";"3044";"3052";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models | Neoplasm Oncology Models";"General Leukemia | L1210 Experimental Leukemia | Neoplasms";"";""
"CHEMBL700909";"F";"In vivo antitumor activity against intraperitoneal murine cyclophosphamide resistant L1210 Leukemia cells at 170 umol/kg";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL1125770";"1920355";"10.1021/jm00114a013";"1991";"J Med Chem";"34";"3044";"3052";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models | Neoplasm Oncology Models";"General Leukemia | L1210 Experimental Leukemia | Neoplasms";"";""
"CHEMBL2150752";"F";"Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 12";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL2146434";"22574992";"10.1021/jm300468t";"2012";"J Med Chem";"55";"5077";"5087";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL1964018";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) ";"";"38940";"39248";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"SF-539";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1964063";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line. (Class of assay: confirmatory) ";"";"27642";"27872";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"MDA-MB-231";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909178";"B";"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)";"Rattus norvegicus";"871";"1742";"BAO_0000221";"tissue-based format";"9";"9 - Direct single protein target assigned";"";"DrugMatrix";"10116";"CHEMBL3638233";"Cerebellum";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909145";"B";"DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"Sf9";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909159";"B";"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)";"Rattus norvegicus";"871";"1742";"BAO_0000249";"cell membrane format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Wistar";"DrugMatrix";"10116";"CHEMBL3559724";"Cerebral cortex";"";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL838188";"F";"Effect (10 mg/kg/day*7 days, i.v.) on cyclophosphamide (CY, i.p.) treated mice (immunosuppressed animal model) assessed by CD4+/CD8+ ratio in peripheral blood mononuclear cells";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1141138";"16078831";"10.1021/jm0493313";"2005";"J Med Chem";"48";"5112";"5122";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors";"General Immunosuppressive Activity";"";""
"CHEMBL4296187";"F";"Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600)";"Pseudomonas aeruginosa";"24161";"24267";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"ATCC 27853";"CO-ADD antimicrobial screening data";"287";"";"";"";"";"CHEMBL4296181";"None";"10.6019/CHEMBL4296181";"None";"None";"None";"None";"None";"standard_type:ASSAY_TEST standard_relation:None standard_value:None standard_units:None comments:None | standard_type:DETECTION_METHOD standard_relation:None standard_value:None standard_units:None comments:None | standard_type:MEDIA standard_relation:None standard_value:None standard_units:None comments:None | standard_type:PLATE_TYPE standard_relation:None standard_value:None standard_units:None comments:None | standard_type:TIME standard_relation:= standard_value:18.0 standard_units:hr comments:None";"";"";"";"";""
"CHEMBL2319272";"F";"Antitumor activity in mouse CT26 colon cancer cells inoculated mouse assessed as tumor inhibition rate at one fifth of LD50 concentration once a day for consecutive 7 days by ip";"Mus musculus";"12";"12";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"CT26";"";"CHEMBL2311304";"23279863";"10.1016/j.ejmech.2012.11.033";"2013";"Eur J Med Chem";"60";"10";"22";"";"";"";"";"";""
"CHEMBL2321011";"F";"Antitumor activity against mouse Sarcoma 180 cells xenografted in mouse assessed as tumor inhibition at 30 mg/kg, ip qd for 7 days measured every 3 days for 21 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Sarcoma-180";"";"CHEMBL2311271";"23291116";"10.1016/j.ejmech.2012.11.045";"2013";"Eur J Med Chem";"60";"135";"143";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL1963921";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line. (Class of assay: confirmatory) ";"";"28183";"28420";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"MDA-MB-435";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL742461";"F";"Immunological activity in mice as the percentage of suppression of the cellular response to EI4 tumor cells at 10 mg/kg";"Mus musculus";"25";"25";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121658";"7277388";"10.1021/jm00139a012";"1981";"J Med Chem";"24";"830";"834";"standard_type:DOSE standard_relation:= standard_value:10.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL728916";"F";"Number of survivors on the toxicity day (day = 15) at a dose of 100x1 mg/kg";"Mus musculus";"2";"5";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123176";"3701785";"10.1021/jm00155a022";"1986";"J Med Chem";"29";"716";"727";"";"";"";"";"";""
"CHEMBL1043587";"A";"Fraction escaping hepatic elimination in human";"Homo sapiens";"308";"308";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1156824";"20070106";"10.1021/jm901371v";"2010";"J Med Chem";"53";"1098";"1108";"";"";"";"";"";""
"CHEMBL1043586";"A";"Fraction escaping gut-wall elimination in human";"Homo sapiens";"308";"308";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL1156824";"20070106";"10.1021/jm901371v";"2010";"J Med Chem";"53";"1098";"1108";"";"";"";"";"";""
"CHEMBL730721";"F";"Average body weight in grams on day 5 minus average body weight on day 1 at the dose of 300 mg/kg in experiment 3";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:300.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL1763416";"F";"Antitumor activity against mouse S180 cells xenografted in Kunming mouse assessed as tumor growth inhibition rate at 20 mg/kg, po administered for 10 days relative to control";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"CCRF S-180";"";"CHEMBL1759888";"21316818";"10.1016/j.ejmech.2011.01.036";"2011";"Eur J Med Chem";"46";"1172";"1180";"standard_type:DOSE standard_relation:= standard_value:20.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL2321077";"F";"Cytotoxicity against human PA1 cells after 24 hrs by MTT assay";"Homo sapiens";"9";"9";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"PA-1";"";"CHEMBL2311276";"23202484";"10.1016/j.ejmech.2012.10.046";"2013";"Eur J Med Chem";"59";"7";"14";"";"";"";"";"";""
"CHEMBL655228";"F";"Antitumor activity against C26 implants through subcutaneous route along with the optimal dose of 125 mg/kg through intraperitoneal injection on 1,4 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Colon 26";"";"CHEMBL1122849";"4067995";"10.1021/jm00149a025";"1985";"J Med Chem";"28";"1685";"1691";"standard_type:DOSE standard_relation:= standard_value:125.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL737223";"F";"Percentage increase in life span of L1210 leukemia implanted mice at a dose of 120 mg/kg";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123954";"3336021";"10.1021/jm00396a036";"1988";"J Med Chem";"31";"226";"230";"standard_type:DOSE standard_relation:= standard_value:120.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models";"General Leukemia | L1210 Experimental Leukemia";"";""
"CHEMBL1948867";"F";"Immunostimulatory activity in Kunming mouse xenografted with human H22 cells assessed as change in thymus mass at 20 mg/kg, po qd for 10 days (Rvb = 1.83 +/- 0.85 mg/kg)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"Kunming";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL1944612";"22196118";"10.1016/j.bmcl.2011.11.104";"2012";"Bioorg Med Chem Lett";"22";"1082";"1085";"";"";"";"";"";""
"CHEMBL2319268";"F";"Antitumor activity in mouse H22 liver cancer cells inoculated mouse assessed as tumor inhibition rate at one fifth of LD50 concentration once a day for consecutive 7 days by ip";"Mus musculus";"12";"12";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL2311304";"23279863";"10.1016/j.ejmech.2012.11.033";"2013";"Eur J Med Chem";"60";"10";"22";"";"";"";"";"";""
"CHEMBL3418968";"T";"Toxicity in human HT-29 cells xenografted BALB/c mouse assessed as change in body weight at 30 mg/kg, ip administered once daily for 18 days (Rvb = 2.5 g)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"HT-29";"";"CHEMBL3414539";"25689111";"10.1021/acs.jmedchem.5b00118";"2015";"J Med Chem";"58";"2538";"2546";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL3788320";"A";"Half life in po dosed lymphoma patient (7 patients) by one compartment open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3061797";"F";"Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells after 48 hr by MTT assay";"Homo sapiens";"11";"11";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"MDA-MB-231";"";"CHEMBL3045968";"None";"10.1007/s00044-011-9737-7";"2012";"Med Chem Res";"21";"2185";"2195";"";"";"";"";"";""
"CHEMBL3061438";"F";"Growth inhibition of Homo sapiens (human) PA1 cells at 10 uM after 48 hr by SRB assay";"Homo sapiens";"21";"21";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"PA-1";"";"CHEMBL3045644";"None";"10.1007/s00044-011-9850-7";"2012";"Med Chem Res";"21";"3043";"3052";"";"";"";"";"";""
"CHEMBL804491";"F";"Ability of compound (220 mg/kg, single dose) to inhibit growth of Sc colon 38 tumor cells in mice";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1124442";"2704025";"10.1021/jm00124a012";"1989";"J Med Chem";"32";"793";"799";"";"";"";"";"";""
"CHEMBL846893";"F";"Antiinflammatory activity dosed orally against carrageenan induced rat paw edema(CPE)";"Rattus norvegicus";"5";"6";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10116";"";"";"";"";"CHEMBL1125290";"1732553";"10.1021/jm00080a022";"1992";"J Med Chem";"35";"350";"361";"";"MUSCULO-SKELETAL SYSTEM | MUSCULO-SKELETAL SYSTEM";"Anti-Inflammatory Activity | Anti-Inflammatory Activity";"General Anti-Inflammatory Models | Paw Edema Test";"";""
"CHEMBL2114780";"F";"PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) ";"Homo sapiens";"58729";"58906";"BAO_0000219";"cell-based format";"9";"9 - Direct single protein target assigned";"";"PubChem BioAssays";"9606";"";"";"SW480";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL879666";"F";"In vivo activity against transplanted Mam-17 tumors of mice";"Mus musculus";"9";"9";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1134487";"11356111";"10.1021/jm0005149";"2001";"J Med Chem";"44";"1758";"1776";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL1948872";"T";"Toxicity in Kunming mouse xenografted with human H22 cells assessed as change in body weight at 20 mg/kg, po qd for 10 days (Rvb = 25.3 +/- 1.5 g)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"Kunming";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL1944612";"22196118";"10.1016/j.bmcl.2011.11.104";"2012";"Bioorg Med Chem Lett";"22";"1082";"1085";"standard_type:DOSE standard_relation:= standard_value:20.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL721787";"F";"Percentage increased life span against L1210 leukemia cells in mice;(1.08 mmol/kg dosage)";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL1128257";"7877150";"10.1021/jm00005a012";"1995";"J Med Chem";"38";"848";"851";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models";"General Leukemia | L1210 Experimental Leukemia";"";""
"CHEMBL3214892";"F";"PubChem BioAssay. qHTS profiling for inhibitors of Plasmodium falciparum (DD2) proliferation.   (Class of assay: confirmatory) ";"";"244";"249";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1963963";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DLD-1 Colon cell line. (Class of assay: confirmatory) ";"";"14626";"14722";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"DLD-1";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1964012";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line. (Class of assay: confirmatory) ";"";"41240";"41578";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"COLO 205";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL2114775";"F";"PubChem BioAssay. qHTS Assay for Inhibitors of Hepatitis C Virus (HCV). (Class of assay: confirmatory) ";"";"75093";"75549";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909165";"B";"DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid)";"Oryctolagus cuniculus";"871";"1742";"BAO_0000221";"tissue-based format";"9";"9 - Direct single protein target assigned";"";"DrugMatrix";"9986";"";"";"Reticulocytes";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909212";"B";"DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HEK293";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909125";"B";"DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"Chem-1";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909163";"B";"DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4)";"Cavia porcellus";"871";"1742";"BAO_0000221";"tissue-based format";"9";"9 - Direct single protein target assigned";"";"DrugMatrix";"10141";"CHEMBL3638235";"Lung";"";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909169";"B";"DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine)";"";"871";"1742";"BAO_0000219";"cell-based format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"BTI-TN-5B1-4";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909195";"B";"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)";"Homo sapiens";"871";"1742";"BAO_0000221";"tissue-based format";"9";"9 - Direct single protein target assigned";"";"DrugMatrix";"9606";"";"";"Neutrophil";"";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1909093";"B";"DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol)";"";"871";"1742";"BAO_0000249";"cell membrane format";"8";"8 - Homologous single protein target assigned";"";"DrugMatrix";"32644";"";"";"HEK293";"Membrane";"CHEMBL1909046";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1614676";"A";"Volume of distribution at steady state in rat after iv administration";"Rattus norvegicus";"103";"103";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"10116";"";"";"";"";"CHEMBL1614629";"15920768";"10.1002/jps.20373";"2005";"J Pharm Sci";"94";"1467";"1483";"";"";"";"";"";""
"CHEMBL1963989";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) ";"";"41040";"41374";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"ACHN";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL958105";"B";"Induction of Escherichia coli pBluescript 2 KS+ DNA cleavage at 10 mM by gel electrophoresis";"Escherichia coli";"1";"1";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"562";"";"";"";"";"CHEMBL1150296";"18434165";"10.1016/j.bmc.2008.04.009";"2008";"Bioorg Med Chem";"16";"5441";"5451";"";"";"";"";"";""
"CHEMBL721400";"F";"Maximum life span of mice after 100 mg/kg ip administration; Increases range 75-100";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121862";"7310817";"10.1021/jm00144a007";"1981";"J Med Chem";"24";"1404";"1408";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL1964034";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line. (Class of assay: confirmatory) ";"";"35810";"36111";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"A498";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1964085";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line. (Class of assay: confirmatory) ";"";"40966";"41294";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"M14";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1964040";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line. (Class of assay: confirmatory) ";"";"41083";"41427";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"MOLT-4";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1964045";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line. (Class of assay: confirmatory) ";"";"28471";"28705";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"NCI/ADR-RES";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL739604";"F";"Number of mice that survived on day 60 at a dose of 400 mg/kg; 7/18";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123954";"3336021";"10.1021/jm00396a036";"1988";"J Med Chem";"31";"226";"230";"standard_type:DOSE standard_relation:= standard_value:400.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL976473";"F";"Antitumor activity in mouse H22 cell xenografted mouse at 20 mg/kg/day, iv after 4 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL1155921";"18644718";"10.1016/j.bmcl.2008.06.097";"2008";"Bioorg Med Chem Lett";"18";"4741";"4744";"standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL726143";"F";"Compound was tested for the ability to suppress humoral immune response in mice treated for days 0,+1,and +2 at dose of 25 mg/kg (control = 7.1)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121811";"7265126";"10.1021/jm00136a008";"1981";"J Med Chem";"24";"393";"398";"standard_type:DOSE standard_relation:= standard_value:25.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL730491";"F";"Median survival time (MST) of treated mice infected by P-388 leukemia, as percent of the MST of untreated controls when treated with a dose of 125 mg/Kg of compound";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1124137";"3373492";"10.1021/jm00401a028";"1988";"J Med Chem";"31";"1240";"1244";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models";"General Leukemia | P388 Experimental Leukemia";"";""
"CHEMBL723592";"F";"Effect of compound on life span of mice inoculated intravenously with lewis lung carcinoma at the dose of 120 mg/kg in experiment 2";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:120.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models | Carcinoma Oncology Models";"Carcinoma | Lewis Lung Carcinoma";"";""
"CHEMBL2071962";"A";"Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins";"Homo sapiens";"221";"221";"BAO_0000357";"single protein format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL2069259";"22931300";"10.1021/tx300075j";"2012";"Chem Res Toxicol";"25";"2067";"2082";"";"";"";"";"";""
"CHEMBL635477";"P";"Partition coefficient (logD7.4)";"";"61";"66";"BAO_0000100";"small-molecule physicochemical format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"";"";"";"";"";"CHEMBL1124835";"2362268";"10.1021/jm00169a014";"1990";"J Med Chem";"33";"1914";"1919";"";"";"";"";"";""
"CHEMBL948107";"F";"Antitumor activity in mouse xenografted with H22 cells assessed as inhibition of tumor growth at 30 mg/kg/day, ip after 10 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL1142371";"18226907";"10.1016/j.bmc.2007.11.048";"2008";"Bioorg Med Chem";"16";"2550";"2557";"standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL2150751";"F";"Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 23";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL2146434";"22574992";"10.1021/jm300468t";"2012";"J Med Chem";"55";"5077";"5087";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL615497";"F";"In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells";"Mus musculus";"3";"3";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"NIH3T3";"";"CHEMBL1130863";"9873412";"10.1016/s0960-894x(98)00287-x";"1998";"Bioorg Med Chem Lett";"8";"1673";"1678";"";"";"";"";"";""
"CHEMBL1963900";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line. (Class of assay: confirmatory) ";"";"26413";"26627";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"T47D";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1634561";"F";"Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as effect on cidofovir-induced effect on viral DNA load in liver at 100 mg/kg, ip treated 8 days before infection for 2 to 3 weeks measured after 62 days postinfection by RT-PCR";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"CHEMBL3559723";"Liver";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors";"General Immunosuppressive Activity";"";""
"CHEMBL722592";"F";"Number of survivors out of 10 mice after 60 days infected with lewis lung carcinoma at the dose of 120 mg/kg in experiment 2";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:120.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models | Carcinoma Oncology Models";"Carcinoma | Lewis Lung Carcinoma";"";""
"CHEMBL3854306";"T";"Toxicity in nude mouse xenografted with human HepG2 cells assessed as body weight change at 10 mg/kg, ip administered every day for 15 times measured from day 12 to 26";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"HepG2";"";"CHEMBL3853295";"27162123";"10.1016/j.ejmech.2016.04.068";"2016";"Eur J Med Chem";"119";"183";"196";"";"";"";"";"";""
"CHEMBL3788641";"A";"Total body clearance in iv dosed patient (7 patients) with renal insufficiency";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL4495582";"F";"SARS-CoV-2 3CL-Pro protease inhibition percentage at 20M  by FRET kind of response from peptide substrate";"Severe acute respiratory syndrome coronavirus 2";"7218";"8702";"BAO_0000019";"assay format";"9";"9 - Direct single protein target assigned";"";"SARS-CoV-2 Screening Data 2020-21";"2697049";"";"";"";"";"CHEMBL4495564";"None";"10.6019/CHEMBL4495564";"2020";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL2319270";"F";"Antitumor activity in mouse Sarcoma 180 cells inoculated mouse assessed as tumor inhibition rate at one fifth of LD50 concentration once a day for consecutive 7 days by ip";"Mus musculus";"12";"12";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Sarcoma-180";"";"CHEMBL2311304";"23279863";"10.1016/j.ejmech.2012.11.033";"2013";"Eur J Med Chem";"60";"10";"22";"";"";"";"";"";""
"CHEMBL1964074";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the M19-MEL Melanoma cell line. (Class of assay: confirmatory) ";"";"15163";"15267";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"M19-MEL";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1283848";"F";"Antibacterial activity against Pasteurella multocida AL435 after 24 hrs by broth dilution method";"Pasteurella multocida";"24";"24";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"AL435";"Scientific Literature";"747";"";"";"";"";"CHEMBL1275542";"18725450";"10.1128/aac.00245-08";"2008";"Antimicrob Agents Chemother";"52";"4166";"4171";"";"";"";"";"";""
"CHEMBL1285392";"B";"Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u";"Candida albicans";"66";"66";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"5476";"";"";"";"";"CHEMBL1275276";"20739103";"10.1016/j.ejmech.2010.07.050";"2010";"Eur J Med Chem";"45";"4813";"4826";"";"";"";"";"";""
"CHEMBL620509";"F";"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor";"Mus musculus";"5";"5";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"CHEMBL3559721";"Plasma";"ADJ/PC6";"";"CHEMBL1121753";"7310816";"10.1021/jm00144a006";"1981";"J Med Chem";"24";"1399";"1403";"";"";"";"";"";""
"CHEMBL734742";"F";"Percentage increase in life span of L1210 leukemia implanted mice at a dose of 300 mg/kg";"Mus musculus";"5";"5";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1123954";"3336021";"10.1021/jm00396a036";"1988";"J Med Chem";"31";"226";"230";"standard_type:DOSE standard_relation:= standard_value:300.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models";"General Leukemia | L1210 Experimental Leukemia";"";""
"CHEMBL3411289";"A";"Stimulation of human OATP1B1-mediated [3H]estrone 3-sulfate at 100 uM after 5 mins relative to control";"Homo sapiens";"7";"7";"BAO_0000357";"single protein format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3407465";"25618019";"10.1016/j.ejmech.2015.01.011";"2015";"Eur J Med Chem";"92";"723";"731";"";"";"";"";"";""
"CHEMBL3137739";"T";"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]";"Homo sapiens";"1214";"1216";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL1266185";"F";"Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay";"Mus musculus";"1252";"1259";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1255231";"17417631";"10.1038/nchembio873";"2007";"Nat Chem Biol";"3";"268";"273";"";"";"";"";"";""
"CHEMBL1964004";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ";"";"38197";"38507";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"NCI-H226";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1963903";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line. (Class of assay: confirmatory) ";"";"40754";"41090";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"UACC-62";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL875426";"F";"Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 50 mg/kg dose";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"B16-F10";"";"CHEMBL1125374";"1542095";"10.1021/jm00082a009";"1992";"J Med Chem";"35";"687";"694";"standard_type:DOSE standard_relation:= standard_value:50.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Melanoma Oncology Models | Melanoma Oncology Models | Metastatic Oncology Models";"Experimental Melanoma | General Melanoma | Metastatic Activity";"";""
"CHEMBL1963981";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) ";"";"41327";"41678";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"SN12C";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL1963922";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line. (Class of assay: confirmatory) ";"";"41592";"41947";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"SF-295";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3790811";"A";"Systemic clearance in patient ( 12 patients) with normal renal function at 0.83 +/- 0.05 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL2071964";"A";"Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins";"Homo sapiens";"221";"221";"BAO_0000357";"single protein format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL2069259";"22931300";"10.1021/tx300075j";"2012";"Chem Res Toxicol";"25";"2067";"2082";"";"";"";"";"";""
"CHEMBL1963874";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line. (Class of assay: confirmatory) ";"";"41314";"41656";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"HCT-116";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL4296189";"F";"Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630";"Candida albicans";"6134";"6236";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"ATCC 90028";"CO-ADD antimicrobial screening data";"5476";"";"";"";"";"CHEMBL4296181";"None";"10.6019/CHEMBL4296181";"None";"None";"None";"None";"None";"standard_type:ASSAY_TEST standard_relation:None standard_value:None standard_units:None comments:None | standard_type:DETECTION_METHOD standard_relation:None standard_value:None standard_units:None comments:None | standard_type:MEDIA standard_relation:None standard_value:None standard_units:None comments:None | standard_type:PLATE_TYPE standard_relation:None standard_value:None standard_units:None comments:None | standard_type:TIME standard_relation:= standard_value:18.0 standard_units:hr comments:None";"";"";"";"";""
"CHEMBL3215086";"F";"PubChem BioAssay. qHTS profiling for inhibitors of Plasmodium falciparum (HB3) proliferation.   (Class of assay: confirmatory) ";"";"200";"206";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3428020";"T";"Toxicity against mouse xenografted with human H22 cells assessed as body weight at 30 mg/kg, ip administered after 7 days of tumor transplantation (Rvb = 18.1 to 18.6 gms)";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL3425458";"25984840";"10.1016/j.ejmech.2015.04.057";"2015";"Eur J Med Chem";"97";"235";"244";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL2354287";"F";"PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) ";"";"39969";"40105";"BAO_0000019";"assay format";"8";"8 - Homologous single protein target assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3257527";"F";"Antileukemic activity against mouse L1210 cells allografted in po dosed BDF1 mouse assessed as survival over 60 days administered 24 hrs";"Mus musculus";"4";"4";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL3253041";"T";"Toxicity in mouse P388 cells allografted ip dosed mouse assessed as maximum tolerated dose administered as once each 4 days for 3 total injection";"Mus musculus";"5";"5";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"P388";"";"CHEMBL3244336";"490545";"10.1021/jm00195a002";"1979";"J Med Chem";"22";"1024";"1030";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models";"P388 Experimental Leukemia";"";""
"CHEMBL3788305";"A";"First order rate constant for rapid dissolution phase in iv dosed lymphoma patient (6 patients) by two-compartmental open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3063281";"F";"Cytotoxicity against Homo sapiens (human) PA1 cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay";"Homo sapiens";"19";"19";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"PA-1";"";"CHEMBL3045323";"None";"10.1007/s00044-011-9899-3";"2012";"Med Chem Res";"21";"3620";"3628";"";"";"";"";"";""
"CHEMBL3788334";"A";"Metabolic clearance in lymphoma patient (7 patients)";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL4025706";"F";"Antitumor activity against human H22 cells xenografted in ICR mouse assessed as tumor weight at 20 mg/kg, iv administered once daily for 21 days measured post last dose (Rvb = 4.38 +/- 0.16 g)";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"H22";"";"CHEMBL4024711";"28359045";"10.1016/j.ejmech.2017.03.027";"2017";"Eur J Med Chem";"132";"173";"183";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL2319271";"F";"Antitumor activity in mouse Lewis lung cancer cells inoculated mouse assessed as tumor inhibition rate at one fifth of LD50 concentration once a day for consecutive 7 days by ip";"Mus musculus";"12";"12";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Cancer cell lines";"";"CHEMBL2311304";"23279863";"10.1016/j.ejmech.2012.11.033";"2013";"Eur J Med Chem";"60";"10";"22";"";"";"";"";"";""
"CHEMBL2150753";"F";"Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 19";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL2146434";"22574992";"10.1021/jm300468t";"2012";"J Med Chem";"55";"5077";"5087";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL2321080";"F";"Cytotoxicity against human HCT15 cells after 24 hrs by MTT assay";"Homo sapiens";"9";"9";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HCT-15";"";"CHEMBL2311276";"23202484";"10.1016/j.ejmech.2012.10.046";"2013";"Eur J Med Chem";"59";"7";"14";"";"";"";"";"";""
"CHEMBL2321083";"F";"Cytotoxicity against human HepG2 cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay";"Homo sapiens";"21";"21";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HepG2";"";"CHEMBL2311276";"23202484";"10.1016/j.ejmech.2012.10.046";"2013";"Eur J Med Chem";"59";"7";"14";"";"";"";"";"";""
"CHEMBL3214997";"F";"PubChem BioAssay. Cell Proliferation Assay Versus the ED40515 IL2 Dependent  ATL cell lines.   (Class of assay: confirmatory) ";"";"198";"198";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3790805";"A";"AUC (0 to infinity) in patient (6 patients) with severe renal insufficiency at 1.1 +/- 0.2 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3790802";"A";"Drug recovery in dialysate of patient (6 patients) with hemodialysis-dependent end-stage renal disease at 1.2 +/- 0.4 g/m'2 administered as pulse therapy with 1 hr infusion followed by hemodialysis for 3 hrs started 7 hrs post dose measured during hemodialysis treatment by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL4011663";"A";"Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-taurocholate by topcount based membrane vesicle transport assay";"Homo sapiens";"216";"216";"BAO_0000019";"assay format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL4011581";"20829430";"10.1093/toxsci/kfq269";"2010";"Toxicol Sci";"118";"485";"500";"";"";"";"";"";""
"CHEMBL706087";"F";"Compound was tested in vitro for its inhibition against replication of L1210 neoplastic cells; Inactive";"Mus musculus";"2";"2";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL1121561";"7452673";"10.1021/jm00185a018";"1980";"J Med Chem";"23";"1235";"1237";"";"";"";"";"";""
"CHEMBL3885863";"F";"In vitro activity on S. mansoni schistosomula at 10 uM";"Schistosoma mansoni";"158";"109770";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"Puerto Rican";"Open TG-GATEs";"6183";"";"";"";"";"CHEMBL3885861";"None";"10.6019/CHEMBL3885861";"None";"None";"None";"None";"None";"standard_type:AGE standard_relation:None standard_value:6.0 standard_units:weeks comments:None | standard_type:GENDER standard_relation:None standard_value:None standard_units:None comments:None | standard_type:REGIMEN standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL3257530";"F";"Antileukemic activity against mouse L1210 cells allografted in po dosed BDF1 mouse assessed as maximum tolerated dose for survival over 60 days administered 24 hrs";"Mus musculus";"4";"4";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL947964";"F";"Effect on body weight in mouse bearing S180 cells at 30 mg/kg/day, ip after 10 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"CCRF S-180";"";"CHEMBL1142371";"18226907";"10.1016/j.bmc.2007.11.048";"2008";"Bioorg Med Chem";"16";"2550";"2557";"standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL725396";"F";"Maximum life span of mice after 200 mg/kg ip administration; Increases range 150-200";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121862";"7310817";"10.1021/jm00144a007";"1981";"J Med Chem";"24";"1404";"1408";"standard_type:DOSE standard_relation:= standard_value:200.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL724972";"F";"Effect of compound on life span of mice inoculated intravenously with lewis lung carcinoma at the dose of 300 mg/kg in experiment 3";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:300.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models | Carcinoma Oncology Models";"Carcinoma | Lewis Lung Carcinoma";"";""
"CHEMBL728960";"F";"Number of survivors out of 10 mice after 60 days infected with lewis lung carcinoma at the dose of 75 mg/kg in experiment 3";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:75.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models | Carcinoma Oncology Models";"Carcinoma | Lewis Lung Carcinoma";"";""
"CHEMBL717770";"F";"Average weight change on day 5 in mice infected by P-388 leukemia when treated with a dose of 250 mg/Kg of compound";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1124137";"3373492";"10.1021/jm00401a028";"1988";"J Med Chem";"31";"1240";"1244";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models";"General Leukemia | P388 Experimental Leukemia";"";""
"CHEMBL3790807";"A";"AUC (0 to infinity) in patient (6 patients) with hemodialysis-dependent end-stage renal disease at 1.2 +/- 0.4 g/m'2 administered as pulse therapy with 1 hr infusion followed by hemodialysis for 3 hrs started 7 hrs post dose measured during hemodialysis treatment by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3788923";"A";"Half life in patient (5 patients) with severe renal insufficiency assessed as unchanged compound level using 14C labeled compound measured over 72 hrs";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL3214945";"F";"PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation.   (Class of assay: confirmatory) ";"";"940";"958";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3788914";"A";"Plasma alkylating activity in patient with normal renal function assessed as elimination rate constant for total NBP alkylating activity at 300 mg/kg by NBP based colorimetric assay";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL3788634";"A";"First order inter-compartment transfer rate constant from central to peripheral compartment in iv dosed patient (7 patients) with renal insufficiency";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL3788642";"A";"Disposition rate constant in patient (7 patients) with renal insufficiency at 350 mg/kg, po";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL3383277";"T";"Toxicity in human H22 cells transplanted ICR mouse assessed as mouse survival at 30 mg/kg, iv administered 7 days post tumor transplantation";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"ICR";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL3351759";"25247772";"10.1016/j.ejmech.2014.09.058";"2014";"Eur J Med Chem";"87";"159";"167";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL802252";"F";"Alkylating activity determined by incubating with rat hepatic microsomes and time dependent release of alkylating species with no pretreatment; Activity expressed as uM of mechlorethamine equiv/g of liver/h";"Rattus norvegicus";"4";"5";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10116";"CHEMBL3559723";"Liver";"";"Microsomes";"CHEMBL1125916";"1995881";"10.1021/jm00106a018";"1991";"J Med Chem";"34";"588";"592";"";"";"";"";"";""
"CHEMBL3788311";"A";"First order inter-compartment transfer rate constant from central to peripheral compartment in iv dosed lymphoma patient (6 patients) by two-compartmental open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3071879";"F";"Growth inhibition of Homo sapiens (human) HepG2 cells at 10 uM after 48 hr by SRB assay";"Homo sapiens";"25";"25";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HepG2";"";"CHEMBL3046244";"None";"10.1007/s00044-012-0438-7";"2013";"Med Chem Res";"22";"4600";"4609";"";"";"";"";"";""
"CHEMBL3788309";"A";"Apparent volume of distribution during terminal log-linear elimination phase in iv dosed lymphoma patient (6 patients) by two-compartmental open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3214813";"F";"PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2).   (Class of assay: confirmatory) ";"";"1069";"1094";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL4605725";"F";"Protective activity in NZBWF1/J mouse SLE model assessed as reduction in proteinuria at 5 mg/kg, ip administered daily for 12 weeks measured weekly from week 28-40";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"NZBWF1/J";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4602710";"32292557";"10.1021/acsmedchemlett.9b00621";"2020";"ACS Med Chem Lett";"11";"506";"513";"";"GENITO URINARY SYSTEM AND SEX HORMONES";"Assessment of Renal Function";"Urinalysis";"";""
"CHEMBL3070543";"F";"Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay";"Homo sapiens";"24";"24";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HepG2";"";"CHEMBL3044972";"None";"10.1007/s00044-012-0439-6";"2013";"Med Chem Res";"22";"4278";"4285";"";"";"";"";"";""
"CHEMBL3562064";"F";"PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel.   (Class of assay: confirmatory) ";"";"1996";"2013";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL2423209";"T";"Mutagenicity in Swiss albino mouse at 50 mg/kg, ip after 30 hrs by micronucleus test";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"Swiss albino";"Scientific Literature";"10090";"";"";"";"";"CHEMBL2417455";"23851115";"10.1016/j.ejmech.2013.04.022";"2013";"Eur J Med Chem";"67";"142";"151";"standard_type:DOSE standard_relation:= standard_value:50.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL3257083";"F";"Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span at 50 mg/kg, ip administered 24 hrs relative to control";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"standard_type:DOSE standard_relation:= standard_value:50.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL3257532";"F";"Ratio of Cmax to Cmin for antileukemic activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as survival over 60 days";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL3215181";"F";"PubChem BioAssay. qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen.   (Class of assay: confirmatory) ";"";"36517";"36531";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL4042861";"F";"Growth inhibition of human NCI-H522 cells at 1 x 10'-5 M after 24 hrs by MTT assay relative to control";"Homo sapiens";"35";"35";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"NCI-H522";"";"CHEMBL4041541";"28011220";"10.1016/j.bmcl.2016.12.031";"2017";"Bioorg Med Chem Lett";"27";"501";"504";"";"";"";"";"";""
"CHEMBL3137733";"T";"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]";"Homo sapiens";"1214";"1216";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL3137728";"T";"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]";"Homo sapiens";"1214";"1216";"BAO_0000221";"tissue-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL3137724";"T";"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]";"Homo sapiens";"1214";"1216";"BAO_0000221";"tissue-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL3070542";"F";"Growth inhibition of Homo sapiens (human) NCI-H522 cells at 10 uM after 48 hr by SRB assay";"Homo sapiens";"25";"25";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"NCI-H522";"";"CHEMBL3046244";"None";"10.1007/s00044-012-0438-7";"2013";"Med Chem Res";"22";"4600";"4609";"";"";"";"";"";""
"CHEMBL728600";"F";"Average body weight in grams on day 5 minus average body weight on day 1 at the dose of 150 mg/kg in experiment 3";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1121997";"7057413";"10.1021/jm00344a002";"1982";"J Med Chem";"25";"107";"108";"standard_type:DOSE standard_relation:= standard_value:150.0 standard_units:mg.kg-1 comments:None";"";"";"";"";""
"CHEMBL3137722";"T";"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]";"Homo sapiens";"1214";"1216";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL4713495";"F";"Antitumor activity against human Lewis lung cancer cells xenografted in BALB/c mouse assessed as tumor growth inhibition at 20 mg/kg, ig administered every day for 10 days relative to control";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL4706663";"33450619";"10.1016/j.ejmech.2020.113142";"2021";"Eur J Med Chem";"212";"113142";"113142";"";"";"";"";"";""
"CHEMBL3137723";"T";"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]";"Homo sapiens";"1214";"1216";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL3137734";"T";"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]";"Homo sapiens";"1214";"1216";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL3061437";"F";"Growth inhibition of Homo sapiens (human) T47D cells at 10 uM after 48 hr by SRB assay";"Homo sapiens";"21";"21";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"T47D";"";"CHEMBL3045644";"None";"10.1007/s00044-011-9850-7";"2012";"Med Chem Res";"21";"3043";"3052";"";"";"";"";"";""
"CHEMBL3788325";"A";"Drug excretion in po dosed lymphoma patient (7 patients) assessed as unchanged parent compound in urine";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"CHEMBL3638201";"Urine";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3788649";"A";"Apparent volume of distribution at central compartment in iv dosed patient with normal renal function";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL3788333";"A";"Extraction ratio in lymphoma patient (7 patients)";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL4025703";"F";"Antitumor activity against human H22 cells xenografted in ICR mouse assessed as tumor growth inhibition at 20 mg/kg, iv administered once daily for 21 days measured post last dose relative to control";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"H22";"";"CHEMBL4024711";"28359045";"10.1016/j.ejmech.2017.03.027";"2017";"Eur J Med Chem";"132";"173";"183";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL3790804";"A";"AUC (0 to infinity) in patient (6 patients) with moderate renal insufficiency at 1.4 +/- 0.1 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3788310";"A";"First order inter-compartment transfer rate constant from peripheral to central compartment in iv dosed lymphoma patient (6 patients) by two-compartmental open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3788265";"A";"Volume of distribution at steady state in patient (6 patients) with severe renal insufficiency at 1.1 +/- 0.2 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3788637";"A";"Terminal half life in iv dosed patient (7 patients) with renal insufficiency";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL4029769";"T";"Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as hemoglobin level at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 15.1 +/- 1.5 g/dl)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4028815";"28342398";"10.1016/j.ejmech.2017.03.028";"2017";"Eur J Med Chem";"132";"63";"80";"";"";"";"";"";""
"CHEMBL3854304";"F";"Antitumor activity against human HepG2 cells xenografted in nude mouse assessed as tumor growth inhibition at 10 mg/kg, ip administered every day for 15 times measured from day 12 to 26";"Homo sapiens";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HepG2";"";"CHEMBL3853295";"27162123";"10.1016/j.ejmech.2016.04.068";"2016";"Eur J Med Chem";"119";"183";"196";"";"";"";"";"";""
"CHEMBL3788269";"A";"Renal clearance in patient (6 patients) with severe renal insufficiency at 1.1 +/- 0.2 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3638241";"Kidney";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3070546";"F";"Cytotoxicity against Homo sapiens (human) NCI-H522 cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay";"Homo sapiens";"24";"24";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"NCI-H522";"";"CHEMBL3044972";"None";"10.1007/s00044-012-0439-6";"2013";"Med Chem Res";"22";"4278";"4285";"";"";"";"";"";""
"CHEMBL3070547";"F";"Cytotoxicity against Homo sapiens (human) T47D cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay";"Homo sapiens";"24";"24";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"T47D";"";"CHEMBL3044972";"None";"10.1007/s00044-012-0439-6";"2013";"Med Chem Res";"22";"4278";"4285";"";"";"";"";"";""
"CHEMBL3788921";"A";"Drug elimination in patient (5 patients) with severe renal insufficiency using 14C labeled compound measured over 72 hrs";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL3885882";"F";"In vitro activity on S. mansoni schistosomula at 50 uM";"Schistosoma mansoni";"654";"247666";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"Puerto Rican";"DrugMatrix";"6183";"";"";"";"";"CHEMBL3885881";"None";"10.6019/CHEMBL3885881";"None";"None";"None";"None";"None";"standard_type:AGE standard_relation:None standard_value:None standard_units:None comments:None | standard_type:GENDER standard_relation:None standard_value:None standard_units:None comments:None | standard_type:REGIMEN standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL2150747";"F";"Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 14";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL2146434";"22574992";"10.1021/jm300468t";"2012";"J Med Chem";"55";"5077";"5087";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL4296783";"F";"Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)";"Escherichia coli";"1581";"1582";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"ATCC 25922";"CO-ADD antimicrobial screening data";"562";"";"";"";"";"CHEMBL4296181";"None";"10.6019/CHEMBL4296181";"None";"None";"None";"None";"None";"standard_type:ASSAY_TEST standard_relation:None standard_value:None standard_units:None comments:None | standard_type:DETECTION_METHOD standard_relation:None standard_value:None standard_units:None comments:None | standard_type:MEDIA standard_relation:None standard_value:None standard_units:None comments:None | standard_type:PLATE_TYPE standard_relation:None standard_value:None standard_units:None comments:None | standard_type:TIME standard_relation:= standard_value:18.0 standard_units:hr comments:None";"";"";"";"";""
"CHEMBL4029765";"T";"Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as lung weight at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 0.2 +/- 0.018 g)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"CHEMBL3638235";"Lung";"";"";"CHEMBL4028815";"28342398";"10.1016/j.ejmech.2017.03.028";"2017";"Eur J Med Chem";"132";"63";"80";"";"";"";"";"";""
"CHEMBL2150748";"F";"Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 16";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL2146434";"22574992";"10.1021/jm300468t";"2012";"J Med Chem";"55";"5077";"5087";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL3071878";"F";"Growth inhibition of Homo sapiens (human) PA1 cells at 10 uM after 48 hr by SRB assay";"Homo sapiens";"25";"25";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"PA-1";"";"CHEMBL3046244";"None";"10.1007/s00044-012-0438-7";"2013";"Med Chem Res";"22";"4600";"4609";"";"";"";"";"";""
"CHEMBL3788266";"A";"Volume of distribution at steady state in patient (6 patients) with hemodialysis-dependent end-stage renal disease at 1.2 +/- 0.4 g/m'2 administered as pulse therapy with 1 hr infusion followed by hemodialysis for 3 hrs started 7 hrs post dose measured during hemodialysis treatment by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3788270";"A";"Renal clearance in patient (6 patients) with hemodialysis-dependent end-stage renal disease at 1.2 +/- 0.4 g/m'2 administered as pulse therapy with 1 hr infusion followed by hemodialysis for 3 hrs started 7 hrs post dose measured during hemodialysis treatment by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3638241";"Kidney";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3788329";"A";"Drug metabolism in lymphoma patient (6 patients) assessed as ratio of dose normalised AUC in po dosed patient to dose normalised AUC in iv dosed patient";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL2321076";"A";"Cytotoxicity against african green monkey COS1 cells after 24 hrs by MTT assay";"Chlorocebus aethiops";"9";"9";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9534";"";"";"COS-1";"";"CHEMBL2311276";"23202484";"10.1016/j.ejmech.2012.10.046";"2013";"Eur J Med Chem";"59";"7";"14";"";"";"";"";"";""
"CHEMBL2321082";"F";"Cytotoxicity against human T47D cells after 24 hrs by MTT assay";"Homo sapiens";"9";"9";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"T47D";"";"CHEMBL2311276";"23202484";"10.1016/j.ejmech.2012.10.046";"2013";"Eur J Med Chem";"59";"7";"14";"";"";"";"";"";""
"CHEMBL2321081";"F";"Cytotoxicity against human HCT15 cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay";"Homo sapiens";"21";"21";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HCT-15";"";"CHEMBL2311276";"23202484";"10.1016/j.ejmech.2012.10.046";"2013";"Eur J Med Chem";"59";"7";"14";"";"";"";"";"";""
"CHEMBL4146308";"F";"Antitumor activity against mouse EAC cells implanted in ICR mouse assessed as tumor growth inhibition at 30 mg/kg, ip qd dosed for 10 consecutive days relative to control";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Ehrlich";"";"CHEMBL4145456";"29288947";"10.1016/j.ejmech.2017.12.008";"2018";"Eur J Med Chem";"144";"504";"516";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models | Neoplasm Oncology Models";"Erhlich ascites carcinoma | Neoplasms";"";""
"CHEMBL3788267";"A";"Renal clearance in patient ( 12 patients) with normal renal function at 0.83 +/- 0.05 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3638241";"Kidney";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL4042863";"F";"Growth inhibition of human PA1 cells at 1 x 10'-5 M after 24 hrs by MTT assay relative to control";"Homo sapiens";"35";"35";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"PA-1";"";"CHEMBL4041541";"28011220";"10.1016/j.bmcl.2016.12.031";"2017";"Bioorg Med Chem Lett";"27";"501";"504";"";"";"";"";"";""
"CHEMBL4042869";"F";"Growth inhibition of human HepG2 cells after 24 hrs by MTT assay";"Homo sapiens";"9";"9";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HepG2";"";"CHEMBL4041541";"28011220";"10.1016/j.bmcl.2016.12.031";"2017";"Bioorg Med Chem Lett";"27";"501";"504";"";"";"";"";"";""
"CHEMBL3562136";"F";"PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel.   (Class of assay: confirmatory) ";"";"1968";"1982";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL4028924";"A";"Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay";"Homo sapiens";"629";"629";"BAO_0000219";"cell-based format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL4028801";"23956101";"10.1093/toxsci/kft176";"2013";"Toxicol Sci";"136";"216";"241";"";"";"";"";"";""
"CHEMBL4685101";"T";"Toxicity in C57BL/6 mouse xenografted with human B16-F10 cells assessed as body weight at 60 mg/kg, ip administered for 20 days and measured on day 20 (Rvb = 21.1 +/- 1.51 g)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"C57BL/6";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4680192";"32028140";"10.1016/j.ejmech.2020.112079";"2020";"Eur J Med Chem";"190";"112079";"112079";"";"";"";"";"";""
"CHEMBL3788910";"A";"Apparent first order elimination rate constant from the central compartment in iv dosed patient with normal renal function";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL4146312";"T";"Toxicity in ICR mouse implanted with EAC cells assessed as decrease in spleen index at 30 mg/kg, ip qd dosed for 10 consecutive days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"ICR";"Scientific Literature";"10090";"CHEMBL3559722";"Spleen";"";"";"CHEMBL4145456";"29288947";"10.1016/j.ejmech.2017.12.008";"2018";"Eur J Med Chem";"144";"504";"516";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models";"Erhlich ascites carcinoma";"";""
"CHEMBL4000899";"T";"Toxicity in Kunming mouse implanted with mouse H22 cells assessed as body weight at 100 mg/kg, ip administered twice (Rvb = 31.1 g)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"Kunming";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4000174";"27871039";"10.1016/j.ejmech.2016.11.013";"2017";"Eur J Med Chem";"125";"1235";"1246";"";"";"";"";"";""
"CHEMBL3252924";"F";"Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as mean survival time at 100 mg/kg, ip administered 24 hrs (Rvb 4.6 +/- 0.16 days)";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL3788315";"A";"Elimination rate constant in lymphoma patient at 11.3 mg/kg, iv by one compartment open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3257531";"F";"Ratio of Cmax to Cmin for antileukemic activity against mouse L1210 cells allografted in iv dosed BDF1 mouse assessed as survival over 60 days";"Mus musculus";"4";"4";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL4148733";"F";"Antitumor activity against mouse Sarcoma 180 cells implanted in mouse assessed as tumor growth inhibition at 30 mg/kg, ip administered once per day for 7 consecutive days starting from 24 hrs post tumor inoculation and measured on day 21 post tumor inoculation relative to control";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Sarcoma-180";"";"CHEMBL4145545";"29448140";"10.1016/j.ejmech.2018.02.003";"2018";"Eur J Med Chem";"147";"253";"265";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Sarcoma Oncology Models | Sarcoma Oncology Models";"Neoplasms | Sarcoma | Sarcoma 180";"";""
"CHEMBL4713519";"F";"Antitumor activity against human H22 cells xenografted in KM mouse assessed as liver weight at 20 mg/kg, ig administered every day for 10 days measured post last dose (Rvb = 1.57 +/- 0.3 g)";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"Liver";"H22";"";"CHEMBL4706663";"33450619";"10.1016/j.ejmech.2020.113142";"2021";"Eur J Med Chem";"212";"113142";"113142";"";"";"";"";"";""
"CHEMBL4685095";"F";"Antitumor activity against human B16-F10 cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 60 mg/kg, ip administered for 20 days and measured on day 20";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"B16-F10";"";"CHEMBL4680192";"32028140";"10.1016/j.ejmech.2020.112079";"2020";"Eur J Med Chem";"190";"112079";"112079";"";"";"";"";"";""
"CHEMBL4713499";"F";"Antitumor activity against human Lewis lung cancer cells xenografted in BALB/c mouse assessed as lung weight at 20 mg/kg, ig administered every day for 10 days measured post last dose (Rvb = 0.13 +/- 0.03 g)";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL4706663";"33450619";"10.1016/j.ejmech.2020.113142";"2021";"Eur J Med Chem";"212";"113142";"113142";"";"";"";"";"";""
"CHEMBL4348164";"T";"Mutagenicity in Swiss albino mouse assessed as frequency of micronucleated reticulocytes per 2000 cells at 50 mg/kg, ip by acridine orange staining-based micronucleus test";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Swiss";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4346679";"30913526";"10.1016/j.ejmech.2019.03.032";"2019";"Eur J Med Chem";"171";"116";"128";"";"";"";"";"";""
"CHEMBL4029774";"T";"Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as serum creatinine level at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 9.3 +/- 1.2 umol/L)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4028815";"28342398";"10.1016/j.ejmech.2017.03.028";"2017";"Eur J Med Chem";"132";"63";"80";"";"GENITO URINARY SYSTEM AND SEX HORMONES";"Assessment of Renal Function";"Assessment of Glomerular Filtration Rate (GFR) by Plasma Chemistry";"";""
"CHEMBL947966";"F";"Antitumor activity in mouse xenografted with S180 cells assessed as inhibition of tumor growth at 30 mg/kg/day, ip after 10 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"CCRF S-180";"";"CHEMBL1142371";"18226907";"10.1016/j.bmc.2007.11.048";"2008";"Bioorg Med Chem";"16";"2550";"2557";"standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL3737302";"T";"Mutagenicity in Kunming mouse bone marrow cells assessed as micronucleated polychromatic erythrocytes level at 0.1 g/kg by May-Grunwald-Giemsa staining-based microscopic analysis (Rvb = 3.2 +/- 1.62 No_unit )";"Mus musculus";"1";"1";"BAO_0000219";"cell-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Kunming";"Scientific Literature";"10090";"";"";"Bone marrow cell";"";"CHEMBL3734751";"26397395";"10.1016/j.ejmech.2015.09.010";"2015";"Eur J Med Chem";"103";"473";"487";"";"";"";"";"";""
"CHEMBL2406884";"F";"Antitumor activity against mouse LLC cells allografted in mouse assessed as tumor growth inhibition at 30 mg/kg, ip qd administered for 7 days measured after 21 days relative to control";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL2401724";"23688697";"10.1016/j.ejmech.2013.04.031";"2013";"Eur J Med Chem";"65";"21";"31";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL3062731";"P";"Distribution coefficient, log D of the compound";"";"10";"10";"BAO_0000100";"small-molecule physicochemical format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"";"";"";"";"";"CHEMBL3046386";"None";"10.1007/s00044-010-9466-3";"2011";"Med Chem Res";"20";"1287";"1293";"";"";"";"";"";""
"CHEMBL3061799";"P";"Lipophilicity, log P of the compound";"";"11";"11";"BAO_0000100";"small-molecule physicochemical format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"";"";"";"";"";"CHEMBL3045968";"None";"10.1007/s00044-011-9737-7";"2012";"Med Chem Res";"21";"2185";"2195";"";"";"";"";"";""
"CHEMBL3061798";"F";"Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay";"Homo sapiens";"11";"11";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HepG2";"";"CHEMBL3045968";"None";"10.1007/s00044-011-9737-7";"2012";"Med Chem Res";"21";"2185";"2195";"";"";"";"";"";""
"CHEMBL3790809";"A";"Elimination half life in patient (6 patients) with severe renal insufficiency at 1.1 +/- 0.2 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL2150146";"T";"Toxicity in Kunming mouse xenografted with mouse H22 cells assessed as increase in body weight at 30 mg/kg, ip for 7 days measured after 7 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"Kunming";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL2146364";"22901410";"10.1016/j.ejmech.2012.07.047";"2012";"Eur J Med Chem";"56";"308";"319";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL2150749";"F";"Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 18";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL2146434";"22574992";"10.1021/jm300468t";"2012";"J Med Chem";"55";"5077";"5087";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL4139666";"F";"Antitumor activity against human MDA-MB-231 cells xenografted in BALB/c nude mouse assessed as tumor size at 30 mg/kg administered every other day for 28 days measured after 30 days relative to control";"Homo sapiens";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"MDA-MB-231";"";"CHEMBL4138107";"28525844";"10.1016/j.ejmech.2017.04.050";"2017";"Eur J Med Chem";"136";"457";"467";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL3377228";"F";"Antitumor activity against human H22 cells xenografted in ICR mouse assessed as tumor growth inhibition at 30 mg/kg, iv administered 7 days post inoculation measured at day 25 of tumor transplantation";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"H22";"";"CHEMBL3352575";"25529742";"10.1016/j.bmcl.2014.11.058";"2015";"Bioorg Med Chem Lett";"25";"728";"732";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL4146313";"T";"Toxicity in ICR mouse implanted with EAC cells assessed as decrease in thymus index at 30 mg/kg, ip qd dosed for 10 consecutive days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"ICR";"Scientific Literature";"10090";"CHEMBL3638252";"Thymus";"";"";"CHEMBL4145456";"29288947";"10.1016/j.ejmech.2017.12.008";"2018";"Eur J Med Chem";"144";"504";"516";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Carcinoma Oncology Models";"Erhlich ascites carcinoma";"";""
"CHEMBL3737306";"T";"Mutagenicity in Kunming mouse bone marrow cells assessed as ratio of polychromatic erythrocyte level to norchromatic erythrocyte level at 0.1 g/kg by May-Grunwald-Giemsa staining-based microscopic analysis (Rvb = 1.32 +/- 0.22 No_unit )";"Mus musculus";"1";"1";"BAO_0000219";"cell-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"Kunming";"Scientific Literature";"10090";"";"";"Bone marrow cell";"";"CHEMBL3734751";"26397395";"10.1016/j.ejmech.2015.09.010";"2015";"Eur J Med Chem";"103";"473";"487";"";"";"";"";"";""
"CHEMBL722937";"F";"Compound was administered to non-tumor bearing female CDF1 mice in,Mean corpuscular hemoglobin concentration (MCHC)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1133719";"10780911";"10.1021/jm990514c";"2000";"J Med Chem";"43";"1541";"1549";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL3788317";"A";"Volume of distribution in lymphoma patient at 11.3 mg/kg, iv by one compartment open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3063278";"F";"Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as growth inhibition at 1 x 10'-5 M after 48 hr by SRB assay";"Homo sapiens";"19";"19";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HepG2";"";"CHEMBL3045323";"None";"10.1007/s00044-011-9899-3";"2012";"Med Chem Res";"21";"3620";"3628";"";"";"";"";"";""
"CHEMBL3071880";"F";"Growth inhibition of Homo sapiens (human) HCT15 cells at 10 uM after 48 hr by SRB assay";"Homo sapiens";"25";"25";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HCT-15";"";"CHEMBL3046244";"None";"10.1007/s00044-012-0438-7";"2013";"Med Chem Res";"22";"4600";"4609";"";"";"";"";"";""
"CHEMBL4685092";"F";"Antitumor activity against human B16-F10 cells xenografted in C57BL/6 mouse assessed as T/C ratio at 60 mg/kg, ip administered for 20 days and measured on day 20";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"B16-F10";"";"CHEMBL4680192";"32028140";"10.1016/j.ejmech.2020.112079";"2020";"Eur J Med Chem";"190";"112079";"112079";"";"";"";"";"";""
"CHEMBL3366072";"F";"Antitumor activity against mouse S180 cells implanted in mouse assessed as inhibition of tumor growth at 40 mg/kg";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"CCRF S-180";"";"CHEMBL3352306";"25160837";"10.1016/j.bmcl.2014.08.024";"2014";"Bioorg Med Chem Lett";"24";"4367";"4371";"standard_type:DOSE standard_relation:= standard_value:40.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL4296193";"F";"Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)";"Acinetobacter baumannii";"1581";"1582";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"ATCC 19606";"CO-ADD antimicrobial screening data";"470";"";"";"";"";"CHEMBL4296181";"None";"10.6019/CHEMBL4296181";"None";"None";"None";"None";"None";"standard_type:ASSAY_TEST standard_relation:None standard_value:None standard_units:None comments:None | standard_type:DETECTION_METHOD standard_relation:None standard_value:None standard_units:None comments:None | standard_type:MEDIA standard_relation:None standard_value:None standard_units:None comments:None | standard_type:PLATE_TYPE standard_relation:None standard_value:None standard_units:None comments:None | standard_type:TIME standard_relation:= standard_value:18.0 standard_units:hr comments:None";"";"";"";"";""
"CHEMBL4713515";"F";"Antitumor activity against human H22 cells xenografted in KM mouse assessed as tumor growth inhibition at 20 mg/kg, ig administered every day for 10 days relative to control";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"H22";"";"CHEMBL4706663";"33450619";"10.1016/j.ejmech.2020.113142";"2021";"Eur J Med Chem";"212";"113142";"113142";"";"";"";"";"";""
"CHEMBL1273719";"F";"Anticancer activity against mouse S180 cells xenografted in ICR mouse assessed as tumor weight inhibition at 100 mg/kg, ip relative to control";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"CCRF S-180";"";"CHEMBL1268940";"20888764";"10.1016/j.bmcl.2010.09.041";"2010";"Bioorg Med Chem Lett";"20";"6555";"6559";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL3061435";"F";"Growth inhibition of Homo sapiens (human) HepG2 cells at 10 uM after 48 hr by SRB assay";"Homo sapiens";"21";"21";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HepG2";"";"CHEMBL3045644";"None";"10.1007/s00044-011-9850-7";"2012";"Med Chem Res";"21";"3043";"3052";"";"";"";"";"";""
"CHEMBL3061436";"F";"Growth inhibition of Homo sapiens (human) HCT15 cells at 10 uM after 48 hr by SRB assay";"Homo sapiens";"21";"21";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HCT-15";"";"CHEMBL3045644";"None";"10.1007/s00044-011-9850-7";"2012";"Med Chem Res";"21";"3043";"3052";"";"";"";"";"";""
"CHEMBL4029819";"F";"Anti-tumor activity against mouse 4T1 cells implanted in BALB/c mdb mouse assessed as tumor growth inhibition at 25 umol/kg, ip administered 3 times weekly measured on day 29 post cell innoculum relative to control";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"4T1";"";"CHEMBL4028815";"28342398";"10.1016/j.ejmech.2017.03.028";"2017";"Eur J Med Chem";"132";"63";"80";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL2154740";"T";"Genotoxicity in human lymphocytes assessed as micronucleated binucleate cells level at 6.25 ug/mL incubated for 3 hrs measured post 45 hrs recovery in presence of rat liver S9 fraction (Rvb = 0.5%)";"Homo sapiens";"1";"1";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"Lymphocyte";"Liver S9 fraction";"CHEMBL2150875";"21353728";"10.1016/j.ejmech.2011.01.071";"2011";"Eur J Med Chem";"46";"1524";"1535";"";"";"";"";"";""
"CHEMBL3062730";"P";"Lipophilicity, log P of the compound";"";"10";"10";"BAO_0000100";"small-molecule physicochemical format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"";"";"";"";"";"CHEMBL3046386";"None";"10.1007/s00044-010-9466-3";"2011";"Med Chem Res";"20";"1287";"1293";"";"";"";"";"";""
"CHEMBL3788268";"A";"Renal clearance in patient (6 patients) with moderate renal insufficiency at 1.4 +/- 0.1 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3638241";"Kidney";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3788331";"A";"Drug metabolism in po dosed lymphoma patient (6 patients) assessed as half life of plasma alkylating activity";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559721";"Plasma";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3232312";"F";"Antitumor activity against mouse ADJ/PC6 cells allografted in mouse";"Mus musculus";"7";"7";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"ADJ/PC6";"";"CHEMBL3227956";"423194";"10.1021/jm00188a006";"1979";"J Med Chem";"22";"151";"158";"";"";"";"";"";""
"CHEMBL2321085";"F";"Cytotoxicity against human NCI-H522 cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay";"Homo sapiens";"21";"21";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"NCI-H522";"";"CHEMBL2311276";"23202484";"10.1016/j.ejmech.2012.10.046";"2013";"Eur J Med Chem";"59";"7";"14";"";"";"";"";"";""
"CHEMBL4605726";"F";"Protective activity in NZBWF1/J mouse SLE model assessed as increase in animal survival rate at 5 mg/kg, po administered daily for 12 weeks measured at week 40";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"NZBWF1/J";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4602710";"32292557";"10.1021/acsmedchemlett.9b00621";"2020";"ACS Med Chem Lett";"11";"506";"513";"";"";"";"";"";""
"CHEMBL4029767";"T";"Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as WBC level at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 212.3 +/- 82.8 10'3/uL)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4028815";"28342398";"10.1016/j.ejmech.2017.03.028";"2017";"Eur J Med Chem";"132";"63";"80";"";"";"";"";"";""
"CHEMBL4303805";"F";"Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging";"Homo sapiens";"5616";"5632";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"SARS-CoV-2 Screening Data 2020-21";"9606";"";"";"Caco-2";"";"CHEMBL4303101";"None";"10.21203/rs.3.rs-23951/v1";"2020";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL4029775";"T";"Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as serum urea level at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 3.8 +/- 0.3 umol/L)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4028815";"28342398";"10.1016/j.ejmech.2017.03.028";"2017";"Eur J Med Chem";"132";"63";"80";"";"";"";"";"";""
"CHEMBL3232306";"T";"Toxicity in mouse allografted with mouse L1210 cells assessed as survival rate at 250 mg/kg, ip administered on day 1 measured on day 30 relative to control";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3227956";"423194";"10.1021/jm00188a006";"1979";"J Med Chem";"22";"151";"158";"standard_type:DOSE standard_relation:= standard_value:250.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL3257084";"F";"Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span at 100 mg/kg, ip administered 24 hrs relative to control";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL3788636";"A";"Disposition rate constant in iv dosed patient (7 patients) with renal insufficiency";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL4042868";"F";"Growth inhibition of human PA1 cells after 24 hrs by MTT assay";"Homo sapiens";"9";"9";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"PA-1";"";"CHEMBL4041541";"28011220";"10.1016/j.bmcl.2016.12.031";"2017";"Bioorg Med Chem Lett";"27";"501";"504";"";"";"";"";"";""
"CHEMBL2150746";"F";"Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 11";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL2146434";"22574992";"10.1021/jm300468t";"2012";"J Med Chem";"55";"5077";"5087";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL3791045";"A";"Systemic clearance in patient (6 patients) with severe renal insufficiency at 1.1 +/- 0.2 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL4029773";"T";"Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as serum AST level at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 136 +/- 10.3 U/L)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4028815";"28342398";"10.1016/j.ejmech.2017.03.028";"2017";"Eur J Med Chem";"132";"63";"80";"";"";"";"";"";""
"CHEMBL3788647";"A";"Terminal half life in iv dosed patient with normal renal function";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL3788263";"A";"Volume of distribution at steady state in patient ( 12 patients) with normal renal function at 0.83 +/- 0.05 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3788911";"A";"Plasma alkylating activity in patient (7 patients) with renal insufficiency assessed as elimination rate constant for total NBP alkylating activity at 300 mg/kg by NBP based colorimetric assay";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL3788913";"A";"Plasma alkylating activity in patient (7 patients) with renal insufficiency assessed as AUC for total NBP alkylating activity at 300 mg/kg by NBP based colorimetric assay";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL4029764";"T";"Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as spleen weight at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 0.603 +/- 0.133 g)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"CHEMBL3559722";"Spleen";"";"";"CHEMBL4028815";"28342398";"10.1016/j.ejmech.2017.03.028";"2017";"Eur J Med Chem";"132";"63";"80";"";"";"";"";"";""
"CHEMBL3788640";"A";"Apparent volume of distribution at steady state in iv dosed patient (7 patients) with renal insufficiency";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL3790812";"A";"Systemic clearance in patient (6 patients) with moderate renal insufficiency at 1.4 +/- 0.1 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3788635";"A";"Drug excretion in human assessed as unchanged parent compound level";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL4611290";"T";"Toxicity in NOD/SCID mouse xenografted with human SKHEP1 cells assessed as effect on behavior phenotypes at 50 mg/kg, po administered on day 4 to day 30 post-tumor cell inoculation";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"10090";"";"";"SK-HEP1";"";"CHEMBL4610036";"31882297";"10.1016/j.bmcl.2019.126899";"2020";"Bioorg Med Chem Lett";"30";"126899";"126899";"";"";"";"";"";""
"CHEMBL4611293";"F";"Antitumor activity against human SKHEP1 cells xenografted in NOD/SCID mouse assessed as tumor weight at 50 mg/kg, po administered on day 4 to day 30 post-tumor cell inoculation (Rvb = 151 +/- 66 mg)";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"SK-HEP1";"";"CHEMBL4610036";"31882297";"10.1016/j.bmcl.2019.126899";"2020";"Bioorg Med Chem Lett";"30";"126899";"126899";"";"ALIMENTARY TRACT AND METABOLISM | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Genetically Diabetic Animals | Methods for Testing Immunological Factors | Neoplasm Oncology Models | Xenograft Oncology Models";"Spontaneously Diabetic Mice: KK Mouse, KK-AY Mouse, NOD Mouse, Obese Hyperglycemic Mice, Diabetic db/db Mice, Diabetes Obesity Syndrome in CBA/Ca Mice, Wellesley Mouse | Spontaneous Autoimmune Diseases In Animals | Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL3420835";"F";"Antitumor activity against mouse LLC cells allografted in C57BL/6 mouse assessed as tumor growth inhibition at 60 mg/kg, ip administerd for 14 days measured on day 15 relative to control";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL3414479";"25668341";"10.1021/jm501123r";"2015";"J Med Chem";"58";"2135";"2148";"standard_type:DOSE standard_relation:= standard_value:60.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL3252926";"F";"Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as mean survival time at 200 mg/kg, ip administered 24 hrs (Rvb 4.6 +/- 0.16 days)";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"standard_type:DOSE standard_relation:= standard_value:200.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL2154845";"T";"Genotoxicity in human lymphocytes assessed as micronucleated binucleate cells level at 6.25 ug/mL incubated for 3 hrs measured post 45 hrs recovery in presence of rat liver S9 fraction (Rvb = 0.8%)";"Homo sapiens";"1";"1";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"Lymphocyte";"Liver S9 fraction";"CHEMBL2150875";"21353728";"10.1016/j.ejmech.2011.01.071";"2011";"Eur J Med Chem";"46";"1524";"1535";"";"";"";"";"";""
"CHEMBL4611289";"T";"Toxicity in NOD/SCID mouse xenografted with human SKHEP1 cells assessed as animal death at 50 mg/kg, po administered on day 4 to day 30 post-tumor cell inoculation";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"10090";"";"";"SK-HEP1";"";"CHEMBL4610036";"31882297";"10.1016/j.bmcl.2019.126899";"2020";"Bioorg Med Chem Lett";"30";"126899";"126899";"";"";"";"";"";""
"CHEMBL4303819";"F";"Inhibition of cell viability relative to arbidol control (inhibition index > 1 indicates higher activity) measured by fluorescence (OD590nm) in Vero E6 cells infected with SARS-CoV-2 (strain BavPat1) at MOI 0.002 after 72hrs";"Chlorocebus sabaeus";"1518";"1520";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"SARS-CoV-2 Screening Data 2020-21";"60711";"";"";"Vero C1008";"";"CHEMBL4303097";"None";"10.1101/2020.04.03.023846";"2020";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3788653";"A";"Apparent first order elimination rate constant from the central compartment in iv dosed patient (7 patients) with renal insufficiency";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL733998";"F";"Tested in vivo for immunosuppressive activity in mouse using graft vs. Host rejection technique (GVHR); body weight at a dose of 200 mg/kg";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1130359";"None";"10.1016/S0960-894X(97)10072-5";"1997";"Bioorg Med Chem Lett";"7";"2781";"2786";"standard_type:DOSE standard_relation:= standard_value:200.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors | Methods for Testing Immunological Factors";"Acute Graft Versus Host Disease GVHD in Rats | General Immunosuppressive Activity";"";""
"CHEMBL3788318";"A";"Clearance in lymphoma patient at 11.3 mg/kg, iv by one compartment open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3788646";"A";"Disposition rate constant in iv dosed patient with normal renal function";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL3790803";"A";"AUC (0 to infinity) in patient ( 12 patients) with normal renal function at 0.83 +/- 0.05 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3788271";"A";"Drug excretion in dialysate of patient (4 patients) with chronic renal failure at 100 mg, iv administered over 10 mins followed by hemodialysis for 4 hrs measured during hemodialysis treatment by GLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL2406890";"F";"Antitumor activity against mouse Sarcoma 180 cells allografted in mouse assessed as tumor growth inhibition at 30 mg/kg, ip qd administered for 7 days measured after 21 days relative to control";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Sarcoma-180";"";"CHEMBL2401724";"23688697";"10.1016/j.ejmech.2013.04.031";"2013";"Eur J Med Chem";"65";"21";"31";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL3790808";"A";"Elimination half life in patient (6 patients) with moderate renal insufficiency at 1.4 +/- 0.1 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3788262";"A";"Drug excretion in urine of patient (6 patients) with hemodialysis-dependent end-stage renal disease at 1.2 +/- 0.4 g/m'2 administered as pulse therapy with 1 hr infusion followed by hemodialysis for 3 hrs started 7 hrs post dose measured during hemodialysis treatment by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000221";"tissue-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"CHEMBL3638201";"Urine";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3788264";"A";"Volume of distribution at steady state in patient (6 patients) with moderate renal insufficiency at 1.4 +/- 0.1 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL4651403";"F";"Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging";"Chlorocebus sabaeus";"4309";"8710";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"IMI-CARE SARS-CoV-2 Data";"60711";"";"";"Vero C1008";"";"CHEMBL4651402";"None";"10.6019/CHEMBL4651402";"2021";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3788308";"A";"Apparent volume of distribution of central compartment in iv dosed lymphoma patient (6 patients) by two-compartmental open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL2319610";"F";"Antitumor activity against mouse LLC cells xenografted in mouse assessed as tumor inhibition at 30 mg/kg, ip qd for 7 days measured every 3 days for 21 days";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL2311271";"23291116";"10.1016/j.ejmech.2012.11.045";"2013";"Eur J Med Chem";"60";"135";"143";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL4029763";"T";"Nephrotoxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as kidney weight at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 0.136 +/- 0.006 g)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4028815";"28342398";"10.1016/j.ejmech.2017.03.028";"2017";"Eur J Med Chem";"132";"63";"80";"";"GENITO URINARY SYSTEM AND SEX HORMONES";"Impaired Renal Function";"General Nephrotoxic and Nephroprotective Models";"";""
"CHEMBL4042865";"F";"Growth inhibition of human T47D cells after 24 hrs by MTT assay";"Homo sapiens";"9";"9";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"T47D";"";"CHEMBL4041541";"28011220";"10.1016/j.bmcl.2016.12.031";"2017";"Bioorg Med Chem Lett";"27";"501";"504";"";"";"";"";"";""
"CHEMBL4042870";"A";"Growth inhibition of HEK293T cells after 24 hrs by MTT assay";"Homo sapiens";"9";"9";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HEK-293T";"";"CHEMBL4041541";"28011220";"10.1016/j.bmcl.2016.12.031";"2017";"Bioorg Med Chem Lett";"27";"501";"504";"";"";"";"";"";""
"CHEMBL4029766";"F";"Anti-tumor activity against mouse 4T1 cells implanted in BALB/c mdb mouse assessed as lung metastasis at 25 mg/kg, ip administered three times weekly measured at 29 days post cell innoculum (Rvb = 56 +/- 25 No_unit)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"4T1";"";"CHEMBL4028815";"28342398";"10.1016/j.ejmech.2017.03.028";"2017";"Eur J Med Chem";"132";"63";"80";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Metastatic Oncology Models | Neoplasm Oncology Models";"Metastatic Activity | Neoplasms";"";""
"CHEMBL2150750";"F";"Antineoplastic activity against mouse LLC cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg/day measured on day 21";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL2146434";"22574992";"10.1021/jm300468t";"2012";"J Med Chem";"55";"5077";"5087";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL4713503";"T";"Toxicity in human Lewis lung cancer cells xenografted BALB/c mouse assessed as net weight at 20 mg/kg, ig administered every day for 10 days (Rvb = 1.16 +/- 1.55 g)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4706663";"33450619";"10.1016/j.ejmech.2020.113142";"2021";"Eur J Med Chem";"212";"113142";"113142";"";"";"";"";"";""
"CHEMBL4713527";"T";"Toxicity in human H22 cells xenografted KM mouse assessed as survival rate at 20 mg/kg, ig administered every day for 10 days relative to control";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"KM";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4706663";"33450619";"10.1016/j.ejmech.2020.113142";"2021";"Eur J Med Chem";"212";"113142";"113142";"";"";"";"";"";""
"CHEMBL3788912";"A";"Plasma alkylating activity in patient (7 patients) with renal insufficiency assessed as half life for total NBP alkylating activity at 300 mg/kg by NBP based colorimetric assay";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL4611298";"T";"Toxicity in NOD/SCID mouse xenografted with human SKHEP1 cells assessed as animal weight at 50 mg/kg, po administered on day 4 to day 30 post-tumor cell inoculation";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"10090";"";"";"SK-HEP1";"";"CHEMBL4610036";"31882297";"10.1016/j.bmcl.2019.126899";"2020";"Bioorg Med Chem Lett";"30";"126899";"126899";"";"";"";"";"";""
"CHEMBL4025709";"T";"Toxicity in ICR mouse xenografted with human H22 cells assessed as body weight at 20 mg/kg, iv administered once daily for 21 days measured post last dose (Rvb = 26 +/- 0.6 g)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"ICR";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4024711";"28359045";"10.1016/j.ejmech.2017.03.027";"2017";"Eur J Med Chem";"132";"173";"183";"";"";"";"";"";""
"CHEMBL3788326";"A";"Renal clearance in lymphoma patient (7 patients)";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3638241";"Kidney";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3232302";"F";"Antitumor activity against mouse L1210 cells allografted in mouse assessed as increase in survival rate at 250 mg/kg, ip administered on day 1 measured on day 30 relative to control";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3227956";"423194";"10.1021/jm00188a006";"1979";"J Med Chem";"22";"151";"158";"standard_type:DOSE standard_relation:= standard_value:250.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL3788572";"A";"Intrinsic hepatic clearance in lymphoma patient (7 patients)";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3582841";"T";"Toxicity in KM mouse assessed as micronucleus frequency in bone marrow polychromatic erythrocyte at 60 mg/kg, po single dose after 48 hrs (Rvb = 2.20 +/- 0.84 %)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"KM";"Scientific Literature";"10090";"";"";"Erythrocyte";"";"CHEMBL3580594";"25905540";"10.1021/jm5012963";"2015";"J Med Chem";"58";"3693";"3703";"";"";"";"";"";""
"CHEMBL3788259";"A";"Drug excretion in urine of patient ( 12 patients) with normal renal function at 0.83 +/- 0.05 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000221";"tissue-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"CHEMBL3638201";"Urine";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL651051";"F";"Effect on metastases of B16F10.9 melanoma cells (intraperitoneally implanted) in B6C3F1/OLAC/HSD mice was observed after administration of 50 mg/kg dose";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"B16-F10";"";"CHEMBL1125374";"1542095";"10.1021/jm00082a009";"1992";"J Med Chem";"35";"687";"694";"standard_type:DOSE standard_relation:= standard_value:50.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Melanoma Oncology Models | Melanoma Oncology Models | Metastatic Oncology Models";"Experimental Melanoma | General Melanoma | Metastatic Activity";"";""
"CHEMBL3788332";"A";"Systemic availability in lymphoma patient (7 patients) relative to control";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3582849";"T";"Toxicity in KM mouse assessed as micronucleus frequency in bone marrow polychromatic erythrocyte at 30 mg/kg, po single dose after 48 hrs (Rvb = 1.20 +/- 0.45 %)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"KM";"Scientific Literature";"10090";"";"";"Erythrocyte";"";"CHEMBL3580594";"25905540";"10.1021/jm5012963";"2015";"J Med Chem";"58";"3693";"3703";"";"";"";"";"";""
"CHEMBL1633757";"F";"Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as effect on leukocyte proliferation by T-cell stimulus alphaCD3 at 100 mg/kg, ip treated 8 days before infection by flow cytometry";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors";"General Immunosuppressive Activity";"";""
"CHEMBL651595";"F";"In vitro cytotoxicity against BALB/c 3T3 cells";"Mus musculus";"4";"4";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"NIH3T3";"";"CHEMBL1128257";"7877150";"10.1021/jm00005a012";"1995";"J Med Chem";"38";"848";"851";"";"";"";"";"";""
"CHEMBL2071966";"A";"Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins";"Homo sapiens";"221";"221";"BAO_0000357";"single protein format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL2069259";"22931300";"10.1021/tx300075j";"2012";"Chem Res Toxicol";"25";"2067";"2082";"";"";"";"";"";""
"CHEMBL3257533";"F";"Ratio of Cmax to Cmin for antileukemic activity against mouse L1210 cells allografted in po dosed BDF1 mouse assessed as survival over 60 days";"Mus musculus";"4";"4";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL3253039";"F";"Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as minimum effective dose administered as once each 4 days for 3 total injection";"Mus musculus";"5";"5";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"P388";"";"CHEMBL3244336";"490545";"10.1021/jm00195a002";"1979";"J Med Chem";"22";"1024";"1030";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Neoplasm Oncology Models";"P388 Experimental Leukemia | Neoplasms";"";""
"CHEMBL3253045";"A";"Therapeutic index, ratio of MTD for mouse P388 cells allografted ip dosed mouse to MED for mouse P388 cells allografted in ip dosed mouse administered as once each 4 days for 3 total injection";"Mus musculus";"5";"5";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"10090";"";"";"P388";"";"CHEMBL3244336";"490545";"10.1021/jm00195a002";"1979";"J Med Chem";"22";"1024";"1030";"";"";"";"";"";""
"CHEMBL2071965";"A";"Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins";"Homo sapiens";"221";"221";"BAO_0000357";"single protein format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL2069259";"22931300";"10.1021/tx300075j";"2012";"Chem Res Toxicol";"25";"2067";"2082";"";"";"";"";"";""
"CHEMBL1634564";"F";"Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as effect portal inflammation in liver at 100 mg/kg, ip treated 8 days before infection for 2 weeks by flow cytometry";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"CHEMBL3559723";"Liver";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | MUSCULO-SKELETAL SYSTEM";"Methods for Testing Immunological Factors | Anti-Inflammatory Activity";"General Immunosuppressive Activity | General Anti-Inflammatory Models";"";""
"CHEMBL3562135";"F";"PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel.   (Class of assay: confirmatory) ";"";"556";"556";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL741463";"F";"Tested in vivo for immunosuppressive activity in mouse using graft vs. Host rejection technique (GVHR); spleen index at a dose of 200 mg/kg";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"CHEMBL3559722";"Spleen";"";"";"CHEMBL1130359";"None";"10.1016/S0960-894X(97)10072-5";"1997";"Bioorg Med Chem Lett";"7";"2781";"2786";"standard_type:DOSE standard_relation:= standard_value:200.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors | Methods for Testing Immunological Factors";"Acute Graft Versus Host Disease GVHD in Rats | General Immunosuppressive Activity";"";""
"CHEMBL4296188";"F";"Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600";"Acinetobacter baumannii";"22588";"22685";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"ATCC 19606";"CO-ADD antimicrobial screening data";"470";"";"";"";"";"CHEMBL4296181";"None";"10.6019/CHEMBL4296181";"None";"None";"None";"None";"None";"standard_type:ASSAY_TEST standard_relation:None standard_value:None standard_units:None comments:None | standard_type:DETECTION_METHOD standard_relation:None standard_value:None standard_units:None comments:None | standard_type:MEDIA standard_relation:None standard_value:None standard_units:None comments:None | standard_type:PLATE_TYPE standard_relation:None standard_value:None standard_units:None comments:None | standard_type:TIME standard_relation:= standard_value:18.0 standard_units:hr comments:None";"";"";"";"";""
"CHEMBL2321078";"F";"Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay";"Homo sapiens";"9";"9";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HepG2";"";"CHEMBL2311276";"23202484";"10.1016/j.ejmech.2012.10.046";"2013";"Eur J Med Chem";"59";"7";"14";"";"";"";"";"";""
"CHEMBL2321079";"F";"Cytotoxicity against human NCI-H522 cells after 24 hrs by MTT assay";"Homo sapiens";"9";"9";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"NCI-H522";"";"CHEMBL2311276";"23202484";"10.1016/j.ejmech.2012.10.046";"2013";"Eur J Med Chem";"59";"7";"14";"";"";"";"";"";""
"CHEMBL2321084";"F";"Cytotoxicity against human PA1 cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay";"Homo sapiens";"21";"21";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"PA-1";"";"CHEMBL2311276";"23202484";"10.1016/j.ejmech.2012.10.046";"2013";"Eur J Med Chem";"59";"7";"14";"";"";"";"";"";""
"CHEMBL4296192";"F";"Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media using NBS plates, by Resazurin F(560/590)";"Staphylococcus aureus subsp. aureus";"1581";"1582";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"ATCC 43300";"CO-ADD antimicrobial screening data";"46170";"";"";"";"";"CHEMBL4296181";"None";"10.6019/CHEMBL4296181";"None";"None";"None";"None";"None";"standard_type:ASSAY_TEST standard_relation:None standard_value:None standard_units:None comments:None | standard_type:DETECTION_METHOD standard_relation:None standard_value:None standard_units:None comments:None | standard_type:MEDIA standard_relation:None standard_value:None standard_units:None comments:None | standard_type:PLATE_TYPE standard_relation:None standard_value:None standard_units:None comments:None | standard_type:TIME standard_relation:= standard_value:18.0 standard_units:hr comments:None";"";"";"";"";""
"CHEMBL700910";"F";"In vivo antitumor activity against intraperitoneal murine cyclophosphamide resistant L1210 Leukemia cells at 510 umol/kg";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL1125770";"1920355";"10.1021/jm00114a013";"1991";"J Med Chem";"34";"3044";"3052";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models | Neoplasm Oncology Models";"General Leukemia | L1210 Experimental Leukemia | Neoplasms";"";""
"CHEMBL1633755";"F";"Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as increase in neutrophils at 100 mg/kg, ip treated 8 days before infection for 2 weeks measured 14 days post infection by flow cytometry";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1629543";"18268085";"10.1128/aac.01311-07";"2008";"Antimicrob Agents Chemother";"52";"1462";"1471";"standard_type:DOSE standard_relation:= standard_value:100.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors";"General Immunosuppressive Activity";"";""
"CHEMBL3257525";"F";"Antileukemic activity against mouse L1210 cells allografted in iv dosed BDF1 mouse assessed as survival over 60 days administered 24 hrs";"Mus musculus";"4";"4";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL3788316";"A";"Elimination half life in lymphoma patient at 11.3 mg/kg, iv by one compartment open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3070544";"F";"Cytotoxicity against Homo sapiens (human) HCT15 cells assessed as growth inhibition at 10 uM after 48 hr by SRB assay";"Homo sapiens";"24";"24";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HCT-15";"";"CHEMBL3044972";"None";"10.1007/s00044-012-0439-6";"2013";"Med Chem Res";"22";"4278";"4285";"";"";"";"";"";""
"CHEMBL4685089";"F";"Antitumor activity against human B16-F10 cells xenografted in C57BL/6 mouse assessed as tumor weight at 60 mg/kg, ip administered for 20 days and measured on day 20 (Rvb = 0.93 +/- 0.78 g)";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"B16-F10";"";"CHEMBL4680192";"32028140";"10.1016/j.ejmech.2020.112079";"2020";"Eur J Med Chem";"190";"112079";"112079";"";"";"";"";"";""
"CHEMBL3062732";"F";"Antiproliferative activity against Homo sapiens (human) K562 cells after 48 hr by MTT assay";"Homo sapiens";"10";"10";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"K562";"";"CHEMBL3046386";"None";"10.1007/s00044-010-9466-3";"2011";"Med Chem Res";"20";"1287";"1293";"";"";"";"";"";""
"CHEMBL3854305";"F";"Antitumor activity against human HepG2 cells xenografted in nude mouse assessed as tumor growth inhibition at 20 mg/kg, ip administered every day for 15 times measured from day 12 to 26";"Homo sapiens";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HepG2";"";"CHEMBL3853295";"27162123";"10.1016/j.ejmech.2016.04.068";"2016";"Eur J Med Chem";"119";"183";"196";"";"";"";"";"";""
"CHEMBL3301366";"A";"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.";"Rattus norvegicus";"717";"717";"BAO_0000366";"cell-free format";"0";"0 - Default value - Target unknown or has yet to be assigned";"SD, HW or BN";"AstraZeneca Deposited Data";"10116";"CHEMBL3559721";"Plasma";"";"";"CHEMBL3301361";"None";"10.6019/CHEMBL3301361";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3885862";"F";"In vitro activity on S. mansoni schistosomula at 50 uM";"Schistosoma mansoni";"143";"100938";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"Puerto Rican";"Open TG-GATEs";"6183";"";"";"";"";"CHEMBL3885861";"None";"10.6019/CHEMBL3885861";"None";"None";"None";"None";"None";"standard_type:AGE standard_relation:None standard_value:6.0 standard_units:weeks comments:None | standard_type:GENDER standard_relation:None standard_value:None standard_units:None comments:None | standard_type:REGIMEN standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL3790806";"A";"Elimination half life in patient ( 12 patients) with normal renal function at 0.83 +/- 0.05 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3252496";"F";"Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as mean survival time at 50 mg/kg, ip administered 24 hrs (Rvb 4.6 +/- 0.16 days)";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"standard_type:DOSE standard_relation:= standard_value:50.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL3788648";"A";"Apparent volume of distribution in beta-phase iv dosed patient with normal renal function";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL3788639";"A";"Apparent volume of distribution at central compartment in iv dosed patient (7 patients) with renal insufficiency";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL4479000";"A";"Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NADPH measured after 24 hrs in absence of compound, CYP3A4 and NADPH by cell titer-glo luminescence assay relative to BSO alone";"Homo sapiens";"90";"90";"BAO_0000219";"cell-based format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL4477225";"27397500";"10.1016/j.bmcl.2016.06.088";"2016";"Bioorg Med Chem Lett";"26";"4003";"4006";"";"";"";"";"";""
"CHEMBL4042866";"F";"Growth inhibition of human NCI-H522 cells after 24 hrs by MTT assay";"Homo sapiens";"9";"9";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"NCI-H522";"";"CHEMBL4041541";"28011220";"10.1016/j.bmcl.2016.12.031";"2017";"Bioorg Med Chem Lett";"27";"501";"504";"";"";"";"";"";""
"CHEMBL4042862";"F";"Growth inhibition of human HCT15 cells at 1 x 10'-5 M after 24 hrs by MTT assay relative to control";"Homo sapiens";"35";"35";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HCT-15";"";"CHEMBL4041541";"28011220";"10.1016/j.bmcl.2016.12.031";"2017";"Bioorg Med Chem Lett";"27";"501";"504";"";"";"";"";"";""
"CHEMBL3257526";"F";"Antileukemic activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as survival over 60 days administered 24 hrs";"Mus musculus";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL4303810";"F";"Antiviral activity against SARS-CoV-2 (USA-WA1/2020 strain) measured by imaging in HRCE cells at MOI 0.4 after 96 hrs (reported as hit score from 0-1 for on-disease vs off-disease activity: scores >0.6 considered hits)";"Homo sapiens";"1629";"1637";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"SARS-CoV-2 Screening Data 2020-21";"9606";"";"";"HRCE";"";"CHEMBL4303122";"None";"10.1101/2020.04.21.054387";"2020";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL880063";"F";"Evaluated for the delayed type hypersensitivity (DTH) response to methylated BSA (mBSA) in sensitive mice after peroral administration of 50 mg/kg";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"";"";"CHEMBL1124858";"2115585";"10.1021/jm00170a003";"1990";"J Med Chem";"33";"2068";"2070";"standard_type:DOSE standard_relation:= standard_value:50.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors";"Delayed Type Hypersensitivity";"";""
"CHEMBL4513082";"F";"Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging";"Chlorocebus sabaeus";"7218";"17404";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"SARS-CoV-2 Screening Data 2020-21";"60711";"";"";"Vero C1008";"";"CHEMBL4495565";"None";"10.6019/CHEMBL4495565";"2020";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL4042864";"F";"Growth inhibition of human HepG2 cells at 1 x 10'-5 M after 24 hrs by MTT assay relative to control";"Homo sapiens";"35";"35";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HepG2";"";"CHEMBL4041541";"28011220";"10.1016/j.bmcl.2016.12.031";"2017";"Bioorg Med Chem Lett";"27";"501";"504";"";"";"";"";"";""
"CHEMBL632735";"A";"The half life at a physiological pH";"";"1";"1";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"";"";"";"";"";"CHEMBL1127411";"7966159";"10.1021/jm00049a018";"1994";"J Med Chem";"37";"3986";"3993";"";"";"";"";"";""
"CHEMBL2321020";"T";"Neurotoxicity in ip dosed C57BL/6 mouse assessed as tremble, twitch, jumping and supination response";"Mus musculus";"11";"11";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"C57BL/6";"Scientific Literature";"10090";"";"";"";"";"CHEMBL2311271";"23291116";"10.1016/j.ejmech.2012.11.045";"2013";"Eur J Med Chem";"60";"135";"143";"";"";"";"";"";""
"CHEMBL4427840";"F";"Cytotoxicity against human COLO320 cells assessed as cell growth inhibition at 156 uM by MTT assay relative to control";"Homo sapiens";"1";"1";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"COLO 320";"";"CHEMBL4425183";"27476145";"10.1016/j.bmcl.2016.07.036";"2016";"Bioorg Med Chem Lett";"26";"4310";"4317";"";"";"";"";"";""
"CHEMBL3137732";"T";"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]";"Homo sapiens";"1214";"1216";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL3137726";"T";"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]";"Homo sapiens";"1214";"1216";"BAO_0000221";"tissue-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL3587742";"F";"Antitumor activity against mouse CT26 cells implanted in mouse assessed as tumor growth inhibition at 114.9 umol/kg, ip qd administered for 7 days starting 24 hrs post tumor implantation measured after day 21 relative to control";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"CT26";"";"CHEMBL3585290";"None";"10.1039/C4MD00098F";"2014";"Medchemcomm";"5";"953";"957";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL3587852";"F";"Antitumor activity against mouse LLC cells implanted in mouse assessed as tumor growth inhibition at 114.9 umol/kg, ip qd administered for 7 days starting 24 hrs post tumor implantation measured after day 21 relative to control";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL3585290";"None";"10.1039/C4MD00098F";"2014";"Medchemcomm";"5";"953";"957";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL2321086";"F";"Cytotoxicity against human T47D cells assessed as growth inhibition at 1 x 10 '-5 M after 24 hrs by MTT assay";"Homo sapiens";"21";"21";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"T47D";"";"CHEMBL2311276";"23202484";"10.1016/j.ejmech.2012.10.046";"2013";"Eur J Med Chem";"59";"7";"14";"";"";"";"";"";""
"CHEMBL3411293";"A";"Stimulation of human OATP1B3-mediated [3H]CCK-8 at 100 uM after 5 mins relative to control";"Homo sapiens";"6";"6";"BAO_0000357";"single protein format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3407465";"25618019";"10.1016/j.ejmech.2015.01.011";"2015";"Eur J Med Chem";"92";"723";"731";"";"";"";"";"";""
"CHEMBL4042860";"F";"Growth inhibition of human T47D cells at 1 x 10'-5 M after 24 hrs by MTT assay relative to control";"Homo sapiens";"35";"35";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"T47D";"";"CHEMBL4041541";"28011220";"10.1016/j.bmcl.2016.12.031";"2017";"Bioorg Med Chem Lett";"27";"501";"504";"";"";"";"";"";""
"CHEMBL3054945";"F";"Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by trypan blue assay";"Homo sapiens";"16";"16";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"MCF7";"";"CHEMBL3045043";"None";"10.1007/s00044-009-9222-8";"2010";"Med Chem Res";"19";"674";"689";"";"";"";"";"";""
"CHEMBL4478999";"A";"Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NADPH measured after 24 hrs in absence of compound, CYP3A4 and NADPH by cell titer-glo luminescence assay relative to BSO alone";"Homo sapiens";"101";"101";"BAO_0000219";"cell-based format";"9";"9 - Direct single protein target assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL4477225";"27397500";"10.1016/j.bmcl.2016.06.088";"2016";"Bioorg Med Chem Lett";"26";"4003";"4006";"";"";"";"";"";""
"CHEMBL3214842";"F";"PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation.   (Class of assay: confirmatory) ";"";"881";"896";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3232315";"F";"Cytotoxicity against rat Walker 256 cells assessed as growth inhibition in absence of microsomal activation";"Rattus norvegicus";"2";"2";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10116";"";"";"W256";"";"CHEMBL3227956";"423194";"10.1021/jm00188a006";"1979";"J Med Chem";"22";"151";"158";"";"";"";"";"";""
"CHEMBL4296186";"F";"Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600)";"Klebsiella pneumoniae";"6160";"6262";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"ATCC 700603";"CO-ADD antimicrobial screening data";"573";"";"";"";"";"CHEMBL4296181";"None";"10.6019/CHEMBL4296181";"None";"None";"None";"None";"None";"standard_type:ASSAY_TEST standard_relation:None standard_value:None standard_units:None comments:None | standard_type:DETECTION_METHOD standard_relation:None standard_value:None standard_units:None comments:None | standard_type:MEDIA standard_relation:None standard_value:None standard_units:None comments:None | standard_type:PLATE_TYPE standard_relation:None standard_value:None standard_units:None comments:None | standard_type:TIME standard_relation:= standard_value:18.0 standard_units:hr comments:None";"";"";"";"";""
"CHEMBL3418965";"F";"Antitumor activity against human HT-29 cells xenografted in BALB/c mouse assessed as reduction in tumor volume at 30 mg/kg, ip administered once daily for 18 days";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HT-29";"";"CHEMBL3414539";"25689111";"10.1021/acs.jmedchem.5b00118";"2015";"J Med Chem";"58";"2538";"2546";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL3137735";"T";"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]";"Homo sapiens";"1214";"1216";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL3137740";"T";"Proposed mechanism(s) of liver damage. [column 'MEC' in source]";"Homo sapiens";"1214";"1216";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL3137730";"T";"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]";"Homo sapiens";"1214";"1216";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL3137737";"T";"Presence of at least one case with successful reintroduction. [column 'REINT' in source]";"Homo sapiens";"1214";"1216";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL3137725";"T";"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]";"Homo sapiens";"1214";"1216";"BAO_0000221";"tissue-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559723";"Liver";"";"";"CHEMBL3137667";"15646539";"10.1016/s0399-8320(04)95062-2";"2004";"Gastroenterol Clin Biol";"28";"720";"759";"";"";"";"";"";""
"CHEMBL3428018";"F";"In vivo antitumor activity against human H22 cells xenografted in mouse assessed as tumor growth inhibitory ratio at 30 mg/kg, ip administered after 7 days of tumor transplantation measured at 25th day after tumor inoculation";"Homo sapiens";"3";"3";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"H22";"";"CHEMBL3425458";"25984840";"10.1016/j.ejmech.2015.04.057";"2015";"Eur J Med Chem";"97";"235";"244";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL4000852";"F";"Antitumor activity against mouse H22 cells implanted in Kunming mouse assessed as tumor growth inhibition at 100 mg/kg, ip administered twice relative to control";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL4000174";"27871039";"10.1016/j.ejmech.2016.11.013";"2017";"Eur J Med Chem";"125";"1235";"1246";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL3788654";"A";"First order inter-compartment transfer rate constant from central to peripheral compartment in iv dosed patient with normal renal function";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL3383273";"F";"Antitumor activity against human H22 cells transplanted in ICR mouse assessed as tumor growth inhibition at 30 mg/kg, iv administered 7 days post tumor transplantation";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"H22";"";"CHEMBL3351759";"25247772";"10.1016/j.ejmech.2014.09.058";"2014";"Eur J Med Chem";"87";"159";"167";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL3788915";"A";"Plasma alkylating activity in patient with normal renal function assessed as half life for total NBP alkylating activity at 300 mg/kg by NBP based colorimetric assay";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL2319274";"T";"Toxicity in C57BL/6 mouse assessed as maximum weight loss at 50 mg/kg, ip";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"C57BL/6";"Scientific Literature";"10090";"";"";"";"";"CHEMBL2311304";"23279863";"10.1016/j.ejmech.2012.11.033";"2013";"Eur J Med Chem";"60";"10";"22";"standard_type:DOSE standard_relation:= standard_value:50.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"";"";"";"";""
"CHEMBL3788312";"A";"Elimination rate constant from central compartment in iv dosed lymphoma patient (6 patients) by two-compartmental open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3788313";"A";"Clearance in iv dosed lymphoma patient (6 patients) by two-compartmental open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3788323";"A";"Clearance in po dosed lymphoma patient (7 patients) by one compartment open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3788924";"A";"Half life in patient with normal renal function assessed as unchanged compound level using 14C labeled compound measured over 72 hrs";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL3788258";"A";"Systemic clearance in patient (6 patients) with hemodialysis-dependent end-stage renal disease at 1.2 +/- 0.4 g/m'2 administered as pulse therapy with 1 hr infusion followed by hemodialysis for 3 hrs started 7 hrs post dose measured during hemodialysis treatment by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3788314";"A";"Initial plasma concentration in lymphoma patient at 11.3 mg/kg, iv by one compartment open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559721";"Plasma";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3788328";"A";"Drug metabolism in po dosed lymphoma patient (6 patients) assessed as dose normalised AUC for plasma alkylating activity";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559721";"Plasma";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3788643";"A";"Terminal half life in patient (7 patients) with renal insufficiency at 350 mg/kg, po";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL4042867";"F";"Growth inhibition of human HCT15 cells after 24 hrs by MTT assay";"Homo sapiens";"9";"9";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"HCT-15";"";"CHEMBL4041541";"28011220";"10.1016/j.bmcl.2016.12.031";"2017";"Bioorg Med Chem Lett";"27";"501";"504";"";"";"";"";"";""
"CHEMBL4039781";"T";"Genotoxicity in rat assessed as micronucleated polychromatic erythrocytes in bone marrow at 40 mg/kg administered via oral gavage measured after 24 hrs post dose by micronucleus assay (Rvb = 0.07 +/- 0.05%)";"Rattus norvegicus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10116";"";"";"";"";"CHEMBL4038305";"28635296";"10.1021/acs.jmedchem.7b00621";"2017";"J Med Chem";"60";"5889";"5908";"";"";"";"";"";""
"CHEMBL3788330";"A";"Drug metabolism in iv dosed lymphoma patient (6 patients) assessed as half life of plasma alkylating activity";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"CHEMBL3559721";"Plasma";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL3788645";"A";"Terminal half life in patient (7 patients) with renal insufficiency at 50 mg/kg, po";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785078";"7250178";"10.1007/bf00548589";"1981";"Eur J Clin Pharmacol";"19";"443";"451";"";"";"";"";"";""
"CHEMBL3788272";"A";"Drug recovery in dialysate of patient (4 patients) with chronic renal failure at 100 mg, iv administered over 10 mins followed by hemodialysis for 6 hrs measured during hemodialysis treatment by GLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3790810";"A";"Elimination half life in patient (6 patients) with hemodialysis-dependent end-stage renal disease at 1.2 +/- 0.4 g/m'2 administered as pulse therapy with 1 hr infusion followed by hemodialysis for 3 hrs started 7 hrs post dose measured during hemodialysis treatment by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3788260";"A";"Drug excretion in urine of patient (6 patients) with moderate renal insufficiency at 1.4 +/- 0.1 g/m'2 administered as pulse therapy with 1 hr infusion by HPLC analysis";"Homo sapiens";"1";"1";"BAO_0000221";"tissue-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"CHEMBL3638201";"Urine";"";"";"CHEMBL3784959";"11918757";"10.1046/j.1523-1755.2002.00279.x";"2002";"Kidney Int";"61";"1495";"1501";"";"";"";"";"";""
"CHEMBL3253043";"F";"Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as dose providing 40% increase in life span administered as once each 4 days for 3 total injection";"Mus musculus";"5";"5";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"P388";"";"CHEMBL3244336";"490545";"10.1021/jm00195a002";"1979";"J Med Chem";"22";"1024";"1030";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Neoplasm Oncology Models";"P388 Experimental Leukemia | Neoplasms";"";""
"CHEMBL4685098";"T";"Toxicity in C57BL/6 mouse xenografted with human B16-F10 cells assessed as body weight at 60 mg/kg, ip administered and measured on day 1 (Rvb = 18.4 +/- 0.3 g)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"C57BL/6";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4680192";"32028140";"10.1016/j.ejmech.2020.112079";"2020";"Eur J Med Chem";"190";"112079";"112079";"";"";"";"";"";""
"CHEMBL3788319";"A";"Elimination rate constant in po dosed lymphoma patient (7 patients) by one compartment open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL4148738";"F";"Antitumor activity against mouse LLC cells implanted in mouse assessed as tumor growth inhibition at 30 mg/kg, ip administered once per day for 7 consecutive days starting from 24 hrs post tumor inoculation and measured on day 21 post tumor inoculation relative to control";"Mus musculus";"2";"2";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"Lewis lung carcinoma cell line";"";"CHEMBL4145545";"29448140";"10.1016/j.ejmech.2018.02.003";"2018";"Eur J Med Chem";"147";"253";"265";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL4713523";"T";"Toxicity in human H22 cells xenografted KM mouse assessed as net weight at 20 mg/kg, ig administered every day for 10 days (Rvb = 9.45 +/- 4 g)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"KM";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4706663";"33450619";"10.1016/j.ejmech.2020.113142";"2021";"Eur J Med Chem";"212";"113142";"113142";"";"";"";"";"";""
"CHEMBL4039775";"T";"Genotoxicity in rat assessed as change in polychromatic erythrocytes in bone marrow at 40 mg/kg administered via oral gavage measured after 24 hrs post dose by micronucleus assay relative to control";"Rattus norvegicus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10116";"";"";"";"";"CHEMBL4038305";"28635296";"10.1021/acs.jmedchem.7b00621";"2017";"J Med Chem";"60";"5889";"5908";"";"";"";"";"";""
"CHEMBL3383279";"T";"Toxicity in human H22 cells transplanted ICR mouse assessed as mouse body weight at 30 mg/kg, iv administered 7 days post tumor transplantation (Rvb = 18.1 +/- 1g)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"ICR";"Scientific Literature";"10090";"";"";"H22";"";"CHEMBL3351759";"25247772";"10.1016/j.ejmech.2014.09.058";"2014";"Eur J Med Chem";"87";"159";"167";"standard_type:DOSE standard_relation:= standard_value:30.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models";"Neoplasms";"";""
"CHEMBL4039428";"F";"Antitumor activity against human U2932 cells xenografted in SCID mouse assessed as reduction in tumor burden at 50 mg/kg, ip administered for 5 consecutive days measured up to day 40 post cell injection";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"U2932";"";"CHEMBL4038303";"28605593";"10.1021/acs.jmedchem.7b00298";"2017";"J Med Chem";"60";"6587";"6597";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Neoplasm Oncology Models | Xenograft Oncology Models";"Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
"CHEMBL3788322";"A";"Volume of distribution in po dosed lymphoma patient (7 patients) by one compartment open model";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"";"";"CHEMBL3785022";"497087";"10.1111/j.1365-2125.1979.tb01004.x";"1979";"Br J Clin Pharmacol";"8";"209";"217";"";"";"";"";"";""
"CHEMBL4713507";"T";"Toxicity in human Lewis lung cancer cells xenografted BALB/c mouse assessed as survival rate at 20 mg/kg, ig administered every day for 10 days (Rvb = 100%)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4706663";"33450619";"10.1016/j.ejmech.2020.113142";"2021";"Eur J Med Chem";"212";"113142";"113142";"";"";"";"";"";""
"CHEMBL3257520";"F";"Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span at 400 mg/kg, ip administered 24 hrs relative to control";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL3244168";"621716";"10.1021/jm00200a013";"1978";"J Med Chem";"21";"208";"214";"standard_type:DOSE standard_relation:= standard_value:400.0 standard_units:mg.kg-1 comments:None | standard_type:ROUTE standard_relation:None standard_value:None standard_units:None comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Methods for Testing Immunological Factors";"General Leukemia | Spontaneous Autoimmune Diseases In Animals";"";""
"CHEMBL4029771";"T";"Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as serum PLT level at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 972 +/- 157 10'3/uL)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4028815";"28342398";"10.1016/j.ejmech.2017.03.028";"2017";"Eur J Med Chem";"132";"63";"80";"";"";"";"";"";""
"CHEMBL4029772";"T";"Toxicity in BALB/c mdb mouse implanted with mouse 4T1 cells assessed as serum ALT level at 25 mg/kg, ip administered three times weekly measured at 29 day post cell innoculum (Rvb = 23.8 +/- 2.2 U/L)";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"BALB/c";"Scientific Literature";"10090";"";"";"";"";"CHEMBL4028815";"28342398";"10.1016/j.ejmech.2017.03.028";"2017";"Eur J Med Chem";"132";"63";"80";"";"";"";"";"";""
"CHEMBL3062877";"F";"Growth inhibition of Homo sapiens (human) NCI-H522 cells at 10 uM after 48 hr by SRB assay";"Homo sapiens";"21";"21";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"NCI-H522";"";"CHEMBL3045644";"None";"10.1007/s00044-011-9850-7";"2012";"Med Chem Res";"21";"3043";"3052";"";"";"";"";"";""
"CHEMBL1964014";"F";"PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-18 Non-Small Cell Lung cell line. (Class of assay: confirmatory) ";"";"11487";"11548";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"HOP-18";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL743346";"F";"Tested in vivo for immunosuppressive activity in mouse using graft vs. Host rejection technique (GVHR); spleen weight normalized to D8 body weight at a dose of 200 mg/kg";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"CHEMBL3559722";"Spleen";"";"";"CHEMBL1130359";"None";"10.1016/S0960-894X(97)10072-5";"1997";"Bioorg Med Chem Lett";"7";"2781";"2786";"standard_type:DOSE standard_relation:= standard_value:200.0 standard_units:mg.kg-1 comments:None";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Methods for Testing Immunological Factors | Methods for Testing Immunological Factors";"Acute Graft Versus Host Disease GVHD in Rats | General Immunosuppressive Activity";"";""
"CHEMBL700913";"F";"In vivo antitumor activity against intraperitoneal murine cyclophosphamide resistant L1210 Leukemia cells at 680 umol/kg; Toxic";"Mus musculus";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"L1210";"";"CHEMBL1125770";"1920355";"10.1021/jm00114a013";"1991";"J Med Chem";"34";"3044";"3052";"";"ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Leukemia Oncology Models | Leukemia Oncology Models | Neoplasm Oncology Models";"General Leukemia | L1210 Experimental Leukemia | Neoplasms";"";""
"CHEMBL3215001";"F";"PubChem BioAssay. qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation.   (Class of assay: confirmatory) ";"";"1150";"1173";"BAO_0000019";"assay format";"1";"1 - Target assigned is non-molecular";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL4713511";"F";"Antitumor activity against human H22 cells xenografted in KM mouse assessed as tumor weight at 20 mg/kg, ig administered every day for 10 days (Rvb = 0.55 +/- 0.57 g)";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"9606";"";"";"H22";"";"CHEMBL4706663";"33450619";"10.1016/j.ejmech.2020.113142";"2021";"Eur J Med Chem";"212";"113142";"113142";"";"";"";"";"";""
"CHEMBL2319269";"F";"Antitumor activity in mouse B16 melanoma cell lines cells inoculated mouse assessed as tumor inhibition rate at one fifth of LD50 concentration once a day for consecutive 7 days by ip";"Mus musculus";"12";"12";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"10090";"";"";"B16";"";"CHEMBL2311304";"23279863";"10.1016/j.ejmech.2012.11.033";"2013";"Eur J Med Chem";"60";"10";"22";"";"";"";"";"";""
"CHEMBL3071881";"F";"Growth inhibition of Homo sapiens (human) T47D cells at 10 uM after 48 hr by SRB assay";"Homo sapiens";"25";"25";"BAO_0000219";"cell-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"T47D";"";"CHEMBL3046244";"None";"10.1007/s00044-012-0438-7";"2013";"Med Chem Res";"22";"4600";"4609";"";"";"";"";"";""
"CHEMBL3562036";"F";"PubChem BioAssay. Immunotoxin (HA22) sensitization/mitigation study - treatment arm (High Dose).   (Class of assay: confirmatory) ";"";"120";"120";"BAO_0000019";"assay format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"PubChem BioAssays";"";"";"";"";"";"CHEMBL1201862";"None";"None";"None";"None";"None";"None";"None";"";"";"";"";"";""
"CHEMBL3253044";"A";"Therapeutic index, ratio of MTD for mouse P388 cells allografted ip dosed mouse to MED for mouse P388 cells allografted in ip dosed mouse administered as single dose";"Mus musculus";"6";"6";"BAO_0000218";"organism-based format";"0";"0 - Default value - Target unknown or has yet to be assigned";"";"Scientific Literature";"10090";"";"";"P388";"";"CHEMBL3244336";"490545";"10.1021/jm00195a002";"1979";"J Med Chem";"22";"1024";"1030";"";"";"";"";"";""
"CHEMBL4611296";"F";"Antitumor activity against human SKHEP1 cells xenografted in NOD/SCID mouse assessed as inhibition of tumor growth at 50 mg/kg, po administered on day 4 to day 30 post-tumor cell inoculation";"Homo sapiens";"1";"1";"BAO_0000218";"organism-based format";"1";"1 - Target assigned is non-molecular";"";"Scientific Literature";"9606";"";"";"SK-HEP1";"";"CHEMBL4610036";"31882297";"10.1016/j.bmcl.2019.126899";"2020";"Bioorg Med Chem Lett";"30";"126899";"126899";"";"ALIMENTARY TRACT AND METABOLISM | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS";"Genetically Diabetic Animals | Methods for Testing Immunological Factors | Neoplasm Oncology Models | Xenograft Oncology Models";"Spontaneously Diabetic Mice: KK Mouse, KK-AY Mouse, NOD Mouse, Obese Hyperglycemic Mice, Diabetic db/db Mice, Diabetes Obesity Syndrome in CBA/Ca Mice, Wellesley Mouse | Spontaneous Autoimmune Diseases In Animals | Neoplasms | Xenograft Models of Anti-Tumor Assays";"";""
